

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 7
July 2011**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2011

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

Cumulative Supplement 7

July 2011

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

**CUMULATIVE SUPPLEMENT 7
July 2011**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ALCON INC (ALCON)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
ALCON LABORATORIES INC (ALCON)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
ALCON RESEARCH LTD (ALCON RES)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
SHIONOGI PHARMA INC (SHIONOGI PHARMA)	SHIONOGI INC (SHIONOGI INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate

for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active

ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2010</u>	<u>MAR 2011</u>	<u>JUN 2011</u>	<u>SEPT 2011</u>	<u>DEC 2011</u>
DRUG PRODUCTS LISTED	13838	14029	14309		
SINGLE SOURCE	2482 (17.9%)	2477 (17.7%)	2468 (17.2%)		
MULTISOURCE	11267 (81.4%)	11463 (81.7%)	11752 (82.1%)		
THERAPEUTICALLY EQUIVALENT	11107 (80.3%)	11301 (80.6%)	11592 (81.0%)		
NOT THERAPEUTICALLY EQUIVALENT	160 (1.2%)	162 (1.2%)	160 (1.1%)		
EXCEPTIONS ¹	89 (0.6%)	89 (0.6%)	89 (0.6%)		
NEW MOLECULAR ENTITIES APPROVED	8	6	8		
NUMBER OF APPLICANTS	752	768	784		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR Change. Dosage Form; Route of Administration.

CFTG Change. A first time generic for the innovator product. A TE Code is added.

CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMS1 Change. Miscellaneous addition to list.

CMS2 Change. Miscellaneous deletion from list.

CPOT Change. Potency amount/unit.

CRLD Change. Reference Listed Drug.

CTEC Change. Therapeutic Equivalence Code.

CTNA Change. Trade Name.

DISC Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 31ST EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

1-1

ABIRATERONE ACETATE

TABLET; ORAL

ZYTIGA

+ CENTOCOR ORTHO 250MG N202379 001 Apr 28, 2011 Apr NEWA

ACARBOSE

TABLET; ORAL

ACARBOSE

>A> AB STRIDES ARCOLAB LTD 25MG A090912 001 Jul 27, 2011 Jul NEWA

>A> AB 50MG A090912 002 Jul 27, 2011 Jul NEWA

>A> AB 100MG A090912 003 Jul 27, 2011 Jul NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA MIRROR PHARMS 325MG;50MG;40MG A040864 001 Dec 01, 2008 Mar CAHN

AA 500MG;50MG;40MG A040883 001 Dec 23, 2008 Mar CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

AA WRASER PHARMS LLC 356.4MG;30MG;16MG A040688 001 Apr 03, 2007 Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>D> AA WATSON LABS FLORIDA 300MG;15MG A040443 001 Jan 22, 2003 Jul DISC

>A> @ 300MG;15MG A040443 001 Jan 22, 2003 Jul DISC

>D> AA 300MG;30MG A040443 002 Jan 22, 2003 Jul DISC

>A> @ 300MG;30MG A040443 002 Jan 22, 2003 Jul DISC

>D> AA 300MG;60MG A040443 003 Jan 22, 2003 Jul DISC

>A> @ 300MG;60MG A040443 003 Jan 22, 2003 Jul DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A> AA BOCA PHARMA 325MG/15ML;7.5MG/15ML A040894 001 Jul 19, 2011 Jul NEWA

>D> + MIKART 325MG/15ML;7.5MG/15ML A040482 001 Sep 25, 2003 Jul CTEC

>A> AA + 325MG/15ML;7.5MG/15ML A040482 001 Sep 25, 2003 Jul CTEC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA BOCA PHARMA 300MG;5MG A090415 001 Jan 24, 2011 Feb CTEC

AB 300MG;5MG A090415 001 Jan 24, 2011 Jan NEWA

AA 300MG;7.5MG A090415 002 Jan 24, 2011 Feb CTEC

AB 300MG;7.5MG A090415 002 Jan 24, 2011 Jan NEWA

AA 300MG;10MG A090415 003 Jan 24, 2011 Feb CTEC

AB 300MG;10MG A090415 003 Jan 24, 2011 Jan NEWA

AA + MIKART 300MG;5MG A040658 001 Jan 19, 2006 Mar CRLD

AA 300MG;5MG A040658 001 Jan 19, 2006 Feb CTEC

AA + 300MG;7.5MG A040556 002 Mar 24, 2006 Feb CTEC

AA + 300MG;10MG A040556 001 Jun 23, 2004 Feb CTEC

@ RANBAXY 500MG;5MG A040825 001 Aug 16, 2007 May DISC

@ 500MG;10MG A040824 001 Aug 16, 2007 May DISC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@ RANBAXY LABS LTD	325MG;10MG	A040826	001	Aug 16, 2007	May	DISC
	@	750MG;7.5MG	A040822	001	Aug 16, 2007	May	DISC
>D>	AA	WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003	Jul DISC
>A>	@	500MG;5MG	A040493	001	May 28, 2003	Jul	DISC
>D>	AA		750MG;7.5MG	A040494	001	May 28, 2003	Jul DISC
>A>	@		750MG;7.5MG	A040494	001	May 28, 2003	Jul DISC
	LORTAB						
AA	UCB INC	500MG;5MG	A087722	001	Jul 09, 1982	Jan	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

>D>	AA	ACTAVIS TOTOWA	500MG;5MG	A040199	001	Dec 30, 1998	Jul DISC
>A>	@		500MG;5MG	A040199	001	Dec 30, 1998	Jul DISC

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

>D>	AA	ACTAVIS TOTOWA	325MG;5MG	A040203	001	Mar 15, 1999	Jul DISC
>A>	@		325MG;5MG	A040203	001	Mar 15, 1999	Jul DISC

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

	@ VINTAGE PHARMS	650MG;65MG	A040507	001	Jul 30, 2003	Mar	DISC
--	------------------	------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET-N 100

	@ XANODYNE PHARM	650MG;100MG	N017122	002		Jan	DISC
--	------------------	-------------	---------	-----	--	-----	------

DARVOCET-N 50

	@ XANODYNE PHARM	325MG;50MG	N017122	001		Jan	DISC
--	------------------	------------	---------	-----	--	-----	------

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

	@ CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004	Mar	DISC
	@	500MG;100MG	A076750	001	Jun 28, 2004	Mar	DISC
	@ MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008	Apr	DISC
AB		650MG;100MG	A077821	001	Feb 11, 2008	Mar	CAHN
	@ TEVA	650MG;100MG	A074119	001	Dec 19, 1994	Mar	DISC
	@ VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001	Mar	DISC
	@	650MG;100MG	A074843	001	Feb 12, 1997	Mar	DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

>A>	AB	INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	Jul NEWA
-----	----	----------------	-------	---------	-----	--------------	----------

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL-E

	+ BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993	Jun	CAHN
--	-------------------	-----------	---------	-----	--------------	-----	------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB	MYLAN	200MG	A074977	001	Apr 13, 1998	Feb	CAHN
----	-------	-------	---------	-----	--------------	-----	------

		CREAM; TOPICAL							
		ZOVIRAX							
>D>	+	GLAXOSMITHKLINE	5%		N021478	001	Dec 30, 2002	Jul	CAHN
>A>	+	VALEANT INTL	5%		N021478	001	Dec 30, 2002	Jul	CAHN
		OINTMENT; TOPICAL							
		ZOVIRAX							
>D>	+	GLAXOSMITHKLINE	5%		N018604	001	Mar 29, 1982	Jul	CAHN
>A>	+	VALEANT INTL	5%		N018604	001	Mar 29, 1982	Jul	CAHN
		TABLET; ORAL							
		ACYCLOVIR							
AB		MYLAN	400MG		A074976	001	Apr 13, 1998	Feb	CAHN
AB			800MG		A074976	002	Apr 13, 1998	Feb	CAHN
		<u>ACYCLOVIR SODIUM</u>							
		INJECTABLE; INJECTION							
		ACYCLOVIR SODIUM							
		@ HOSPIRA	EQ 50MG BASE/ML		A075065	001	Feb 25, 1999	Feb	DISC
		<u>ACYCLOVIR; HYDROCORTISONE</u>							
		CREAM; TOPICAL							
		XERESE							
	+	MEDA PHARMS	5%;1%		N022436	001	Jul 31, 2009	May	CTNA
		<u>ALBENDAZOLE</u>							
		TABLET; ORAL							
		ALBENZA							
	+	COREPHARMA	200MG		N020666	001	Jun 11, 1996	Jun	CAHN
		<u>ALBUTEROL SULFATE</u>							
		SOLUTION; INHALATION							
		ALBUTEROL SULFATE							
>D>	AN	HOLOPACK INTL	EQ 0.083% BASE		A077839	001	Dec 16, 2008	Jul	CAHN
>A>	AN	RITEDOSE CORP	EQ 0.083% BASE		A077839	001	Dec 16, 2008	Jul	CAHN
		<u>ALCAFTADINE</u>							
		SOLUTION/DROPS; OPHTHALMIC							
		LASTACFT							
	+	ALLERGAN	0.25%		N022134	001	Jul 28, 2010	Jun	CAHN
		<u>ALCLOMETASONE DIPROPIONATE</u>							
		OINTMENT; TOPICAL							
		ACLOVATE							
AB	+	NYCOMED US	0.05%		N018702	001	Dec 14, 1982	Mar	CAHN
		<u>ALENDRONATE SODIUM</u>							
		TABLET; ORAL							
		ALENDRONATE SODIUM							
AB		MYLAN	EQ 35MG BASE		A078638	001	Aug 04, 2008	Feb	CAHN
AB			EQ 70MG BASE		A078638	002	Aug 04, 2008	Feb	CAHN
		@ SANDOZ	EQ 5MG BASE		A075871	001	Apr 22, 2009	Mar	DISC
		@	EQ 10MG BASE		A075871	002	Apr 22, 2009	Mar	DISC
		@	EQ 35MG BASE		A075871	004	Apr 22, 2009	Mar	DISC
		@	EQ 40MG BASE		A075871	003	Apr 22, 2009	Mar	DISC
		@	EQ 70MG BASE		A075871	005	Apr 22, 2009	Mar	DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

>A> ALFUZOSIN HYDROCHLORIDE

>A>	AB	APOTEX INC	10MG	A079013	001	Jul 18, 2011	Jul	NEWA
>A>	AB	MYLAN	10MG	A079014	001	Jul 18, 2011	Jul	NEWA
>A>	AB	SUN PHARMA GLOBAL	10MG	A079057	001	Jul 18, 2011	Jul	NEWA
>A>	AB	TEVA PHARMS	10MG	A079056	001	Jul 18, 2011	Jul	NEWA
>A>	AB	TORRENT PHARMS	10MG	A079054	001	Jul 18, 2011	Jul	NEWA

UROXATRAL

>D>	+	SANOFI AVENTIS US	10MG	N021287	001	Jun 12, 2003	Jul	CFTG
>A>	AB	+	10MG	N021287	001	Jun 12, 2003	Jul	CFTG

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	IPCA LABS LTD	100MG	A090637	001	Mar 16, 2011	Feb	NEWA
AB		300MG	A090637	002	Mar 16, 2011	Feb	NEWA

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALOPRIM

>D>	AP	+	BIONICHE PHARMA	EQ 500MG BASE/VIAL	N020298	001	May 17, 1996	Jul	CAHN
>A>	AP	+	MYLAN INSTITUTIONAL	EQ 500MG BASE/VIAL	N020298	001	May 17, 1996	Jul	CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB	AUROBINDO PHARMA USA	0.5MG	A090871	001	Jun 07, 2011	May	NEWA
AB		1MG	A090871	002	Jun 07, 2011	May	NEWA
AB		2MG	A090871	003	Jun 07, 2011	May	NEWA
AB		3MG	A090871	004	Jun 07, 2011	May	NEWA

ALPROSTADIL

SUPPOSITORY; URETHRAL

MUSE

	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	May	CAHN
		0.25MG	N020700	002	Nov 19, 1996	May	CAHN
		0.5MG	N020700	003	Nov 19, 1996	May	CAHN
+		1MG	N020700	004	Nov 19, 1996	May	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

>D>	AB	ACTAVIS TOTOWA	100MG	A077659	001	Feb 23, 2006	Jul	DISC
>A>	@		100MG	A077659	001	Feb 23, 2006	Jul	DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	EPIC PHARMA LLC	EQ 2.5MG BASE	A078552	001	Apr 08, 2009	Apr	CAHN	
AB		EQ 5MG BASE	A078552	002	Apr 08, 2009	Apr	CAHN	
AB		EQ 10MG BASE	A078552	003	Apr 08, 2009	Apr	CAHN	
>D>	AB	GEDEON RICHTER USA	EQ 2.5MG BASE	A077333	001	Jul 17, 2007	Jul	DISC
>A>	@		EQ 2.5MG BASE	A077333	001	Jul 17, 2007	Jul	DISC
>D>	AB		EQ 5MG BASE	A077333	002	Jul 17, 2007	Jul	DISC

TABLET; ORAL

AMLODIPINE BESYLATE

>A>	@ GEDEON RICHTER USA	EQ 5MG BASE	A077333 002	Jul 17, 2007	Jul	DISC
>D>	AB	EQ 10MG BASE	A077333 003	Jul 17, 2007	Jul	DISC
>A>	@	EQ 10MG BASE	A077333 003	Jul 17, 2007	Jul	DISC
AB	HIKMA PHARMS	EQ 2.5MG BASE	A077771 001	Apr 12, 2011	Mar	NEWA
AB		EQ 5MG BASE	A077771 002	Apr 12, 2011	Mar	NEWA
AB		EQ 10MG BASE	A077771 003	Apr 12, 2011	Mar	NEWA
AB	PURACAP PHARM	EQ 2.5MG BASE	A078131 001	Sep 04, 2007	May	CAHN
AB		EQ 5MG BASE	A078131 002	Sep 04, 2007	May	CAHN
AB		EQ 10MG BASE	A078131 003	Sep 04, 2007	May	CAHN
AB	SECAN PHARMS	EQ 5MG BASE	A090752 001	Apr 15, 2011	Apr	NEWA
AB		EQ 10MG BASE	A090752 002	Apr 15, 2011	Apr	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	DR REDDYS LABS INC	EQ 5MG BASE;40MG	A090149 001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A090149 002	Jul 05, 2011	Jun	NEWA
AB	LUPIN PHARMS	EQ 5MG BASE;40MG	A078466 005	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A078466 006	Jul 05, 2011	Jun	NEWA
AB	MYLAN	EQ 5MG BASE;40MG	A079047 001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A079047 002	Jul 05, 2011	Jun	NEWA
AB	TEVA PHARMS	EQ 5MG BASE;40MG	A077179 005	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A077179 006	Jul 05, 2011	Jun	NEWA
AB	WATSON LABS INC	EQ 5MG BASE;40MG	A090364 001	Jul 05, 2011	Jun	NEWA
AB		EQ 10MG BASE;40MG	A090364 002	Jul 05, 2011	Jun	NEWA
	LOTREL					
AB	NOVARTIS	EQ 5MG BASE;40MG	N020364 007	Apr 11, 2006	Jan	CFTG
AB	+	EQ 10MG BASE;40MG	N020364 006	Apr 11, 2006	Jan	CFTG

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	AM ANTIBIOTICS	250MG	A062058 001		Feb	CDFR
AB		500MG	A062058 002		Feb	CDFR

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+	DAVA PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824 001	Feb 08, 2011	Feb	NEWA
---	-----------------	--	-------------	--------------	-----	------

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

AP	+	X GEN PHARMS	50MG/VIAL	A063206 001	Apr 29, 1992	Jun	CRLD
		FUNGIZONE					
		@ APOTHECON	50MG/VIAL	A060517 001		Jun	DISC
		INJECTABLE, LIPID COMPLEX; INJECTION					
		AMPHOTEC					
>A>	+	ALDOPHARMA USA	50MG/VIAL	N050729 001	Nov 22, 1996	Jul	CAHN
>A>	+		100MG/VIAL	N050729 002	Nov 22, 1996	Jul	CAHN
>D>	+	THREE RIVERS PHARMS	50MG/VIAL	N050729 001	Nov 22, 1996	Jul	CAHN
>D>	+		100MG/VIAL	N050729 002	Nov 22, 1996	Jul	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340 001	Sep 20, 2010	Apr	CAIN
AP		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090349 001	Sep 20, 2010	Apr	CAIN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349 002	Sep 20, 2010	Apr	CAIN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340 002	Sep 20, 2010	Apr	CAIN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090339 001	Sep 20, 2010	Apr	CAIN

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

>D>	AB	DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982 001	Feb 10, 1989	Jul	CTEC
>A>			EQ 125MG BASE/5ML	A062982 001	Feb 10, 1989	Jul	CTEC
>D>		PRINCIPEN					
>D>	AB	APOTHECON	EQ 125MG BASE/5ML	A061394 002		Jul	DISC
>A>		@	EQ 125MG BASE/5ML	A061394 002		Jul	DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	SANTOS BIOTECH	1MG	A078944 001	Jun 28, 2010	Feb	CAHN	
>A>	AB	SUN PHARM INDS LTD	1MG	A091177 001	Jul 15, 2011	Jul	NEWA
>D>	AB	SYNTHON PHARMS	1MG	A078322 001	Jun 28, 2010	Jul	DISC
>A>		@	1MG	A078322 001	Jun 28, 2010	Jul	DISC

ARGATROBAN

INJECTABLE; IV (INFUSION)

ARGATROBAN IN SODIUM CHLORIDE

+	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434 001	Jun 29, 2011	Jun	NEWA
+	SANDOZ	125MG/125ML (1MG/ML)	N022485 001	May 09, 2011	May	NEWA

SOLUTION; IV (INFUSION)

ARGATROBAN IN DEXTROSE

@	SANDOZ	125MG/125ML (1MG/ML)	N201743 001	May 09, 2011	May	DISC
---	--------	----------------------	-------------	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@	PURACAP PHARM	325MG;50MG;40MG	A087048 002	Dec 09, 1983	Jun	CAHN
---	---------------	-----------------	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	MIRROR PHARMS	325MG;200MG	A040832 001	Jan 07, 2010	Mar	CAHN
AB	PROSAM LABS	325MG;200MG	A040252 001	Dec 10, 1997	Feb	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	MIRROR PHARMS	325MG;200MG;16MG	A040860 001	Jan 07, 2010	Mar	CAHN
AB	PROSAM LABS	325MG;200MG;16MG	A040283 001	Dec 29, 1998	Feb	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA	COASTAL PHARMS	325MG;4.8355MG	A091670 001	Mar 16, 2011	Feb	NEWA
AA	WATSON LABS	325MG;4.8355MG	A090084 001	Mar 22, 2011	Mar	NEWA
PERCODAN						
AA	+ ENDO PHARMS	325MG;4.8355MG	N007337 007	Aug 05, 2005	Feb	CFTG

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	MYLAN	25MG	A074126 003	Aug 26, 1998	Feb	CAHN
AB		50MG	A074126 001	Mar 23, 1994	Feb	CAHN
AB		100MG	A074126 002	Mar 23, 1994	Feb	CAHN

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	250MG;100MG	A091211 001	Jan 12, 2011	Jan	NEWA
MALARONE						
AB	+ GLAXOSMITHKLINE	250MG;100MG	N021078 001	Jul 14, 2000	Jan	CFTG

ATROPINE

INJECTABLE; INJECTION

ATROPINE

>D>	@ SOLVAY	EQ 2MG SULFATE/0.7ML	A071295 001	Jan 30, 1987	Jul	CAHN
>A>	@	EQ 2MG SULFATE/0.7ML	A071295 001	Jan 30, 1987	Jul	CAHN

AZILSARTAN MEDOXOMIL

TABLET; ORAL

EDARBI

	TAKEDA PHARMS	40MG	N200796 001	Feb 25, 2011	Feb	NEWA
	+	80MG	N200796 002	Feb 25, 2011	Feb	NEWA

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

>A>	AB APOTEX CORP	EQ 250MG BASE	A065507 001	Jul 13, 2011	Jul	NEWA
>A>	AB	EQ 500MG BASE	A065509 001	Jul 13, 2011	Jul	NEWA
>A>	AB	EQ 600MG BASE	A065508 001	Jul 13, 2011	Jul	NEWA

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

AP	BEDFORD	1GM/VIAL	A065286 001	Mar 23, 2011	Mar	NEWA
AP		2GM/VIAL	A065286 002	Mar 23, 2011	Mar	NEWA

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

	+ FERA PHARMS	500 UNITS/GM	A061212 001		Feb	CAHN
	+ NYCOMED US	500 UNITS/GM	A061212 001		Jan	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	FERA PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764 002		Feb	CAHN
AT	NYCOMED US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764 002		Jan	CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	FERA PHARMS	500 UNITS/GM;10,000 UNITS/GM	A065022 001	Feb 27, 2002	Feb	CAHN
AT	NYCOMED US	500 UNITS/GM;10,000 UNITS/GM	A065022 001	Feb 27, 2002	Jan	CAHN

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+	FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002		Feb	CAHN
+	NYCOMED US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002		Jan	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP	CNS THERAPS INC	0.05MG/ML	N022462 001	Nov 19, 2010	Feb	CTEC	
AP		0.5MG/ML	N022462 002	Nov 19, 2010	Feb	CTEC	
AP		2MG/ML	N022462 003	Nov 19, 2010	Feb	CTEC	
AP	+	LIORESAL					
AP	+	MEDTRONIC	0.05MG/ML	N020075 003	Nov 07, 1996	Feb	CTEC
AP	+		0.5MG/ML	N020075 001	Jun 17, 1992	Feb	CTEC
AP	+		2MG/ML	N020075 002	Jun 17, 1992	Feb	CTEC

TABLET; ORAL

BACLOFEN

AB	PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb	CAHN
AB		20MG	A077088 001	Oct 31, 2007	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB	PRINSTON PHARM LLC	5MG	A076118 001	Feb 11, 2004	May	CAHN
AB		10MG	A076118 002	Feb 11, 2004	May	CAHN
AB		20MG	A076118 003	Feb 11, 2004	May	CAHN
AB		40MG	A076118 004	Feb 11, 2004	May	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	5MG;6.25MG	A076612 001	Feb 11, 2004	Feb	CAHN
AB		10MG;12.5MG	A076612 002	Feb 11, 2004	Feb	CAHN
AB		20MG;12.5MG	A076612 003	Feb 11, 2004	Feb	CAHN
AB		20MG;25MG	A076612 004	Feb 11, 2004	Feb	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP LUITPOLD 1MG/ML A091152 001 Mar 29, 2010 Feb CAHN

TABLET; ORAL

BENZTROPINE MESYLATE

>D> AA ACTAVIS TOTOWA 0.5MG A040699 001 Feb 14, 2008 Jul DISC
 >A> @ 0.5MG A040699 001 Feb 14, 2008 Jul DISC
 >D> AA 1MG A040705 001 Feb 14, 2008 Jul DISC
 >A> @ 1MG A040705 001 Feb 14, 2008 Jul DISC
 >D> AA 2MG A040706 001 Feb 14, 2008 Jul DISC
 >A> @ 2MG A040706 001 Feb 14, 2008 Jul DISC

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB STI PHARMA LLC EQ 0.1% BASE A070052 001 Jul 31, 1985 Apr CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

>D> AA ACTAVIS TOTOWA 5MG A040552 001 Oct 28, 2004 Jul DISC
 >A> @ 5MG A040552 001 Oct 28, 2004 Jul DISC
 >D> AA 10MG A040553 001 Oct 28, 2004 Jul DISC
 >A> @ 10MG A040553 001 Oct 28, 2004 Jul DISC
 >D> AA 25MG A040554 001 Oct 28, 2004 Jul DISC
 >A> @ 25MG A040554 001 Oct 28, 2004 Jul DISC

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB ROXANE 50MG A078285 001 Mar 24, 2011 Mar NEWA

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

+ AXCAN 140MG;125MG;125MG N050786 001 Sep 28, 2006 Jun CAHN

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

+ SCHERING 200MG N202258 001 May 13, 2011 May NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

@ HOSPIRA 50MG/ML N019030 001 Apr 29, 1986 Jun DISC

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

+ ISTA PHARMS INC 0.09% N021664 002 Oct 16, 2010 Mar CRLD

BROMFENAC SODIUM

COASTAL PHARMS 0.09% A201211 001 May 11, 2011 Apr NEWA

SOLUTION/DROPS; OPHTHALMIC

XIBROM

@	ISTA PHARMS INC	0.09%	N021664	001	Mar 24, 2005	Mar	DISC
---	-----------------	-------	---------	-----	--------------	-----	------

BUDESONIDE

CAPSULE; ORAL

BUDESONIDE

AB	MYLAN	3MG	A090410	001	May 16, 2011	May	NEWA
----	-------	-----	---------	-----	--------------	-----	------

ENTOCORT EC

AB	+	ASTRAZENECA	3MG	N021324	001	Oct 02, 2001	May	CFTG
----	---	-------------	-----	---------	-----	--------------	-----	------

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

@	AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496	001	May 23, 2003	Jun	CAHN
---	----------------------	--	---------	-----	--------------	-----	------

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

	VALEANT INTL	174MG	N022108	001	Apr 23, 2008	Jun	CAHN
--	--------------	-------	---------	-----	--------------	-----	------

+		348MG	N022108	002	Apr 23, 2008	Jun	CAHN
---	--	-------	---------	-----	--------------	-----	------

		522MG	N022108	003	Apr 23, 2008	Jun	CAHN
--	--	-------	---------	-----	--------------	-----	------

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1	ANCHEN PHARMS	100MG	A091459	001	Jun 09, 2011	May	NEWA
-----	---------------	-------	---------	-----	--------------	-----	------

AB1		150MG	A091459	002	Jun 09, 2011	May	NEWA
-----	--	-------	---------	-----	--------------	-----	------

AB2		150MG	A091520	001	Jun 09, 2011	May	NEWA
-----	--	-------	---------	-----	--------------	-----	------

AB1		200MG	A091459	003	Jun 09, 2011	May	NEWA
-----	--	-------	---------	-----	--------------	-----	------

AB1	WATSON LABS FLORIDA	100MG	A079095	001	Mar 24, 2009	May	CAHN
-----	---------------------	-------	---------	-----	--------------	-----	------

AB1		150MG	A079095	002	Mar 24, 2009	May	CAHN
-----	--	-------	---------	-----	--------------	-----	------

AB2		150MG	A079094	001	Mar 24, 2009	May	CAHN
-----	--	-------	---------	-----	--------------	-----	------

AB1		200MG	A079095	003	Mar 24, 2009	May	CAHN
-----	--	-------	---------	-----	--------------	-----	------

WELLBUTRIN XL

>D>	AB3	+	BIOVAIL LABS INTL	150MG	N021515	001	Aug 28, 2003	Jul	CAHN
-----	-----	---	-------------------	-------	---------	-----	--------------	-----	------

>D>	AB3			300MG	N021515	002	Aug 28, 2003	Jul	CAHN
-----	-----	--	--	-------	---------	-----	--------------	-----	------

>A>	AB3	+	VALEANT INTL	150MG	N021515	001	Aug 28, 2003	Jul	CAHN
-----	-----	---	--------------	-------	---------	-----	--------------	-----	------

>A>	AB3			300MG	N021515	002	Aug 28, 2003	Jul	CAHN
-----	-----	--	--	-------	---------	-----	--------------	-----	------

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

>D>	AB		ACTAVIS TOTOWA	5MG	A075388	001	May 09, 2002	Jul	DISC
-----	----	--	----------------	-----	---------	-----	--------------	-----	------

>A>		@		5MG	A075388	001	May 09, 2002	Jul	DISC
-----	--	---	--	-----	---------	-----	--------------	-----	------

>D>	AB			10MG	A075388	002	May 09, 2002	Jul	DISC
-----	----	--	--	------	---------	-----	--------------	-----	------

>A>		@		10MG	A075388	002	May 09, 2002	Jul	DISC
-----	--	---	--	------	---------	-----	--------------	-----	------

>D>	AB			15MG	A075388	003	May 09, 2002	Jul	DISC
-----	----	--	--	------	---------	-----	--------------	-----	------

>A>		@		15MG	A075388	003	May 09, 2002	Jul	DISC
-----	--	---	--	------	---------	-----	--------------	-----	------

>D>	AB			30MG	A078302	001	Dec 17, 2007	Jul	DISC
-----	----	--	--	------	---------	-----	--------------	-----	------

>A>		@		30MG	A078302	001	Dec 17, 2007	Jul	DISC
-----	--	---	--	------	---------	-----	--------------	-----	------

CALCIPOTRIENE

SOLUTION; TOPICAL
 CALCIPOTRIENE
 AT G AND W LABS INC 0.005% A078468 001 Mar 24, 2011 Mar NEWA

CALCIUM ACETATE

SOLUTION; ORAL
 PHOSLYRA
 + FRESENIUS MEDCL EQ 169MG CALCIUM/5ML N022581 001 Apr 18, 2011 Apr NEWA
 TABLET; ORAL
 CALCIUM ACETATE
 AB PADDOCK LABS EQ 169MG CALCIUM A091561 001 Apr 13, 2011 Mar NEWA
 ELIPHOS
 AB + CYPRESS PHARM EQ 169MG CALCIUM A078502 001 Nov 25, 2008 Mar CTEC

CAPTOPRIL

TABLET; ORAL
 CAPTOPRIL
 AB PRINSTON PHARM LLC 12.5MG A074477 001 Feb 13, 1996 May CAHN
 AB 25MG A074477 002 Feb 13, 1996 May CAHN
 AB 50MG A074477 003 Feb 13, 1996 May CAHN
 AB 100MG A074477 004 Feb 13, 1996 May CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL
 CARBAMAZEPINE
 AB NOSTRUM 100MG A076697 001 May 20, 2011 May NEWA
 AB 200MG A076697 002 May 20, 2011 May NEWA
 AB 300MG A076697 003 May 20, 2011 May NEWA
 CARBATROL
 AB SHIRE 100MG N020712 003 Sep 30, 1997 May CFTG
 AB 200MG N020712 001 Sep 30, 1997 May CFTG
 AB + 300MG N020712 002 Sep 30, 1997 May CFTG
 TABLET, CHEWABLE; ORAL
 CARBAMAZEPINE
 @ JUBILANT CADISTA 100MG A071940 001 Feb 01, 1988 Jan CAHN

CARBIDOPA; LEVODOPA

TABLET; ORAL
 SINEMET
 AB MERCK SHARP DOHME 10MG;100MG N017555 001 Jan CAHN
 AB 25MG;100MG N017555 003 Jan CAHN
 AB + 25MG;250MG N017555 002 Jan CAHN
 TABLET, EXTENDED RELEASE; ORAL
 SINEMET CR
 AB MERCK SHARP DOHME 25MG;100MG N019856 002 Dec 24, 1992 Jan CAHN
 AB + 50MG;200MG N019856 001 May 30, 1991 Jan CAHN

CARBINOXAMINE MALEATE

TABLET; ORAL
 CARBINOXAMINE MALEATE
 AA RIVERS EDGE PHARMS 4MG A090756 001 May 27, 2011 May NEWA

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	MIRROR PHARMS	350MG	A040823 001	Oct 22, 2008	Mar	CAHN
AA	PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN

CEFACLOR

TABLET, EXTENDED RELEASE; ORAL

CEFACLOR

>D>	AB	TEVA	EQ 500MG BASE	A065058 002	Sep 04, 2002	Jul	CRLD
>A>		+	EQ 500MG BASE	A065058 002	Sep 04, 2002	Jul	CRLD
>D>	AB	+ WORLD GEN	EQ 500MG BASE	A065057 001	Jan 05, 2001	Jul	DISC
>A>		@	EQ 500MG BASE	A065057 001	Jan 05, 2001	Jul	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065226 001	Apr 21, 2005	Jan	CAHN	
AP		EQ 1GM BASE/VIAL	A065244 001	Aug 12, 2005	Jan	CAHN	
AP		EQ 1GM BASE/VIAL	A065226 002	Apr 21, 2005	Jan	CAHN	
AP		EQ 10GM BASE/VIAL	A065247 001	Aug 12, 2005	Jan	CAHN	
>D>		@ STERI PHARMA	EQ 500MG BASE/VIAL	A063216 001	Dec 27, 1991	Jul	CMFD
>D>		@	EQ 500MG BASE/VIAL	A063214 001	Dec 27, 1991	Jul	CMFD
>A>	AP		EQ 500MG BASE/VIAL	A063216 001	Dec 27, 1991	Jul	CMFD
>A>	AP		EQ 500MG BASE/VIAL	A063214 001	Dec 27, 1991	Jul	CMFD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065369 001	Jun 18, 2007	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065369 002	Jun 18, 2007	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065369 003	Jun 18, 2007	Jan	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065290 001	Aug 11, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065293 001	Aug 10, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065290 002	Aug 11, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065293 002	Aug 10, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065290 003	Aug 11, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065292 001	Aug 10, 2006	Jan	CAHN

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065313 001	Jan 23, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065313 002	Jan 23, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065312 001	Feb 13, 2006	Jan	CAHN

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

AB	+ SANDOZ	EQ 200MG BASE	A065462 002	May 28, 2008	Jan	CRLD
----	----------	---------------	-------------	--------------	-----	------

TABLET; ORAL

VANTIN

@ PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674 001	Aug 07, 1992	Jan	DISC
@	EQ 200MG BASE	N050674 002	Aug 07, 1992	Jan	DISC

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME IN DEXTROSE CONTAINER

B BRAUN	EQ 1GM BASE	N050823 001	Jun 13, 2011	Jun	NEWA
+	EQ 2GM BASE	N050823 002	Jun 13, 2011	Jun	NEWA

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A065230 001	Aug 02, 2005	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A065230 002	Aug 02, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065230 003	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065230 004	Aug 02, 2005	Jan	CAHN

INJECTABLE; INJECTION

CEFTRIAZONE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231 001	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065231 002	Aug 02, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065232 001	Aug 02, 2005	Jan	CAHN
AP	+ SANDOZ	EQ 10GM BASE/VIAL	A065168 001	May 17, 2005	Jan	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	ALKEM LABS LTD	EQ 250MG BASE	A065496 001	Jun 07, 2010	May	CAHN
AB		EQ 500MG BASE	A065496 002	Jun 07, 2010	May	CAHN
AB	APOTEX	EQ 250MG BASE	A065069 001	Oct 02, 2002	Jun	CAHN
AB		EQ 500MG BASE	A065069 002	Oct 02, 2002	Jun	CAHN

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	A065048 001	Jan 09, 2004	Mar	CTEC
AP	HOSPIRA INC	EQ 750MG BASE/VIAL	A065483 001	Oct 15, 2008	Jan	CAHN

INJECTABLE; INJECTION

CEFUROXIME SODIUM

AP	HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483 002	Oct 15, 2008	Jan	CAHN
AP		EQ 1.5GM BASE/VIAL	A065503 001	Oct 15, 2008	Jan	CAHN
AP		EQ 7.5GM BASE/VIAL	A065484 001	Oct 15, 2008	Jan	CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

AB	@ ACS DOBFAR	EQ 100MG BASE/ML	A062117 001		Jan	CAHN
AB		EQ 125MG BASE/5ML	A062117 002		Jan	CAHN
AB	+	EQ 250MG BASE/5ML	A062117 003		Jan	CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT	LYNE	0.12%	A074291 001	Dec 28, 1995	Feb	CAHN
----	------	-------	-------------	--------------	-----	------

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA	NATCO PHARMA LTD	EQ 150MG BASE	A091621 001	Jan 21, 2011	Jan	NEWA
AA		EQ 300MG BASE	A090612 001	Jan 21, 2011	Jan	NEWA

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

>A>	AP	SUN PHARMA GLOBAL	EQ 500MG BASE/VIAL	A091546 001	Jul 26, 2011	Jul	NEWA
-----	----	-------------------	--------------------	-------------	--------------	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

ZUTRIPRO

+	CYPRESS PHARM	4MG/5ML;5MG/5ML;60MG/5ML	N022439 001	Jun 08, 2011	Jun	NEWA
---	---------------	--------------------------	-------------	--------------	-----	------

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

>D>	AA	ACTAVIS TOTOWA	250MG	A088928 001	May 08, 1987	Jul	DISC
>A>		@	250MG	A088928 001	May 08, 1987	Jul	DISC
>D>	AA		500MG	A040113 001	Sep 29, 1995	Jul	DISC
>A>		@	500MG	A040113 001	Sep 29, 1995	Jul	DISC

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074557 001	Aug 15, 1996	Apr	CRLD
----	---	--------	---------------------	-------------	--------------	-----	------

CHOLESTYRAMINE LIGHT

AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074558 001	Aug 15, 1996	Apr	CRLD
----	---	--------	---------------------	-------------	--------------	-----	------

QUESTRAN

@	BRISTOL MYERS	EQ 4GM RESIN/SCOOPFUL	N016640 003			Apr	DISC
---	---------------	-----------------------	-------------	--	--	-----	------

@		EQ 4GM RESIN/PACKET	N016640 001			Apr	DISC
---	--	---------------------	-------------	--	--	-----	------

QUESTRAN LIGHT

@	BRISTOL MYERS	EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Apr	DISC
---	---------------	---------------------	-------------	--------------	-----	------

@		EQ 4GM RESIN/SCOOPFUL	N019669 003	Dec 05, 1988	Apr	DISC
---	--	-----------------------	-------------	--------------	-----	------

AB	+		EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Mar	CRLD
----	---	--	---------------------	-------------	--------------	-----	------

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

AT		TARO	1%	A090269 001	Feb 23, 2011	Feb	NEWA
----	--	------	----	-------------	--------------	-----	------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

>D>	AB	ACTAVIS TOTOWA	100MG	A077028 002	Nov 26, 2004	Jul	DISC
>A>		@	100MG	A077028 002	Nov 26, 2004	Jul	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PROQUIN XR

@	DEPOMED INC	EQ 500MG BASE	N021744 001	May 19, 2005	May	DISC
---	-------------	---------------	-------------	--------------	-----	------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166 002	Nov 27, 2007	Jun	CMFD
AB		425.2MG;EQ 574.9MG BASE	A078166 001	Nov 27, 2007	Jun	CMFD

CISPLATIN

INJECTABLE; INJECTION

PLATINOL

@	BRISTOL MYERS	50MG/VIAL	N018057 002		Jun	DISC
---	---------------	-----------	-------------	--	-----	------

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	MYLAN	EQ 10MG BASE	A077042 001	Nov 05, 2004	Apr	CAHN
AB		EQ 20MG BASE	A077042 002	Nov 05, 2004	Apr	CAHN
AB		EQ 40MG BASE	A077042 003	Nov 05, 2004	Apr	CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	MATRIX LABS LTD	EQ 75MG BASE	A091225 001	May 31, 2011	May	NEWA
AB		EQ 150MG BASE	A091225 002	May 31, 2011	May	NEWA
AB		EQ 300MG BASE	A091225 003	May 31, 2011	May	NEWA

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAGEL

BT	+ GALDERMA LABS LP	EQ 1% BASE	N050782 001	Nov 27, 2000	Mar	CRLD
----	--------------------	------------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

@	COREPHARMA	EQ 1% BASE	A064108 001	Sep 27, 1996	Apr	CAHN
---	------------	------------	-------------	--------------	-----	------

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

OLUX

AB	+ STIEFEL LABS INC	0.05%	N021142 001	May 26, 2000	May	CAHN
----	--------------------	-------	-------------	--------------	-----	------

CREAM; TOPICAL

CLOBETASOL PROPIONATE

@	COREPHARMA	0.05%	A075338 001	Feb 09, 2001	Apr	CAHN
---	------------	-------	-------------	--------------	-----	------

CLOBETASOL PROPIONATE (EMOLLIENT)

@	COREPHARMA	0.05%	A075733 001	Aug 22, 2001	Apr	CAHN
---	------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

@	COREPHARMA	0.05%	A075057 001	Aug 12, 1998	Apr	CAHN
---	------------	-------	-------------	--------------	-----	------

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

AB	ACTAVIS MID ATLANTIC	0.05%	A078854 001	Jun 07, 2011	May	NEWA
----	----------------------	-------	-------------	--------------	-----	------

CLOBEX

AB	+ GALDERMA LABS	0.05%	N021644 001	Feb 05, 2004	May	CFTG
----	-----------------	-------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT	NYCOMED US	0.05%	A075391 001	Feb 08, 1999	Apr	CAHN
----	------------	-------	-------------	--------------	-----	------

SPRAY; TOPICAL

CLOBETASOL PROPIONATE									
AT	PADDOCK LABS	0.05%	A090898	001	Jun 16, 2011	May	NEWA		
CLOBEX									
AT	+ GALDERMA LABS LP	0.05%	N021835	001	Oct 27, 2005	Jun	CTEC		
	+	0.05%	N021835	001	Oct 27, 2005	May	CFTG		

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

+	PROMIUS PHARMA LLC	0.1%	N017765	001		Jun	CAHN		
---	--------------------	------	---------	-----	--	-----	------	--	--

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AP	APP PHARMS	1MG/10ML (0.1MG/ML)	A200673	001	Jul 08, 2011	Jun	NEWA		
AP		5MG/10ML (0.5MG/ML)	A200673	002	Jul 08, 2011	Jun	NEWA		
>A>	AP	HIKMA FARMACEUTICA	1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011	Jul	CAHN	
>A>	AP		5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jul	CAHN	
>D>	AP	WEST WARD	1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011	Jul	CAHN	
	AP		1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011	Jan	NEWA	
>D>	AP		5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jul	CAHN	
	AP		5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jan	NEWA	

CODEINE SULFATE

SOLUTION; ORAL

CODEINE SULFATE

+	ROXANE	30MG/5ML	N202245	001	Jun 30, 2011	Jun	NEWA		
---	--------	----------	---------	-----	--------------	-----	------	--	--

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

AB	MIRROR PHARMS	0.5MG;500MG	A040618	001	May 13, 2008	Mar	CAHN		
----	---------------	-------------	---------	-----	--------------	-----	------	--	--

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

AP	+ AMPHASTAR PHARMS INC	0.25MG/VIAL	N016750	001		Jun	CAHN		
----	------------------------	-------------	---------	-----	--	-----	------	--	--

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB	ANESTA AG	15MG	N021777	001	Feb 01, 2007	Apr	CFTG		
AB	+	30MG	N021777	002	Feb 01, 2007	Apr	CFTG		
CYCLOBENZAPRINE HYDROCHLORIDE									
AB	MYLAN	15MG	A090738	001	Apr 18, 2011	Apr	NEWA		
AB		30MG	A090738	002	Apr 18, 2011	Apr	NEWA		

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	JUBILANT CADISTA	5MG	A077563	001	Apr 19, 2006	Jan	CAHN		
AB		10MG	A077563	002	Apr 19, 2006	Jan	CAHN		
AB	KVK TECH	5MG	A078048	001	Feb 28, 2011	Feb	NEWA		
AB		10MG	A078048	002	Feb 28, 2011	Feb	NEWA		
AB	PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN		
AB		10MG	A077209	001	Oct 04, 2005	Feb	CAHN		

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

>D>	AB	ACTAVIS TOTOWA	25MG	A076686 001	Oct 24, 2005	Jul	DISC
>A>		@	25MG	A076686 001	Oct 24, 2005	Jul	DISC
>D>	AB		50MG	A076686 002	Oct 24, 2005	Jul	DISC
>A>		@	50MG	A076686 002	Oct 24, 2005	Jul	DISC
>D>	AB		100MG	A076686 003	Oct 24, 2005	Jul	DISC
>A>		@	100MG	A076686 003	Oct 24, 2005	Jul	DISC

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

ENABLEX

		WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513 001	Dec 22, 2004	May	CAHN
	+		EQ 15MG BASE	N021513 002	Dec 22, 2004	May	CAHN

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

		@ TIBOTEC	EQ 300MG BASE	N021976 001	Jun 23, 2006	May	DISC
--	--	-----------	---------------	-------------	--------------	-----	------

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

	+	GALEN (UK)	EQ 2MG BASE/ML	N050704 002	Apr 08, 1996	Jun	CAHN
--	---	------------	----------------	-------------	--------------	-----	------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

		@ COREPHARMA	75MG	N050261 001		May	CAHN
AB			150MG	N050261 002		May	CAHN
AB	+		300MG	N050261 003		May	CAHN
			DEMECLOCYCLINE HYDROCHLORIDE				
AB		VERSAPHARM	150MG	A065389 001	Dec 01, 2008	May	CAHN
AB			300MG	A065389 002	Dec 01, 2008	May	CAHN

DESLORATADINE

TABLET; ORAL

DESLORATADINE

AB		DR REDDYS LABS LTD	5MG	A078365 001	Mar 08, 2011	Feb	NEWA
----	--	--------------------	-----	-------------	--------------	-----	------

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

AB	+	SCHERING	5MG;240MG	N021605 001	Mar 03, 2005	Apr	CFTG
			DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR				
AB		DR REDDYS LABS LTD	5MG;240MG	A078366 001	Apr 26, 2011	Apr	NEWA

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

STIMATE

		@ CSL BEHRING	0.15MG/SPRAY	N020355 001	Mar 07, 1994	May	DISC
--	--	---------------	--------------	-------------	--------------	-----	------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
 EMOQUETTE
 AB VINTAGE 0.15MG;0.03MG A076675 001 Feb 25, 2011 Feb NEWA

DESOXIMETASONE

GEL; TOPICAL
 DESOXIMETASONE
 AB VERSAPHARM 0.05% A090727 001 Mar 10, 2011 Feb NEWA
 OINTMENT; TOPICAL
 TOPICORT
 + TARO PHARMS NORTH 0.05% N018594 001 Jan 17, 1985 May CMFD

DEXAMETHASONE

ELIXIR; ORAL
 DEXAMETHASONE
 AA LYNE 0.5MG/5ML A090891 001 Jul 12, 2011 Jun NEWA
 AA VINTAGE PHARMS 0.5MG/5ML A091188 001 May 11, 2011 Apr NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
 DEXAMETHASONE SODIUM PHOSPHATE
 AP PFIZER EQ 4MG PHOSPHATE/ML A040803 001 Aug 29, 2008 May CAHN
 AP EQ 10MG PHOSPHATE/ML A040802 001 Aug 29, 2008 May CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE
 AT FERA PHARMS 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM A062938 001 Jul 31, 1989 Feb CAHN
 AT NYCOMED US 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM A062938 001 Jul 31, 1989 Jan CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
 FOCALIN XR
 NOVARTIS 25MG N021802 008 Apr 21, 2011 May NEWA
 35MG N021802 007 Apr 21, 2011 May NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
 DEXEDRINE
 AB COREPHARMA 5MG N017078 001 Jun CAHN
 AB 10MG N017078 002 Jun CAHN
 AB + 15MG N017078 003 Jun CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE
 AA AMNEAL PHARMS 15MG/5ML;6.25MG/5ML A090575 001 Feb 08, 2011 Jan NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER
 AP BAXTER HLTHCARE 5GM/100ML;75MG/100ML N017634 004 Jun CAHN

INJECTABLE; INJECTION

				DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER		
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML	N017634 001		Jun	CAHN
				DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER		
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634 003		Jun	CAHN
				DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML	N017634 002		Jun	CAHN

DICLOFENAC SODIUM

	TABLET, EXTENDED RELEASE; ORAL					
	DICLOFENAC SODIUM					
AB	VALEANT INTL	100MG	A075492 001	Feb 11, 2000	Apr	CAHN

DIETHYLPROPION HYDROCHLORIDE

	TABLET; ORAL					
	DIETHYLPROPION HYDROCHLORIDE					
>A>	AA	LANNETT HOLDINGS INC	25MG	A200177 001	Jul 18, 2011	Jul NEWA

DIFLUPREDNATE

	EMULSION; OPHTHALMIC					
	DUREZOL					
	+	ALCON PHARMS LTD	0.05%	N022212 001	Jun 23, 2008	May CAHN

DIGOXIN

	TABLET; ORAL					
	DIGOXIN					
>D>	AB	ACTAVIS TOTOWA	0.125MG	A040282 001	Dec 23, 1999	Jul DISC
>A>		@	0.125MG	A040282 001	Dec 23, 1999	Jul DISC
>D>	AB		0.25MG	A040282 002	Dec 23, 1999	Jul DISC
>A>		@	0.25MG	A040282 002	Dec 23, 1999	Jul DISC

DILTIAZEM HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL					
	CARDIZEM CD					
AB3	VALEANT INTL	120MG	N020062 001	Aug 10, 1992	Jun	CAHN
AB3		180MG	N020062 002	Dec 27, 1991	Jun	CAHN
AB3		240MG	N020062 003	Dec 27, 1991	Jun	CAHN
AB3	+	300MG	N020062 004	Dec 27, 1991	Jun	CAHN
BC	+	360MG	N020062 005	Aug 24, 1999	Jun	CAHN
	DILTIAZEM HYDROCHLORIDE					
AB3	VALEANT INTL	120MG	A075116 001	Dec 23, 1999	Apr	CAHN
AB3		180MG	A075116 002	Dec 23, 1999	Apr	CAHN
AB3		240MG	A075116 003	Dec 23, 1999	Apr	CAHN
AB3		300MG	A075116 004	Dec 23, 1999	Apr	CAHN
	TIAZAC					
AB4	VALEANT INTL	120MG	N020401 001	Sep 11, 1995	Jun	CAHN
AB4		180MG	N020401 002	Sep 11, 1995	Jun	CAHN
AB4		240MG	N020401 003	Sep 11, 1995	Jun	CAHN
AB4		300MG	N020401 004	Sep 11, 1995	Jun	CAHN
AB4		360MG	N020401 005	Sep 11, 1995	Jun	CAHN
AB4	+	420MG	N020401 006	Oct 16, 1998	Jun	CAHN
	TABLET; ORAL					
	CARDIZEM					
AB	VALEANT INTL	30MG	N018602 001	Nov 05, 1982	Jun	CAHN
AB		60MG	N018602 002	Nov 05, 1982	Jun	CAHN
AB		90MG	N018602 003	Dec 08, 1986	Jun	CAHN

TABLET; ORAL

CARDIZEM

AB	+	VALEANT INTL	120MG	N018602 004	Dec 08, 1986	Jun	CAHN
----	---	--------------	-------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

AB		VALEANT INTL	120MG	N021392 001	Feb 06, 2003	Jun	CAHN
AB			180MG	N021392 002	Feb 06, 2003	Jun	CAHN
AB			240MG	N021392 003	Feb 06, 2003	Jun	CAHN
AB			300MG	N021392 004	Feb 06, 2003	Jun	CAHN
AB			360MG	N021392 005	Feb 06, 2003	Jun	CAHN
AB	+		420MG	N021392 006	Feb 06, 2003	Jun	CAHN

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB		PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb	CAHN
AB			50MG	A040542 002	Apr 21, 2006	Feb	CAHN
AB			75MG	A040542 003	Apr 21, 2006	Feb	CAHN

DISULFIRAM

TABLET; ORAL

ANTABUSE

AB		ODYSSEY PHARMS	250MG	A088482 001	Dec 08, 1983	Mar	CTEC
AB	+		500MG	A088483 001	Dec 08, 1983	Mar	CTEC

DISULFIRAM

AB		SIGMAPHARM LABS LLC	250MG	A091619 001	Mar 28, 2011	Mar	NEWA
AB			500MG	A091619 002	Mar 28, 2011	Mar	NEWA

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DIVALPROEX SODIUM

AB		MYLAN	EQ 125MG VALPROIC ACID	A090407 001	Mar 28, 2011	Mar	NEWA
----	--	-------	------------------------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB		AUROBINDO PHARMA LTD	EQ 125MG VALPROIC ACID	A090554 001	Apr 21, 2011	Apr	NEWA
AB			EQ 250MG VALPROIC ACID	A090554 002	Apr 21, 2011	Apr	NEWA
AB			EQ 500MG VALPROIC ACID	A090554 003	Apr 21, 2011	Apr	NEWA
AB		UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163 001	Apr 05, 2011	Mar	NEWA
AB			EQ 250MG VALPROIC ACID	A079163 002	Apr 05, 2011	Mar	NEWA
AB			EQ 500MG VALPROIC ACID	A079163 003	Apr 05, 2011	Mar	NEWA
AB		WATSON LABS FLORIDA	EQ 500MG VALPROIC ACID	A079080 001	Feb 25, 2011	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCEFREZ

+		SUN PHARMA GLOBAL	20MG/VIAL	N022534 001	May 03, 2011	May	NEWA
+			80MG/VIAL	N022534 002	May 03, 2011	May	NEWA

DOCETAXEL

		ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011	Jun	NEWA
			80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011	Jun	NEWA
AP	+	HOSPIRA INC	20MG/2ML (10MG/ML)	N022234 001	Mar 08, 2011	Jun	CTEC
	+		20MG/2ML (10MG/ML)	N022234 001	Mar 08, 2011	Mar	NEWA
AP	+		80MG/8ML (10MG/ML)	N022234 002	Mar 08, 2011	Jun	CTEC
	+		80MG/8ML (10MG/ML)	N022234 002	Mar 08, 2011	Mar	NEWA
AP	+		160MG/16ML (10MG/ML)	N022234 003	Mar 08, 2011	Jun	CTEC
	+		160MG/16ML (10MG/ML)	N022234 003	Mar 08, 2011	Mar	NEWA

INJECTABLE; INJECTION

DOCETAXEL

AP	SANDOZ	20MG/2ML (10MG/ML)	N201525 001	Jun 29, 2011	Jun	NEWA
AP		80MG/8ML(10MG/ML)	N201525 002	Jun 29, 2011	Jun	NEWA
AP		160MG/16ML (10MG/ML)	N201525 003	Jun 29, 2011	Jun	NEWA
	TAXOTERE					
	@ SANOFI AVENTIS US	40MG/ML	N020449 001	May 14, 1996	Mar	DISC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	ACTAVIS PHARMA	5MG	A090551 001	May 31, 2011	May	NEWA
AB		10MG	A090551 002	May 31, 2011	May	NEWA
AB	APOTEX	5MG	A078841 001	Jun 02, 2011	May	NEWA
AB		10MG	A078841 002	Jun 02, 2011	May	NEWA
AB	AUROBINDO	5MG	A090056 001	May 31, 2011	May	NEWA
AB		10MG	A090056 002	May 31, 2011	May	NEWA
AB	CIPLA LTD	5MG	A077518 001	May 31, 2011	May	NEWA
AB		10MG	A077518 002	May 31, 2011	May	NEWA
AB	DR REDDYS LABS LTD	5MG	A201001 001	May 31, 2011	May	NEWA
AB		10MG	A201001 002	May 31, 2011	May	NEWA
AB	HIKMA PHARMS	5MG	A090247 001	May 31, 2011	May	NEWA
AB		10MG	A090247 002	May 31, 2011	May	NEWA
AB	HUAHAI US INC	5MG	A200292 001	May 31, 2011	May	NEWA
AB		10MG	A200292 002	May 31, 2011	May	NEWA
AB	JUBILANT LIFE	5MG	A090768 001	May 31, 2011	May	NEWA
AB		10MG	A090768 002	May 31, 2011	May	NEWA
AB	MATRIX LABS LTD	5MG	A090521 001	May 31, 2011	May	NEWA
AB		10MG	A090521 002	May 31, 2011	May	NEWA
AB	PLIVA HRVATSKA DOO	5MG	A090425 001	May 31, 2011	May	NEWA
AB		10MG	A090425 002	May 31, 2011	May	NEWA
AB	ROXANE	5MG	A078662 001	May 31, 2011	May	NEWA
AB		10MG	A078662 002	May 31, 2011	May	NEWA
AB	SANDOZ	5MG	A090290 001	May 31, 2011	May	NEWA
AB		10MG	A090290 002	May 31, 2011	May	NEWA
AB	SUN PHARM INDS	5MG	A090493 001	May 31, 2011	May	NEWA
AB		10MG	A090493 002	May 31, 2011	May	NEWA
AB	TEVA	5MG	A077344 001	May 31, 2011	May	NEWA
AB		10MG	A077344 002	May 31, 2011	May	NEWA
AB	TORRENT PHARMS	5MG	A090686 001	May 31, 2011	May	NEWA
AB		10MG	A090686 002	May 31, 2011	May	NEWA
AB	WOCKHARDT	5MG	A091267 001	May 31, 2011	May	NEWA
AB		10MG	A091267 002	May 31, 2011	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

AB	SANDOZ	5MG	A091198 001	May 10, 2011	Apr	NEWA
AB		10MG	A091198 002	May 10, 2011	Apr	NEWA
AB	ZYDUS PHARMS USA INC	5MG	A090175 001	May 10, 2011	Apr	NEWA
AB		10MG	A090175 002	May 10, 2011	Apr	NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	IMPAX LABS INC	EQ 150MG BASE	A200065 001	Feb 17, 2011	Jan	NEWA
AB	MYLAN	40MG	A090855 001	Jul 01, 2010	Jan	CDFR
AB	+ PAR PHARM	EQ 150MG BASE	A065055 003	Jul 15, 2005	Feb	CTEC

CAPSULE; ORAL

DOXYCYCLINE

AB	+	PAR PHARM	EQ 150MG BASE	A065055 003	Jul 15, 2005	Jan	CTEC
----	---	-----------	---------------	-------------	--------------	-----	------

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB		WATSON LABS FLORIDA	EQ 50MG BASE	A062031 002	Oct 13, 1982	May	CAHN
AB			EQ 100MG BASE	A062031 001		May	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

LORYNA

AB		SANDOZ	3MG;0.02MG	A079221 001	Mar 28, 2011	Mar	NEWA
----	--	--------	------------	-------------	--------------	-----	------

TABLET; ORAL-28

SYEDA

AB		SANDOZ	3MG;0.03MG	A090114 001	Mar 28, 2011	Mar	NEWA
----	--	--------	------------	-------------	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

SPECTAZOLE

>A>		@ ORTHO JANSSEN	1%	N018751 001	Dec 23, 1982	Jul	CAHN
>D>		@ ORTHONEUTROGENA	1%	N018751 001	Dec 23, 1982	Jul	CAHN

ENALAPRIL MALEATE

TABLET; ORAL

VASOTEC

AB		VALEANT INTL	2.5MG	N018998 005	Jul 26, 1988	Jun	CAHN
AB			5MG	N018998 001	Dec 24, 1985	Jun	CAHN
AB			10MG	N018998 002	Dec 24, 1985	Jun	CAHN
AB	+		20MG	N018998 003	Dec 24, 1985	Jun	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

VASERETIC

AB		VALEANT INTL	5MG;12.5MG	N019221 003	Jul 12, 1995	Jun	CAHN
AB	+		10MG;25MG	N019221 001	Oct 31, 1986	Jun	CAHN

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

LOVENOX

		SANOFI AVENTIS US	300MG/3ML (100MG/ML)	N020164 009	Jan 23, 2003	Feb	CDFR
--	--	-------------------	----------------------	-------------	--------------	-----	------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

AT	+	ALLERGAN	0.05%	N021565 001	Oct 16, 2003	Feb	CFTG
----	---	----------	-------	-------------	--------------	-----	------

EPINASTINE HYDROCHLORIDE

AT		CYPRESS PHARM	0.05%	A090870 001	Mar 14, 2011	Feb	NEWA
----	--	---------------	-------	-------------	--------------	-----	------

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP		MUSTAFA NEVSAT	200MG/100ML (2MG/ML)	A090266 002	Apr 15, 2011	Apr	NEWA
AP			50MG/25ML (2MG/ML)	A090266 001	Apr 15, 2011	Apr	NEWA

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL						
ERYTHROMYCIN						
AB	ARBOR PHARMS INC	250MG	A062746	001	Dec 22, 1986	Jan CAHN
GEL; TOPICAL						
E-GLADES						
AT	COREPHARMA	2%	A065009	001	Mar 18, 2002	Apr CAHN
OINTMENT; OPHTHALMIC						
ERYTHROMYCIN						
AT	+ FERA PHARMS	0.5%	A062447	001	Sep 26, 1983	Feb CAHN
AT	+ NYCOMED US	0.5%	A062447	001	Sep 26, 1983	Jan CAHN
SOLUTION; TOPICAL						
ERYDERM						
	@ ARBOR PHARMS INC	2%	A062290	001		Jan CAHN
ERYTHROMYCIN						
	@ COREPHARMA	2%	A064127	001	Feb 14, 1997	Apr CAHN
SWAB; TOPICAL						
ERYCETE						
>A>	@ ORTHO JANSSEN	2%	N050594	001	Feb 15, 1985	Jul CAHN
>D>	@ ORTHONEUTROGENA	2%	N050594	001	Feb 15, 1985	Jul CAHN
ERYTHROMYCIN						
	@ COREPHARMA	2%	A064128	001	Jul 03, 1996	Apr CAHN
TABLET; ORAL						
ERYTHROMYCIN						
	ARBOR PHARMS INC	250MG	A061621	001		Jan CAHN
	+	500MG	A061621	002		Jan CAHN
TABLET, COATED PARTICLES; ORAL						
PCE						
	ARBOR PHARMS INC	333MG	N050611	001	Sep 09, 1986	Jan CAHN
	+	500MG	N050611	002	Aug 22, 1990	Jan CAHN
TABLET, DELAYED RELEASE; ORAL						
E-MYCIN						
	@ ARBOR PHARMS INC	250MG	A060272	001		Jan CAHN
	@	333MG	A060272	002		Jan CAHN
ERY-TAB						
	+ ARBOR PHARMS INC	250MG	A062298	001		Jan CAHN
	+	333MG	A062298	003	Mar 29, 1982	Jan CAHN
	+	500MG	A062298	002		Jan CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL						
E.E.S.						
AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207	001		Jan CAHN
ERYPED						
AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Jan CAHN
	+	EQ 400MG BASE/5ML	N050207	002		Jan CAHN
SUSPENSION; ORAL						
E.E.S. 200						
AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	A061639	001		Jan CAHN
E.E.S. 400						
AB	+ ARBOR PHARMS INC	EQ 400MG BASE/5ML	A061639	002		Jan CAHN
PEDIAMYCIN						
AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	A062304	001		Jan CAHN
PEDIAMYCIN 400						
AB	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A062304	002		Jan CAHN

TABLET; ORAL

E.E.S. 400

BX	+	ARBOR PHARMS INC	EQ 400MG BASE	A061905 002	Aug 12, 1982	Jan	CAHN
		@	EQ 400MG BASE	A061905 001		Jan	CAHN

ERYTHROMYCIN ETHYLSUCCINATE

BX	+	ARBOR PHARMS INC	EQ 400MG BASE	A061904 001		Jan	CAHN
----	---	------------------	---------------	-------------	--	-----	------

TABLET, CHEWABLE; ORAL

E.E.S.

@ ARBOR PHARMS INC

EQ 200MG BASE

N050297 002

Jan CAHN

ERYPED

@ ARBOR PHARMS INC

EQ 200MG BASE

N050297 003 Jul 05, 1988 Jan CAHN

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

@ ARBOR PHARMS INC

EQ 125MG BASE

A060359 002

Jan CAHN

EQ 250MG BASE

A060359 001

Jan CAHN

+

EQ 500MG BASE

A060359 003

Jan CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ACTIVELLA

AB		NOVO NORDISK INC	0.5MG;0.1MG	N020907 002	Dec 28, 2006	Mar	CTEC
----	--	------------------	-------------	-------------	--------------	-----	------

ESTRADIOL AND NORETHINDRONE ACETATE

AB		BRECKENRIDGE PHARM	0.5MG;0.1MG	A078324 002	Jun 09, 2011	May	NEWA
----	--	--------------------	-------------	-------------	--------------	-----	------

ESTROPIPATE

CREAM; VAGINAL

OGEN

@ PHARMACIA AND UPJOHN

1.5MG/GM

A084710 001

Apr DISC

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

@ TEVA

1MG

A091169 001 May 23, 2011 Jun DISC

AB			1MG	A091169 001	May 23, 2011	May	NEWA
----	--	--	-----	-------------	--------------	-----	------

@ 2MG

A091169 002 May 23, 2011 Jun DISC

AB			2MG	A091169 002	May 23, 2011	May	NEWA
----	--	--	-----	-------------	--------------	-----	------

@ 3MG

A091169 003 May 23, 2011 Jun DISC

AB			3MG	A091169 003	May 23, 2011	May	NEWA
----	--	--	-----	-------------	--------------	-----	------

>A>		@ WOCKHARDT LTD	1MG	A091165 001	Jul 14, 2011	Jul	NEWA
-----	--	-----------------	-----	-------------	--------------	-----	------

>A>		@	2MG	A091165 002	Jul 14, 2011	Jul	NEWA
-----	--	---	-----	-------------	--------------	-----	------

>A>		@	3MG	A091165 003	Jul 14, 2011	Jul	NEWA
-----	--	---	-----	-------------	--------------	-----	------

LUNESTA

SUNOVION PHARMS INC

1MG

N021476 001 Dec 15, 2004 Jun CTEC

AB			1MG	N021476 001	Dec 15, 2004	May	CFTG
----	--	--	-----	-------------	--------------	-----	------

2MG

N021476 002 Dec 15, 2004 Jun CTEC

AB			2MG	N021476 002	Dec 15, 2004	May	CFTG
----	--	--	-----	-------------	--------------	-----	------

+

3MG

N021476 003 Dec 15, 2004 Jun CTEC

AB	+		3MG	N021476 003	Dec 15, 2004	May	CFTG
----	---	--	-----	-------------	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB		WATSON LABS	0.02MG;0.09MG	A079218 001	Jun 06, 2011	May	NEWA
----	--	-------------	---------------	-------------	--------------	-----	------

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

AB	WATSON LABS	0.03MG,0.01MG;0.15MG,N/A	A078834	001	May 31, 2011	May	NEWA
	LYBREL						
AB	+ WYETH PHARMS INC	0.02MG;0.09MG	N021864	001	May 22, 2007	May	CFTG
	SEASONIQUE						
AB	+ TEVA WOMENS	0.03MG,0.01MG;0.15MG,N/A	N021840	001	May 25, 2006	May	CFTG

TABLET; ORAL-21

ALESSE

>A>	@ AKRIMAX PHARMS	0.02MG;0.1MG	N020683	001	Mar 27, 1997	Jul	CAHN
>D>	@ WYETH PHARMS INC	0.02MG;0.1MG	N020683	001	Mar 27, 1997	Jul	CAHN

TABLET; ORAL-28

ALESSE

>A>	@ AKRIMAX PHARMS	0.02MG;0.1MG	N020683	002	Mar 27, 1997	Jul	CAHN
>D>	@ WYETH PHARMS INC	0.02MG;0.1MG	N020683	002	Mar 27, 1997	Jul	CAHN

ORSYTHIA

AB1	VINTAGE PHARMS	0.02MG;0.1MG	A077099	001	May 11, 2011	Apr	NEWA
-----	----------------	--------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

BRIELLYN

AB	GLENMARK GENERICS	0.035MG;0.4MG	A090538	001	Mar 22, 2011	Mar	NEWA
----	-------------------	---------------	---------	-----	--------------	-----	------

TABLET, CHEWABLE; ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

+	WARNER CHILCOTT	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan	CRLD
+	WATSON LABS INC	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jun	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

LO LOESTRIN FE

+	WARNER CHILCOTT CO	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	May	CRLD
---	--------------------	-----------------------	---------	-----	--------------	-----	------

TABLET; ORAL-28

GILDESS FE 1.5/30

AB	VINTAGE	0.03MG;1.5MG	A077075	001	Apr 28, 2005	Jan	CTNA
----	---------	--------------	---------	-----	--------------	-----	------

GILDESS FE 1/20

AB	VINTAGE	0.02MG;1MG	A077077	001	May 20, 2005	Jan	CTNA
----	---------	------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A200494	001	Jun 17, 2011	Jun	NEWA
----	-------------------	---	---------	-----	--------------	-----	------

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479	001	Mar 09, 2011	Feb	NEWA
----	-------------	---	---------	-----	--------------	-----	------

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB	VERSAPHARM	250MG	A040686	001	May 28, 2008	May	CAHN
----	------------	-------	---------	-----	--------------	-----	------

ETODOLAC

CAPSULE; ORAL

ETODOLAC

@ MYLAN

200MG

A075071 001 Sep 30, 1998 Feb CAHN

CAPSULE; ORAL

ETODOLAC

@ MYLAN

300MG

A075071 002 Sep 30, 1998 Feb CAHN

TABLET; ORAL

ETODOLAC

@ MYLAN

400MG

A075012 001 Sep 30, 1998 Feb CAHN

@

500MG

A075012 002 Sep 30, 1998 Feb CAHN

ETONOGESTREL

IMPLANT; IMPLANTATION

NEXPLANON

+ ORGANON USA INC

68MG/IMPLANT

N021529 002 May 31, 2011 May NEWA

ETRAVIRINE

TABLET; ORAL

INTELENCE

TIBOTEC

100MG

N022187 001 Jan 18, 2008 Jan CRLD

+

200MG

N022187 002 Dec 22, 2010 Jan NEWA

EXEMESTANE

TABLET; ORAL

AROMASIN

AB + PHARMACIA AND UPJOHN

25MG

N020753 001 Oct 21, 1999 Mar CFTG

EXEMESTANE

AB ROXANE

25MG

A077431 001 Apr 01, 2011 Mar NEWA

EZOGABINE

TABLET; ORAL

POTIGA

VALEANT PHARMS

50MG

N022345 001 Jun 10, 2011 Jun NEWA

200MG

N022345 002 Jun 10, 2011 Jun NEWA

300MG

N022345 003 Jun 10, 2011 Jun NEWA

+

400MG

N022345 004 Jun 10, 2011 Jun NEWA

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

>A> AB APOTEX 125MG

A091480 001 Jul 22, 2011 Jul NEWA

>A> AB 250MG

A091480 002 Jul 22, 2011 Jul NEWA

>A> AB 500MG

A091480 003 Jul 22, 2011 Jul NEWA

AB AUROBINDO PHARMA LTD 125MG

A091114 001 Mar 21, 2011 Mar NEWA

AB 250MG

A091114 002 Mar 21, 2011 Mar NEWA

AB 500MG

A091114 003 Mar 21, 2011 Mar NEWA

AB MYLAN 125MG

A201333 001 Mar 24, 2011 Mar NEWA

AB 250MG

A201333 002 Mar 24, 2011 Mar NEWA

AB 500MG

A201333 003 Mar 24, 2011 Mar NEWA

AB ROXANE 125MG

A090128 001 Mar 21, 2011 Mar NEWA

AB 250MG

A090128 002 Mar 21, 2011 Mar NEWA

AB 500MG

A090128 003 Mar 21, 2011 Mar NEWA

AB WATSON LABS 125MG

A078278 001 Mar 21, 2011 Mar NEWA

AB 250MG

A078278 002 Mar 21, 2011 Mar NEWA

AB 500MG

A078278 003 Mar 21, 2011 Mar NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP	PFIZER	10MG/ML	A078641	001	Jun 25, 2008	May	CAHN
	FAMOTIDINE PRESERVATIVE FREE						
AP	PFIZER	10MG/ML	A078642	001	Jun 25, 2008	May	CAHN
	PEPCID						
	@ MERCK	10MG/ML	N019510	001	Nov 04, 1986	Jan	DISC
	PEPCID PRESERVATIVE FREE						
	@ MERCK	10MG/ML	N019510	004	Nov 04, 1986	Jan	DISC
	PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER						
	@ MERCK	0.4MG/ML	N020249	001	Feb 18, 1994	Jan	DISC

TABLET; ORAL

FAMOTIDINE

>D>	AB	ALEMBIC LTD	20MG	A078916	001	May 22, 2009	Jul	CAHN
>D>	AB		40MG	A078916	002	May 22, 2009	Jul	CAHN
>A>	AB	ALEMBIC PHARMS LTD	20MG	A078916	001	May 22, 2009	Jul	CAHN
>A>	AB		40MG	A078916	002	May 22, 2009	Jul	CAHN
	AB	MYLAN	20MG	A075457	001	Apr 18, 2001	Feb	CAHN
	AB		40MG	A075457	002	Apr 18, 2001	Feb	CAHN

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

+	HORIZON PHARMA	26.6MG;800MG	N022519	001	Apr 23, 2011	Apr	NEWA
---	----------------	--------------	---------	-----	--------------	-----	------

FENOFIBRATE

TABLET; ORAL

FENOGLIDE

	SHORE THERAP	40MG	N022118	001	Aug 10, 2007	Feb	CAHN
+		120MG	N022118	002	Aug 10, 2007	Feb	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB	MALLINCKRODT INC	100MCG/HR	A077154	004	Feb 09, 2011	Jan	NEWA
	FENTANYL-25						
AB	MALLINCKRODT INC	25MCG/HR	A077154	001	Feb 09, 2011	Jan	NEWA
	FENTANYL-50						
AB	MALLINCKRODT INC	50MCG/HR	A077154	002	Feb 09, 2011	Jan	NEWA
	FENTANYL-75						
AB	MALLINCKRODT INC	75MCG/HR	A077154	003	Feb 09, 2011	Jan	NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

	ARCHIMEDES	100MCG	N022569	001	Jun 30, 2011	Jun	NEWA
+		400MCG	N022569	002	Jun 30, 2011	Jun	NEWA

TABLET; SUBLINGUAL

ABSTRAL

	PROSTRAKAN INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Jan	NEWA
		EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Jan	NEWA
		EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Jan	NEWA
+		EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Jan	NEWA
		EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Jan	NEWA

TABLET; SUBLINGUAL

ABSTRAL

PROSTRAKAN INC

EQ 0.8MG BASE

N022510 006 Jan 07, 2011 Jan NEWA

FIDAXOMICIN

TABLET; ORAL

DIFICID

+ OPTIMER PHARMS

200MG

N201699 001 May 27, 2011 May NEWA

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

AB AMNEAL PHARM

50MG

A078423 001 Mar 07, 2011 Feb NEWA

AB 100MG

A078423 002 Mar 07, 2011 Feb NEWA

AB 150MG

A078423 003 Mar 07, 2011 Feb NEWA

AB 200MG

A078423 004 Mar 07, 2011 Feb NEWA

AB MYLAN 50MG

A076042 001 Jul 29, 2004 Feb CAHN

AB 100MG

A076042 002 Jul 29, 2004 Feb CAHN

AB 150MG

A076042 003 Jul 29, 2004 Feb CAHN

AB 200MG

A076042 004 Jul 29, 2004 Feb CAHN

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

AB VALEANT

250MG

N017001 001 Jun CFTG

AB + 500MG

N017001 002 Jun CFTG

FLUCYTOSINE

AB SIGMAPHARM LABS LLC 250MG

A201566 001 Jun 28, 2011 Jun NEWA

AB 500MG

A201566 002 Jun 28, 2011 Jun NEWA

FLUDARABINE PHOSPHATE

TABLET; ORAL

OFORTA

+ SANOFI AVENTIS US

10MG

N022273 001 Dec 18, 2008 Apr CMFD

@ 10MG

N022273 001 Dec 18, 2008 Jan DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP + FEINSTEIN 20-200mCi/ML

N021870 001 Aug 19, 2005 Feb CTEC

AP PETNET 20-200mCi/ML

A079086 001 Feb 25, 2011 Feb NEWA

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

>A> AB WEST-WARD PHARM CORP 0.1MG

A091302 001 Jul 22, 2011 Jul NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP PFIZER 0.5MG/5ML (0.1MG/ML)

A078595 001 May 13, 2008 May CAHN

AP 1MG/10ML (0.1MG/ML)

A078595 002 May 13, 2008 May CAHN

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

SYNALAR

AT	+	MEDIMETRIKS PHARMS	0.01%	N012787 004		Jun	CAHN
AT	+		0.025%	N012787 005		Jun	CAHN
AT	+		0.025%	N012787 002		Jun	CAHN

SYNALAR-HP

@ MEDIMETRIKS PHARMS

0.2%

N016161 002

Jun CAHN

OINTMENT; TOPICAL

SYNALAR

AT	+	MEDIMETRIKS PHARMS	0.025%	N013960 001		Jun	CAHN
----	---	--------------------	--------	-------------	--	-----	------

SOLUTION; TOPICAL

SYNALAR

AT	+	MEDIMETRIKS PHARMS	0.01%	N015296 001		Jun	CAHN
----	---	--------------------	-------	-------------	--	-----	------

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP		SANDOZ	2.5GM/50ML (50MG/ML)	A091299 001	May 02, 2011	Apr	NEWA
AP			5GM/100ML (50MG/ML)	A091299 002	May 02, 2011	Apr	NEWA
		@ VALEANT	500MG/10ML (50MG/ML)	N012209 001		Mar	DISC

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1		ALEMBIC PHARMS LTD	EQ 10MG BASE	A090223 001	Mar 19, 2009	Apr	CAHN
AB1			EQ 20MG BASE	A090223 002	Mar 19, 2009	Apr	CAHN
AB			EQ 40MG BASE	A090223 003	Mar 19, 2009	Apr	CAHN

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

>D>	+	WATSON PHARMS	0.025%	N012806 003		Jul	DISC
>A>	@		0.025%	N012806 003		Jul	DISC
>D>	+		0.05%	N012806 002		Jul	DISC
>A>	@		0.05%	N012806 002		Jul	DISC

OINTMENT; TOPICAL

CORDRAN

@ WATSON PHARMS

0.025%

N012806 004

Jun DISC

@

0.05%

N012806 001

Jun DISC

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB		MYLAN	125MG	A076224 001	May 09, 2003	Feb	CAHN
----	--	-------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

LOTION; TOPICAL

CUTIVATE

AB	+	NYCOMED US	0.05%	N021152 001	Mar 31, 2005	Apr	CFTG
----	---	------------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

AB		GLENMARK GENERICS	0.05%	A090759 001	May 02, 2011	Apr	NEWA
----	--	-------------------	-------	-------------	--------------	-----	------

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@	MYLAN	50MG	A075950	001	Oct 15, 2001	Feb	CAHN
@		100MG	A075950	002	Oct 15, 2001	Feb	CAHN

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA	+	AMNEAL PHARM	1MG	A040625	001	Jul 21, 2005	Apr	CAHN
AA		JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005	Jan	CAHN

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

AP	+	GLAXOSMITHKLINE	2.5MG/0.5ML	N021345	001	Dec 07, 2001	Jun	CFTG
AP	+		5MG/0.4ML	N021345	002	May 28, 2004	Jun	CFTG
AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	Jun	CFTG
AP	+		10MG/0.8ML	N021345	004	May 28, 2004	Jun	CFTG

FONDAPARINUX SODIUM

AP		DR REDDYS LABS LTD	2.5MG/0.5ML	A091316	001	Jul 11, 2011	Jun	NEWA
AP			5MG/0.4ML	A091316	002	Jul 11, 2011	Jun	NEWA
AP			7.5MG/0.6ML	A091316	003	Jul 11, 2011	Jun	NEWA
AP			10MG/0.8ML	A091316	004	Jul 11, 2011	Jun	NEWA

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL CERTIHALER

@	NOVARTIS	0.0085MG/INH	N021592	001	Dec 15, 2006	Jun	DISC
---	----------	--------------	---------	-----	--------------	-----	------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB		AUROBINDO PHARMA LTD	10MG	A091163	001	Mar 30, 2011	Mar	NEWA
AB			20MG	A091163	002	Mar 30, 2011	Mar	NEWA
AB			40MG	A091163	003	Mar 30, 2011	Mar	NEWA

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	+	APP PHARMS	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Apr	CRLD
AP		PFIZER	EQ 50MG PNENYTOIN NA/ML	A078476	001	Mar 18, 2008	May	CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

>A>	AB	MARKSANS PHARMA	100MG	A090007	001	Jul 21, 2011	Jul	NEWA
>A>	AB		300MG	A090007	002	Jul 21, 2011	Jul	NEWA
>A>	AB		400MG	A090007	003	Jul 21, 2011	Jul	NEWA
	AB	MATRIX LABS LTD	100MG	A090158	001	Feb 14, 2011	Jan	NEWA
	AB		300MG	A090158	002	Feb 14, 2011	Jan	NEWA
	AB		400MG	A090158	003	Feb 14, 2011	Jan	NEWA
	AB	MYLAN	100MG	A090158	001	Feb 14, 2011	May	CAHN
	AB		300MG	A090158	002	Feb 14, 2011	May	CAHN
	AB		400MG	A090158	003	Feb 14, 2011	May	CAHN

SOLUTION; ORAL

GABAPENTIN

AA		HI TECH PHARMA	250MG/5ML	A078974	001	Feb 18, 2011	Feb	NEWA
----	--	----------------	-----------	---------	-----	--------------	-----	------

NEURONTIN

AA	+	PARKE DAVIS	250MG/5ML	N021129	001	Mar 02, 2000	Feb	CFTG
----	---	-------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

GABAPENTIN

>A>	AB	HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011	Jul	NEWA
-----	----	--------------	-------	---------	-----	--------------	-----	------

>A>	AB		800MG	A078782	002	Jul 21, 2011	Jul	NEWA
-----	----	--	-------	---------	-----	--------------	-----	------

	AB	ZYDUS PHARMS USA INC	600MG	A078926	001	Feb 11, 2011	Jan	NEWA
--	----	----------------------	-------	---------	-----	--------------	-----	------

	AB		800MG	A078926	002	Feb 11, 2011	Jan	NEWA
--	----	--	-------	---------	-----	--------------	-----	------

GRALISE

>D>	BX	+	ABBOTT PRODS	300MG	N022544	001	Jan 28, 2011	Jul	CAHN
-----	----	---	--------------	-------	---------	-----	--------------	-----	------

	BX	+		300MG	N022544	001	Jan 28, 2011	Jan	NEWA
--	----	---	--	-------	---------	-----	--------------	-----	------

>D>	BX	+		600MG	N022544	002	Jan 28, 2011	Jul	CAHN
-----	----	---	--	-------	---------	-----	--------------	-----	------

	BX	+		600MG	N022544	002	Jan 28, 2011	Jan	NEWA
--	----	---	--	-------	---------	-----	--------------	-----	------

>A>	BX	+	DEPOMED INC	300MG	N022544	001	Jan 28, 2011	Jul	CAHN
-----	----	---	-------------	-------	---------	-----	--------------	-----	------

>A>	BX	+		600MG	N022544	002	Jan 28, 2011	Jul	CAHN
-----	----	---	--	-------	---------	-----	--------------	-----	------

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

	+	GLAXO GRP LTD	600MG	N022399	001	Apr 06, 2011	Apr	NEWA
--	---	---------------	-------	---------	-----	--------------	-----	------

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

	+	BAYER HLTHCARE	4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011	Mar	NEWA
--	---	----------------	------------------------------	---------	-----	--------------	-----	------

	+		6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011	Mar	NEWA
--	---	--	-----------------------------	---------	-----	--------------	-----	------

	+		9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011	Mar	NEWA
--	---	--	-----------------------------	---------	-----	--------------	-----	------

	+		18.1416GM/30ML (604.72MG/ML)	N201277	004	Mar 14, 2011	Mar	NEWA
--	---	--	------------------------------	---------	-----	--------------	-----	------

	+		39.3068GM/65ML (604.72MG/ML)	N201277	005	Mar 14, 2011	Mar	NEWA
--	---	--	------------------------------	---------	-----	--------------	-----	------

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB		MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011	Jan	NEWA
----	--	-------	-------------	---------	-----	--------------	-----	------

AB			EQ 16MG BASE	A090900	002	Jan 24, 2011	Jan	NEWA
----	--	--	--------------	---------	-----	--------------	-----	------

AB			EQ 24MG BASE	A090900	003	Jan 24, 2011	Jan	NEWA
----	--	--	--------------	---------	-----	--------------	-----	------

AB		SUN PHARMA GLOBAL	EQ 8MG BASE	A090178	001	Feb 02, 2011	Jan	NEWA
----	--	-------------------	-------------	---------	-----	--------------	-----	------

AB			EQ 16MG BASE	A090178	002	Feb 02, 2011	Jan	NEWA
----	--	--	--------------	---------	-----	--------------	-----	------

AB			EQ 24MG BASE	A090178	003	Feb 02, 2011	Jan	NEWA
----	--	--	--------------	---------	-----	--------------	-----	------

RAZADYNE ER

>A>	AB	+	JANSSEN PHARMS	EQ 8MG BASE	N021615	001	Apr 01, 2005	Jul	CAHN
-----	----	---	----------------	-------------	---------	-----	--------------	-----	------

>A>	AB			EQ 16MG BASE	N021615	002	Apr 01, 2005	Jul	CAHN
-----	----	--	--	--------------	---------	-----	--------------	-----	------

>A>	AB			EQ 24MG BASE	N021615	003	Apr 01, 2005	Jul	CAHN
-----	----	--	--	--------------	---------	-----	--------------	-----	------

>D>	AB	+	ORTHO MCNEIL JANSSEN	EQ 8MG BASE	N021615	001	Apr 01, 2005	Jul	CAHN
-----	----	---	----------------------	-------------	---------	-----	--------------	-----	------

>D>	AB			EQ 16MG BASE	N021615	002	Apr 01, 2005	Jul	CAHN
-----	----	--	--	--------------	---------	-----	--------------	-----	------

>D>	AB			EQ 24MG BASE	N021615	003	Apr 01, 2005	Jul	CAHN
-----	----	--	--	--------------	---------	-----	--------------	-----	------

SOLUTION; ORAL

RAZADYNE

>A>	AA	+	JANSSEN PHARMS	4MG/ML	N021224	001	Jun 22, 2001	Jul	CAHN
-----	----	---	----------------	--------	---------	-----	--------------	-----	------

>D>	AA	+	ORTHO MCNEIL JANSSEN	4MG/ML	N021224	001	Jun 22, 2001	Jul	CAHN
-----	----	---	----------------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB		AUROBINDO PHARMA LTD	EQ 4MG BASE	A090957	001	Mar 29, 2011	Mar	NEWA
----	--	----------------------	-------------	---------	-----	--------------	-----	------

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB	AUROBINDO PHARMA LTD	EQ 8MG BASE	A090957 002	Mar 29, 2011	Mar	NEWA
AB		EQ 12MG BASE	A090957 003	Mar 29, 2011	Mar	NEWA
AB	ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898 001	Feb 17, 2011	Jan	NEWA
AB		EQ 8MG BASE	A078898 002	Feb 17, 2011	Jan	NEWA
AB		EQ 12MG BASE	A078898 003	Feb 17, 2011	Jan	NEWA

RAZADYNE

>A>	AB +	JANSSEN PHARMS	EQ 4MG BASE	N021169 001	Feb 28, 2001	Jul	CAHN
>A>	AB		EQ 8MG BASE	N021169 002	Feb 28, 2001	Jul	CAHN
>A>	AB		EQ 12MG BASE	N021169 003	Feb 28, 2001	Jul	CAHN
>D>	AB +	ORTHO MCNEIL JANSSEN	EQ 4MG BASE	N021169 001	Feb 28, 2001	Jul	CAHN
>D>	AB		EQ 8MG BASE	N021169 002	Feb 28, 2001	Jul	CAHN
>D>	AB		EQ 12MG BASE	N021169 003	Feb 28, 2001	Jul	CAHN

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE

+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183 001	Nov 15, 2010	Feb	CRLD
---	-------------	------------------	-------------	--------------	-----	------

GEMCITABINE HYDROCHLORIDE

>A>	AP	ACCORD HLTHCARE	EQ 200MG BASE/VIAL	A091594 001	Jul 25, 2011	Jul	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A091594 002	Jul 25, 2011	Jul	NEWA
>A>	AP		EQ 2GM BASE/VIAL	A091594 003	Jul 25, 2011	Jul	NEWA
>A>	AP	ACTAVIS TOTOWA	EQ 200MG BASE/VIAL	A079160 001	Jul 25, 2011	Jul	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A079160 002	Jul 25, 2011	Jul	NEWA
	AP	APP PHARMS	EQ 2GM BASE/VIAL	A090242 003	May 16, 2011	May	NEWA
>A>	AP	DR REDDYS LABS LTD	EQ 200MG BASE/VIAL	A091365 001	Jul 25, 2011	Jul	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A091365 002	Jul 25, 2011	Jul	NEWA
>A>	AP	FRESENIUS KABI ONCOL	EQ 200MG BASE/VIAL	A090799 001	Jul 25, 2011	Jul	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A090799 002	Jul 25, 2011	Jul	NEWA
	AP		EQ 2GM BASE/VIAL	A090799 003	May 16, 2011	May	NEWA
>A>	AP	HOSPIRA	EQ 200MG BASE/VIAL	A078339 001	Jul 25, 2011	Jul	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A078339 002	Jul 25, 2011	Jul	NEWA
>D>	+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183 001	Nov 15, 2010	Jul	CTEC
>A>	AP +		EQ 2GM BASE/VIAL	A079183 001	Nov 15, 2010	Jul	CTEC
	+		EQ 2GM BASE/VIAL	A079183 001	Nov 15, 2010	May	CTNA
>A>	AP	ONCO THERAPIES LTD	EQ 200MG BASE/VIAL	A200145 001	Jul 25, 2011	Jul	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A200145 002	Jul 25, 2011	Jul	NEWA
>A>	AP		EQ 2GM BASE/VIAL	A200145 003	Jul 25, 2011	Jul	NEWA
>A>	AP	SUN PHARMA GLOBAL	EQ 200MG BASE/VIAL	A078433 001	Jul 25, 2011	Jul	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A078433 002	Jul 25, 2011	Jul	NEWA
	AP	TEVA PARENTERAL	EQ 200MG BASE/VIAL	A077983 002	Jan 25, 2011	Jan	NEWA
	AP		EQ 1GM BASE/VIAL	A077983 001	Jan 25, 2011	Jan	NEWA
>A>	AP	WATSON LABS	EQ 200MG BASE/VIAL	A078759 001	Jul 25, 2011	Jul	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A078759 002	Jul 25, 2011	Jul	NEWA
		GEMZAR					
AP	+	LILLY	EQ 200MG BASE/VIAL	N020509 001	May 15, 1996	Jan	CFTG
AP	+		EQ 1GM BASE/VIAL	N020509 002	May 15, 1996	Jan	CFTG

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB	BLU CARIBE	600MG	A078012 001	Mar 26, 2007	Feb	CAHN
----	------------	-------	-------------	--------------	-----	------

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT	FERA PHARMS	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb	CAHN
AT	NYCOMED US	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Jan	CAHN

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

AT	FERA PHARMS	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Feb	CAHN
----	-------------	--------------	---------	-----	--------------	-----	------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	MYLAN	1MG	A077486	001	Feb 10, 2006	Feb	CAHN
AB		2MG	A077486	002	Feb 10, 2006	Feb	CAHN
AB		4MG	A077486	003	Feb 10, 2006	Feb	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	2.5MG;250MG	A078905	001	Jan 31, 2011	Jan	NEWA
AB		2.5MG;500MG	A078905	002	Jan 31, 2011	Jan	NEWA
AB		5MG;500MG	A078905	003	Jan 31, 2011	Jan	NEWA

GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

+	EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	May	CAHN
---	--------------	------------	---------	-----	--------------	-----	------

GLYBURIDE

TABLET; ORAL

GLYBURIDE

>D>	AB	ACTAVIS TOTOWA	1.5MG	A075947	001	Nov 14, 2002	Jul	DISC
>A>		@	1.5MG	A075947	001	Nov 14, 2002	Jul	DISC
>D>	AB		3MG	A075947	002	Nov 14, 2002	Jul	DISC
>A>		@	3MG	A075947	002	Nov 14, 2002	Jul	DISC
>D>	AB		6MG	A075947	003	Nov 14, 2002	Jul	DISC
>A>		@	6MG	A075947	003	Nov 14, 2002	Jul	DISC
	AB	HERITAGE PHARMS INC	1.25MG	A090937	001	Feb 28, 2011	May	CAHN
	AB		2.5MG	A090937	002	Feb 28, 2011	May	CAHN
	AB		5MG	A090937	003	Feb 28, 2011	May	CAHN
	AB	INDICUS PHARMA	1.25MG	A090937	001	Feb 28, 2011	Feb	NEWA
	AB		2.5MG	A090937	002	Feb 28, 2011	Feb	NEWA
	AB		5MG	A090937	003	Feb 28, 2011	Feb	NEWA

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL

SANCUSO

+	PROSTRAKAN INC	3.1MG/24HR	N022198	001	Sep 12, 2008	Jun	CAHN
---	----------------	------------	---------	-----	--------------	-----	------

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

@	ELORAC	125MG	A061996	001		Jan	CAHN
@		250MG	A061996	002		Jan	CAHN

TABLET; ORAL

FULVICIN P/G 165

@ ELORAC 165MG

A061996 003 Apr 06, 1982 Jan CAHN

FULVICIN P/G 330

@ ELORAC 330MG

A061996 004 Apr 06, 1982 Jan CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP PFIZER EQ 5MG BASE/ML

A078347 001 Sep 14, 2009 May CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

>A> PFIZER 1,000 UNITS/ML

N201370 001 Jul 21, 2011 Jul NEWA

>A> 5,000 UNITS/ML

N201370 002 Jul 21, 2011 Jul NEWA

>A> 10,000 UNITS/ML

N201370 003 Jul 21, 2011 Jul NEWA

AP SANDOZ 1,000 UNITS/ML

A091682 001 Jun 08, 2011 May NEWA

AP 5,000 UNITS/ML

A091682 002 Jun 08, 2011 May NEWA

AP 5,000 UNITS/ML

A091659 001 Jun 08, 2011 May NEWA

AP 10,000 UNITS/ML

A201002 001 Jun 08, 2011 May NEWA

HEPARIN SODIUM PRESERVATIVE FREE

>A> PFIZER 1,000 UNITS/ML

N201370 004 Jul 21, 2011 Jul NEWA

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+ GE HEALTHCARE 100MG/VIAL

N022555 001 May 28, 2010 May CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AB NOVEL LABS INC 1.5MG;5MG

A091528 001 Apr 20, 2011 Apr NEWA

TUSSIGON

AB + KING PHARMS 1.5MG;5MG

A088508 001 Jul 30, 1985 Apr CTEC

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

>A> + AKORN INC 150 UNITS/ML

N021716 001 Oct 25, 2005 Jul CAHN

>D> + PRIMAPHARM 150 UNITS/ML

N021716 001 Oct 25, 2005 Jul CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>D> AA HETERO DRUGS LTD 10MG

A040901 001 Sep 12, 2008 Jul CAHN

>D> AA 25MG

A040901 002 Sep 12, 2008 Jul CAHN

>D> AA 50MG

A040901 003 Sep 12, 2008 Jul CAHN

>D> AA 100MG

A040901 004 Sep 12, 2008 Jul CAHN

>A> AA HETERO LABS UNIT III 10MG

A040901 001 Sep 12, 2008 Jul CAHN

>A> AA 25MG

A040901 002 Sep 12, 2008 Jul CAHN

>A> AA 50MG

A040901 003 Sep 12, 2008 Jul CAHN

>A> AA 100MG

A040901 004 Sep 12, 2008 Jul CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG	A200645 001	Nov 30, 2010	Apr	CAHN
AB	JUBILANT CADISTA	12.5MG	A078391 001	Feb 11, 2008	Jan	CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	JUBILANT CADISTA	25MG	A040809 001	Sep 04, 2007	Jan	CAHN
AB		50MG	A040809 002	Sep 04, 2007	Jan	CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

	@ SANOFI AVENTIS	12.5MG;75MG	N020758 001	Sep 30, 1997	Jun	CAHN
		12.5MG;150MG	N020758 002	Sep 30, 1997	Jun	CAHN
		12.5MG;300MG	N020758 003	Aug 31, 1998	Jun	CAHN
+		25MG;300MG	N020758 004	Mar 15, 2005	Jun	CAHN

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	PRINSTON PHARM LLC	12.5MG;10MG	A076230 001	Jul 01, 2002	May	CAHN
AB		12.5MG;20MG	A076230 002	Jul 01, 2002	May	CAHN
AB		25MG;20MG	A076230 003	Jul 01, 2002	May	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	12.5MG;50MG	A200180 001	Jan 12, 2011	Jan	NEWA
AB		12.5MG;100MG	A200180 002	Jan 12, 2011	Jan	NEWA
AB		25MG;100MG	A200180 003	Jan 12, 2011	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;10MG	A201356 001	Apr 20, 2011	Apr	NEWA
AB		12.5MG;20MG	A201356 002	Apr 20, 2011	Apr	NEWA
AB		25MG;20MG	A201356 003	Apr 20, 2011	Apr	NEWA

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

REZIRA

+	CYPRESS PHARM	5MG/5ML;60MG/5ML	N022442 001	Jun 08, 2011	Jun	NEWA
---	---------------	------------------	-------------	--------------	-----	------

HYDROCORTISONE

SOLUTION; TOPICAL

TEXACORT

+	TIBER LABS	2.5%	A081271 001	Apr 17, 1992	May	CAHN
---	------------	------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCORTISONE

AB	COREPHARMA	5MG	A040646 001	Mar 30, 2007	Apr	CAHN
AB		10MG	A040646 002	Mar 30, 2007	Apr	CAHN
AB		20MG	A040646 003	Mar 30, 2007	Apr	CAHN

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

@ FERA PHARMS	0.5%	A080828 001	Mar	CAHN
---------------	------	-------------	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

HYDROFLUMETHIAZIDE

@ PAR PHARM	50MG	A088850 001	May 31, 1985	May	DISC
-------------	------	-------------	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB	ELITE LABS	8MG	A076723 001	Oct 18, 2005	Feb	CAHN
----	------------	-----	-------------	--------------	-----	------

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

@ MERCK SANTE SAS	5GM/VIAL (5GM/KIT)	N022041 001	Apr 08, 2011	Apr	DISC
-------------------	--------------------	-------------	--------------	-----	------

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRINE

@ PHARMICS	1%	N000004 004		Jan	CAHN
------------	----	-------------	--	-----	------

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

+ KV PHARM	1250MG/5ML (250MG/ML)	N021945 001	Feb 03, 2011	Feb	NEWA
------------	-----------------------	-------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

>D>	AB	ACTAVIS TOTOWA	10MG	A040600 001	Dec 28, 2004	Jul	DISC
>A>		@	10MG	A040600 001	Dec 28, 2004	Jul	DISC
>D>	AB		25MG	A040602 001	Dec 28, 2004	Jul	DISC
>A>		@	25MG	A040602 001	Dec 28, 2004	Jul	DISC
>D>	AB		50MG	A040604 001	Dec 28, 2004	Jul	DISC
>A>		@	50MG	A040604 001	Dec 28, 2004	Jul	DISC
>D>	AB	HETERO DRUGS LTD	10MG	A040805 001	May 29, 2008	Jul	CAHN
>D>	AB		25MG	A040805 002	May 29, 2008	Jul	CAHN
>D>	AB		50MG	A040805 003	May 29, 2008	Jul	CAHN
>A>	AB	HETERO LABS UNIT III	10MG	A040805 001	May 29, 2008	Jul	CAHN
>A>	AB		25MG	A040805 002	May 29, 2008	Jul	CAHN
>A>	AB		50MG	A040805 003	May 29, 2008	Jul	CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

AP	SANDOZ	1MG/ML	A091293 001	Mar 29, 2011	Mar	NEWA
----	--------	--------	-------------	--------------	-----	------

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

AP	BEDFORD LABS	1GM/20ML(50MG/ML)	A076619 001	Jun 29, 2011	Jun	NEWA
AP		3GM/60ML(50MG/ML)	A076619 002	Jun 29, 2011	Jun	NEWA

ILOPERIDONE

TABLET; ORAL

FANAPT

NOVARTIS

	2MG	N022192 002	May 06, 2009	Jan	CAHN
	4MG	N022192 003	May 06, 2009	Jan	CAHN
	6MG	N022192 004	May 06, 2009	Jan	CAHN
	8MG	N022192 005	May 06, 2009	Jan	CAHN
	10MG	N022192 006	May 06, 2009	Jan	CAHN

ILOPROST

SOLUTION; INHALATION

VENTAVIS

@ ACTELION PHARMS LTD 20MCG/2ML (10MCG/ML)

N021779 001 Dec 29, 2004 Jun DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

>D>	AB	ACTAVIS TOTOWA	10MG	A040753 001	Feb 28, 2008	Jul	DISC
>A>		@	10MG	A040753 001	Feb 28, 2008	Jul	DISC
>D>	AB		25MG	A040752 001	Feb 28, 2008	Jul	DISC
>A>		@	25MG	A040752 001	Feb 28, 2008	Jul	DISC
>D>	AB		50MG	A040751 001	Feb 28, 2008	Jul	DISC
>A>		@	50MG	A040751 001	Feb 28, 2008	Jul	DISC

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB	TARO	5%	A200173 001	Apr 15, 2011	Apr	NEWA	
AB	TEVA PHARMS USA	5%	A200481 001	Apr 18, 2011	Apr	NEWA	
AB	TOLMAR	5%	A091044 001	Feb 28, 2011	Feb	NEWA	
	ZYCLARA						
>A>	+	GRACEWAY	2.5%	N022483 002	Jul 15, 2011	Jul	NEWA

INDACATEROL MALEATE

>A> POWDER; INHALATION

>A> ARCAPTA NEOHALER

>A> + NOVARTIS EQ 75MCG BASE N022383 001 Jul 01, 2011 Jul NEWA

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

>D>	AB	HETERO DRUGS LTD	25MG	A091240 001	Apr 12, 2011	Jul	CAHN
	AB		25MG	A091240 001	Apr 12, 2011	Mar	NEWA
>D>	AB		50MG	A091240 002	Apr 12, 2011	Jul	CAHN
	AB		50MG	A091240 002	Apr 12, 2011	Mar	NEWA
>A>	AB	HETERO LABS UNIT III	25MG	A091240 001	Apr 12, 2011	Jul	CAHN
>A>	AB		50MG	A091240 002	Apr 12, 2011	Jul	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB	+	SANDOZ	75MG	A074464	001	May 28, 1998	Jan	CTNA
----	---	--------	------	---------	-----	--------------	-----	------

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

	+	GE HLTHCARE INC	5MCI/2.5ML (2MCI/ML)	N022454	001	Jan 14, 2011	Jan	NEWA
--	---	-----------------	----------------------	---------	-----	--------------	-----	------

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

	@	HOSPIRA	41%	A074898	001	Dec 30, 1997	Feb	DISC
--	---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-200 IN PLASTIC CONTAINER

	@	HOSPIRA	41%	A074636	001	Dec 30, 1997	Feb	DISC
--	---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-250

	@	HOSPIRA	51%	A074898	002	Dec 30, 1997	Feb	DISC
--	---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-250 IN PLASTIC CONTAINER

	@	HOSPIRA	51%	A074636	002	Dec 30, 1997	Feb	DISC
--	---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-300

	@	HOSPIRA	61%	A074898	003	Dec 30, 1997	Feb	DISC
--	---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-300 IN PLASTIC CONTAINER

	@	HOSPIRA	61%	A074636	003	Dec 30, 1997	Feb	DISC
--	---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-370

	@	HOSPIRA	76%	A074898	004	Dec 30, 1997	Feb	DISC
--	---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-370 IN PLASTIC CONTAINER

	@	HOSPIRA	76%	A074636	004	Dec 30, 1997	Feb	DISC
--	---	---------	-----	---------	-----	--------------	-----	------

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>D>	AN	HOLOPACK INTL	0.02%	A075693	001	Jan 26, 2001	Jul	CAHN
-----	----	---------------	-------	---------	-----	--------------	-----	------

>A>	AN	RITEDOSE CORP	0.02%	A075693	001	Jan 26, 2001	Jul	CAHN
-----	----	---------------	-------	---------	-----	--------------	-----	------

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP		BIONICHE PHARMA	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	May	NEWA
----	--	-----------------	--------------------	---------	-----	--------------	-----	------

AP			100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	May	NEWA
----	--	--	---------------------	---------	-----	--------------	-----	------

>D>	AP	PHARMAFORCE	40MG/2ML (20MG/ML)	A090016	001	Jan 28, 2009	Jul	CAHN
-----	----	-------------	--------------------	---------	-----	--------------	-----	------

>D>	AP		100MG/5ML (20MG/ML)	A090016	002	Jan 28, 2009	Jul	CAHN
-----	----	--	---------------------	---------	-----	--------------	-----	------

>A>	AP	X-GEN PHARMS	40MG/2ML (20MG/ML)	A090016	001	Jan 28, 2009	Jul	CAHN
-----	----	--------------	--------------------	---------	-----	--------------	-----	------

>A>	AP		100MG/5ML (20MG/ML)	A090016	002	Jan 28, 2009	Jul	CAHN
-----	----	--	---------------------	---------	-----	--------------	-----	------

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD

			EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005	Apr	CMFD
--	--	--	--------------------------------------	---------	-----	--------------	-----	------

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

AB		VALEANT INTL	5MG	N012093	007	Jul 29, 1988	Jun	CAHN
----	--	--------------	-----	---------	-----	--------------	-----	------

AB			10MG	N012093	002	Jul 29, 1988	Jun	CAHN
----	--	--	------	---------	-----	--------------	-----	------

AB			20MG	N012093	006	Jul 29, 1988	Jun	CAHN
----	--	--	------	---------	-----	--------------	-----	------

TABLET; ORAL						
ISORDIL						
AB	+	VALEANT INTL	30MG	N012093 005	Jul 29, 1988	Jun CAHN
	+		40MG	N012093 001	Jul 29, 1988	Jun CAHN
<u>ISOSORBIDE MONONITRATE</u>						
TABLET, EXTENDED RELEASE; ORAL						
ISOSORBIDE MONONITRATE						
AB		TORRENT PHARMS	30MG	A200270 001	Jun 03, 2011	May NEWA
AB			60MG	A200495 001	Jun 03, 2011	May NEWA
AB			120MG	A200495 002	Jun 03, 2011	May NEWA
<u>ISRADIPINE</u>						
CAPSULE; ORAL						
ISRADIPINE						
AB		MIKAH PHARMA	2.5MG	A077169 001	Apr 24, 2006	Feb CAHN
AB			5MG	A077169 002	Apr 24, 2006	Feb CAHN
<u>ITRACONAZOLE</u>						
INJECTABLE; INJECTION						
SPORANOX						
		@ ORTHO MCNEIL JANSSEN	10MG/ML	N020966 001	Mar 30, 1999	May DISC
TABLET; ORAL						
ONMEL						
	+	STIEFEL LABS INC	200MG	N022484 001	Apr 29, 2010	May CTNA
<u>KETOCONAZOLE</u>						
GEL; TOPICAL						
XOLEGEL						
	+	AQUA PHARMS	2%	N021946 001	Jul 28, 2006	May CAHN
<u>KETOROLAC TROMETHAMINE</u>						
INJECTABLE; INJECTION						
KETOROLAC TROMETHAMINE						
AP		PFIZER	15MG/ML	A078299 001	Jul 16, 2007	May CAHN
AP			30MG/ML	A078299 002	Jul 16, 2007	May CAHN
SPRAY, METERED; NASAL						
SPRIX						
	+	LUITPOLD	15.75MG/SPRAY	N022382 001	May 14, 2010	May CAHN
<u>LAMIVUDINE; ZIDOVUDINE</u>						
TABLET; ORAL						
COMBIVIR						
AB	+	VIIV HLTHCARE	150MG;300MG	N020857 001	Sep 26, 1997	May CFTG
LAMIVUDINE AND ZIDOVUDINE						
AB		TEVA PHARMS	150MG;300MG	A079081 001	May 25, 2011	May NEWA
<u>LAMOTRIGINE</u>						
TABLET; ORAL						
LAMOTRIGINE						
AB		ACTAVIS TOTOWA	25MG	A078669 001	Apr 08, 2011	Mar NEWA
AB			100MG	A078669 002	Apr 08, 2011	Mar NEWA
AB			150MG	A078669 003	Apr 08, 2011	Mar NEWA
AB			200MG	A078669 004	Apr 08, 2011	Mar NEWA
AB		ALEMBIC LTD	25MG	A090607 001	Jan 13, 2011	Jan NEWA
AB			100MG	A090607 002	Jan 13, 2011	Jan NEWA

TABLET; ORAL

LAMOTRIGINE

AB	ALEMBIC LTD	150MG	A090607 003	Jan 13, 2011	Jan	NEWA
AB		200MG	A090607 004	Jan 13, 2011	Jan	NEWA
AB	ALEMBIC PHARMS LTD	25MG	A090607 001	Jan 13, 2011	Apr	CAHN
AB		100MG	A090607 002	Jan 13, 2011	Apr	CAHN
AB		150MG	A090607 003	Jan 13, 2011	Apr	CAHN
AB		200MG	A090607 004	Jan 13, 2011	Apr	CAHN
AB	HIKMA PHARMS	25MG	A078134 001	Apr 19, 2011	Apr	NEWA
AB		100MG	A078134 002	Apr 19, 2011	Apr	NEWA
AB		150MG	A078134 003	Apr 19, 2011	Apr	NEWA
AB		200MG	A078134 004	Apr 19, 2011	Apr	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	JUBILANT LIFE	5MG	A200220 001	Feb 28, 2011	Feb	NEWA
AB		25MG	A200220 002	Feb 28, 2011	Feb	NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT	ALCON RES	0.005%	A091449 001	Mar 22, 2011	Mar	NEWA
AT	APOTEX	0.005%	A077697 001	Mar 22, 2011	Mar	NEWA
AT	BAUSCH AND LOMB	0.005%	A201006 001	Mar 22, 2011	Mar	NEWA
AT	LUITPOLD	0.005%	A200925 001	Mar 22, 2011	May	CAHN
AT	MYLAN	0.005%	A201786 001	Mar 22, 2011	Mar	NEWA
>A>	PADDOCK LABS	0.005%	A090887 001	Jul 19, 2011	Jul	NEWA
AT	PHARMAFORCE	0.005%	A200925 001	Mar 22, 2011	Mar	NEWA

XALATAN

AT	+ PHARMACIA AND UPJOHN	0.005%	N020597 001	Jun 05, 1996	Mar	CFTG
----	------------------------	--------	-------------	--------------	-----	------

LETROZOLE

TABLET; ORAL

LETROZOLE

AB	ACCORD HLTHCARE	2.5MG	A090934 001	Jun 03, 2011	May	NEWA
>A>	AMIDE PHARM	2.5MG	A090292 001	Jul 13, 2011	Jul	NEWA
AB	DR REDDYS LABS LTD	2.5MG	A091191 001	Jun 03, 2011	May	NEWA
AB	ENDO PHARMS	2.5MG	A090789 001	Jun 03, 2011	May	NEWA
AB	FRESENIUS KABI ONCOL	2.5MG	A090491 001	Jun 03, 2011	May	NEWA
AB	IMPAX LABS	2.5MG	A091638 001	Jun 03, 2011	May	NEWA
AB	INDICUS PHARMA	2.5MG	A201804 001	Jun 03, 2011	May	NEWA
AB	KUDCO IRELAND	2.5MG	A091098 001	Jun 03, 2011	May	NEWA
AB	NATCO PHARMA LTD	2.5MG	A200161 001	Jun 03, 2011	May	NEWA
AB	ROXANE	2.5MG	A090838 001	Jun 03, 2011	May	NEWA
AB	SUN PHARM INDS LTD	2.5MG	A091466 001	Jun 03, 2011	May	NEWA
	@ SYNTHON PHARMS	2.5MG	A090196 001	Jun 03, 2011	Jun	DISC
AB		2.5MG	A090196 001	Jun 03, 2011	May	NEWA
AB	TEVA PHARMS	2.5MG	A090289 001	Jun 03, 2011	May	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

@ GENZYME

1MG/0.2ML

A075721 001 Nov 29, 2001 Apr DISC

LUPRON DEPOT

+ ABBOTT ENDOCRINE

22.5MG/VIAL

N020517 001 Dec 22, 1995 Jun CAHN

+

30MG/VIAL

N020517 002 May 30, 1997 Jun CAHN

45MG/VIAL

N020517 003 Jun 17, 2011 Jun NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

>A>	AP	INNOPHARMA LLC	500MG/ML (100MG/ML)	A091485 001	Aug 05, 2011	Jul	NEWA
-----	----	----------------	---------------------	-------------	--------------	-----	------

SOLUTION; ORAL

LEVETIRACETAM

>A>	AA	APOTEX	100MG/ML	A090187 001	Aug 05, 2011	Jul	NEWA
-----	----	--------	----------	-------------	--------------	-----	------

TABLET; ORAL

LEVETIRACETAM

AB		ACCORD HLTHCARE	250MG	A090843 001	Feb 14, 2011	Jan	NEWA
AB			500MG	A090843 002	Feb 14, 2011	Jan	NEWA
AB			750MG	A090843 003	Feb 14, 2011	Jan	NEWA
AB			1GM	A090843 004	Feb 14, 2011	Jan	NEWA
AB		AJANTA PHARMA	250MG	A201293 001	Jun 14, 2011	May	NEWA
AB			500MG	A201293 002	Jun 14, 2011	May	NEWA
AB			750MG	A201293 003	Jun 14, 2011	May	NEWA
AB			1GM	A201293 004	Jun 14, 2011	May	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		DR REDDYS LABS LTD	5MG	A090392 001	Feb 24, 2011	Feb	NEWA
AB		GLENMARK GENERICS	5MG	A090385 001	Feb 24, 2011	Feb	NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

AP	+	ORTHO MCNEIL PHARM	EQ 500MG/20ML (EQ 25MG/ML)	N020635 001	Dec 20, 1996	Jun	CFTG
AP	+		EQ 750MG/30ML (EQ 25MG/ML)	N020635 004	Dec 20, 1996	Jun	CFTG
		LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	+	ORTHO MCNEIL PHARM	EQ 250MG/50ML (EQ 5MG/ML)	N020635 002	Dec 20, 1996	Jun	CFTG
AP	+		EQ 500MG/100ML (EQ 5MG/ML)	N020635 003	Dec 20, 1996	Jun	CFTG
AP	+		EQ 750MG/150ML (EQ 5MG/ML)	N020635 005	Dec 20, 1996	Jun	CFTG

LEVOFLOXACIN

AP		AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644 001	Jun 20, 2011	Jun	NEWA
AP			EQ 750MG/30ML (EQ 25MG/ML)	A091644 002	Jun 20, 2011	Jun	NEWA
AP		SAGENT PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A200560 001	Jun 20, 2011	Jun	NEWA
AP			EQ 750MG/30ML (EQ 25MG/ML)	A200560 002	Jun 20, 2011	Jun	NEWA
		LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP		ACS DOBFAR INFO SA	EQ 250MG/50ML (EQ 5MG/ML)	A090343 001	Jul 07, 2011	Jun	NEWA
AP			EQ 500MG/100ML (EQ 5MG/ML)	A090343 002	Jul 07, 2011	Jun	NEWA
AP			EQ 750MG/150ML (EQ 5MG/ML)	A090343 003	Jul 07, 2011	Jun	NEWA

SOLUTION; ORAL

LEVAQUIN

AA	+	ORTHO MCNEIL JANSSEN	250MG/10ML	N021721 001	Oct 21, 2004	Jun	CFTG
----	---	----------------------	------------	-------------	--------------	-----	------

LEVOFLOXACIN

AA		HI TECH PHARMA	250MG/10ML	A091678 001	Jun 20, 2011	Jun	NEWA
----	--	----------------	------------	-------------	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

AT		HI TECH PHARMA	0.5%	A076826 001	Feb 10, 2011	Jan	NEWA
----	--	----------------	------	-------------	--------------	-----	------

TABLET; ORAL

LEVAQUIN

AB		ORTHO MCNEIL JANSSEN	250MG	N020634 001	Dec 20, 1996	Jun	CFTG
AB			500MG	N020634 002	Dec 20, 1996	Jun	CFTG
AB	+		750MG	N020634 003	Sep 08, 2000	Jun	CFTG

TABLET; ORAL

LEVOFLOXACIN

AB	AUROBINDO PHARMA LTD	250MG	A201043 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A201043 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A201043 003	Jun 20, 2011	Jun	NEWA
AB	DR REDDYS LABS INC	250MG	A076710 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A076710 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A076710 003	Jun 20, 2011	Jun	NEWA
AB	GLENMARK GENERICS	250MG	A200250 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A200250 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A200250 003	Jun 20, 2011	Jun	NEWA
AB	LUPIN	250MG	A078424 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A078424 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A078424 003	Jun 20, 2011	Jun	NEWA
AB	MYLAN	250MG	A076276 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A076276 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A077097 001	Jun 20, 2011	Jun	NEWA
AB	SANDOZ	250MG	A077438 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A077438 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A077438 003	Jun 20, 2011	Jun	NEWA
AB	TEVA	250MG	A076361 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A076361 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A076361 003	Jun 20, 2011	Jun	NEWA
AB	TORRENT PHARMS	250MG	A090722 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A090722 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A090722 003	Jun 20, 2011	Jun	NEWA
AB	WOCKHARDT	250MG	A090367 001	Jun 20, 2011	Jun	NEWA
AB		500MG	A090367 002	Jun 20, 2011	Jun	NEWA
AB		750MG	A090367 003	Jun 20, 2011	Jun	NEWA

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

FUSILEV

+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140 002	Apr 20, 2011	Apr	NEWA
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140 003	Apr 20, 2011	Apr	NEWA

SOLUTION; IV (INFUSION)

FUSILEV

+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140 002	Apr 20, 2011	May	CDFR
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140 003	Apr 20, 2011	May	CDFR

LEVONORGESTREL

TABLET; ORAL

PLAN B

	@ TEVA WOMENS	0.75MG	N021045 001	Jul 28, 1999	Feb	CAHN
AB	+	0.75MG	N021045 002	Aug 24, 2006	Feb	CAHN

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

@ VALEANT PHARM INTL

LEVORPHANOL TARTRATE

ROXANE

2MG	N008720 001	Dec 19, 1991	Mar	DISC
2MG	A074278 001	Mar 31, 2000	Mar	CTEC

LEVOTHYROXINE SODIUM

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

+	APP PHARMS	100MCG/VIAL	N202231 001	Jun 24, 2011	Jun	NEWA
+		200MCG/VIAL	N202231 002	Jun 24, 2011	Jun	NEWA
+		500MCG/VIAL	N202231 003	Jun 24, 2011	Jun	NEWA

TABLET; ORAL

LEVO-T

AB1, AB2, AB3	ALARA PHARM	0.025MG	N021342 001	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.05MG	N021342 002	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.075MG	N021342 003	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.088MG	N021342 004	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.1MG	N021342 005	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.112MG	N021342 006	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.125MG	N021342 007	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.137MG	N021342 012	Dec 08, 2003	Feb	CTEC
AB1, AB2, AB3		0.15MG	N021342 008	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.175MG	N021342 009	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3		0.2MG	N021342 010	Mar 01, 2002	Feb	CTEC
AB1, + AB2, AB3		0.3MG	N021342 011	Mar 01, 2002	Feb	CTEC

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

AT	NOVOCOL INC	5%	A040911 001	May 23, 2011	May	NEWA
----	-------------	----	-------------	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	HI TECH PHARMA	2%	A040837 001	Mar 23, 2011	Mar	NEWA
----	----------------	----	-------------	--------------	-----	------

SYSTEM; INTRADERMAL

ZINGO

@ POWDER PHARMS

		0.5MG	N022114 001	Aug 16, 2007	Jun	CAHN
--	--	-------	-------------	--------------	-----	------

LINAGLIPTIN

TABLET; ORAL

TRADJENTA

+	BOEHRINGER INGELHEIM	5MG	N201280 001	May 02, 2011	May	NEWA
---	----------------------	-----	-------------	--------------	-----	------

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	PRINSTON PHARM LLC	2.5MG	A076180 001	Jul 01, 2002	May	CAHN
AB		5MG	A076180 002	Jul 01, 2002	May	CAHN
AB		10MG	A076180 003	Jul 01, 2002	May	CAHN
AB		20MG	A076164 001	Jul 01, 2002	May	CAHN
AB		30MG	A076164 002	Jul 01, 2002	May	CAHN
AB		40MG	A076164 003	Jul 01, 2002	May	CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	GLENMARK GENERICS	450MG	A091616 001	Feb 14, 2011	Jan	NEWA
----	-------------------	-------	-------------	--------------	-----	------

LORAZEPAM

TABLET; ORAL

ATIVAN

>D>	AB	BIOVAIL	0.5MG	N017794 001		Jul	CAHN
>D>	AB		1MG	N017794 002		Jul	CAHN
>D>	AB	+	2MG	N017794 003		Jul	CAHN
>A>	AB	VALEANT INTL	0.5MG	N017794 001		Jul	CAHN
>A>	AB		1MG	N017794 002		Jul	CAHN
>A>	AB	+	2MG	N017794 003		Jul	CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	ALEMBIC PHARMS LTD	25MG	A090428 001	Oct 06, 2010	Apr	CAHN
AB		50MG	A090428 002	Oct 06, 2010	Apr	NEWA
AB		100MG	A090428 003	Oct 06, 2010	Apr	CAHN
AB	HUAHAI US INC	25MG	A091497 001	Jun 06, 2011	May	NEWA
AB		50MG	A091497 002	Jun 06, 2011	May	NEWA
AB		100MG	A091497 003	Jun 06, 2011	May	NEWA
AB	MYLAN	25MG	A091590 001	Oct 06, 2010	Jan	NEWA
AB		50MG	A091590 002	Oct 06, 2010	Jan	NEWA
AB		100MG	A091590 003	Oct 06, 2010	Jan	NEWA

LOTEPREDNOL ETABONATE

OINTMENT; OPHTHALMIC

LOTEMAX

+	BAUSCH AND LOMB	0.5%	N200738 001	Apr 15, 2011	Apr	NEWA
---	-----------------	------	-------------	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451 001	Feb 23, 2011	Feb	NEWA
AA		25MG	A201451 002	Feb 23, 2011	Feb	NEWA
AA		50MG	A201451 003	Feb 23, 2011	Feb	NEWA
AA	JUBILANT CADISTA	12.5MG	A040659 001	Jun 04, 2010	Jan	CAHN
AA		25MG	A040659 002	Jun 04, 2010	Jan	CAHN

MEFENAMIC ACIDCAPSULE; ORAL
MEFENAMIC ACID

>A>	AB	LUPIN LTD	250MG	A091322 001	Jul 22, 2011	Jul	NEWA
-----	----	-----------	-------	-------------	--------------	-----	------

MELOXICAMTABLET; ORAL
MELOXICAM

AB	MYLAN		7.5MG	A077934 001	Jul 20, 2006	Feb	CAHN
AB			15MG	A077934 002	Jul 20, 2006	Feb	CAHN
AB	PURACAP PHARM		7.5MG	A077938 001	Jul 19, 2006	Jun	CAHN
AB			15MG	A077938 002	Jul 19, 2006	Jun	CAHN

MEMANTINE HYDROCHLORIDETABLET; ORAL
MEMANTINE

@	SUN PHARMA GLOBAL		5MG	A090058 001	May 05, 2010	May	CAHN
@			10MG	A090058 002	May 05, 2010	May	CAHN

MEPERIDINE HYDROCHLORIDEINJECTABLE; INJECTION
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

AP	BAXTER HLTHCARE CORP		10MG/ML	A081002 001	Jul 30, 1993	May	CAHN
----	----------------------	--	---------	-------------	--------------	-----	------

MEPROBAMATETABLET; ORAL
MEPROBAMATE

AA	ALEMBIC PHARMS LTD		200MG	A090122 001	Feb 18, 2009	May	CAHN
AA			400MG	A090122 002	Feb 18, 2009	May	CAHN
AA	TARO		200MG	A200998 001	May 23, 2011	May	NEWA
AA			400MG	A200998 002	May 23, 2011	May	NEWA

MEQUINOL; TRETINOINSOLUTION; TOPICAL
SOLAGE

+	AQUA PHARMS		2%:0.01%	N020922 001	Dec 10, 1999	May	CAHN
---	-------------	--	----------	-------------	--------------	-----	------

MEROPENEMINJECTABLE; INJECTION
MEROPENEM

AP	SANDOZ		500MG/VIAL	A091201 001	Mar 29, 2011	Mar	NEWA
AP			1GM/VIAL	A091201 002	Mar 29, 2011	Mar	NEWA
AP	+	MERREM					
AP	+	ASTRAZENECA	500MG/VIAL	N050706 003	Jun 21, 1996	Mar	CTNA
AP	+		1GM/VIAL	N050706 001	Jun 21, 1996	Mar	CTNA

MESALAMINEENEMA; RECTAL
ROWASA

AB	+	MEDA PHARMS	4GM/60ML	N019618 001	Dec 24, 1987	Jun	CAHN
AB		SFROWASA					
AB		MEDA PHARMS	4GM/60ML	N019618 002	Jun 20, 2008	Jun	CAHN
		TABLET, DELAYED RELEASE; ORAL					
		ASACOL					
	+	WARNER CHILCOTT LLC	400MG	N019651 001	Jan 31, 1992	Jun	CAHN

TABLET, DELAYED RELEASE; ORAL

ASACOL HD

+	WARNER CHILCOTT LLC	800MG	N021830	001	May 29, 2008	Jun	CAHN
---	---------------------	-------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	MYLAN	500MG	A075973	001	Jan 25, 2002	Feb	CAHN
AB		850MG	A075973	002	Jan 25, 2002	Feb	CAHN
AB		1GM	A075973	003	Jan 25, 2002	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

FORTAMET

AB2	ANDRX LABS LLC	500MG	N021574	001	Apr 27, 2004	Jun	CTEC
AB	+	1GM	N021574	002	Apr 27, 2004	Jun	CTEC

GLUCOPHAGE XR

AB1	BRISTOL MYERS SQUIBB	500MG	N021202	001	Oct 13, 2000	Jun	CTEC
-----	----------------------	-------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE

AB1	ACTAVIS ELIZABETH	500MG	A076450	001	Oct 01, 2004	Jun	CTEC
AB1	AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Jun	CTEC
AB1	APOTEX	500MG	A076706	001	Dec 14, 2004	Jun	CTEC
AB		750MG	A076706	002	Dec 29, 2005	Jun	CAHN
AB1	IMPAX LABS	500MG	A076249	001	Jul 30, 2004	Jun	CTEC
AB2	LUPIN LTD	500MG	A090692	001	Jun 29, 2011	Jun	NEWA
AB		1GM	A090692	002	Jun 29, 2011	Jun	NEWA
AB1	MYLAN	500MG	A076650	001	Sep 13, 2005	Jun	CTEC
AB1	NEUROSCI INC	500MG	A078321	001	Apr 17, 2008	Jun	CTEC
AB1	NOSTRUM	500MG	A076756	001	Jul 26, 2006	Jun	CTEC
AB1	RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004	Jun	CTEC
AB1	SANDOZ	500MG	A076873	001	Dec 14, 2004	Jun	CTEC
AB1	SUN PHARM INDS (IN)	500MG	A077336	001	Feb 09, 2006	Jun	CTEC
AB1	TEVA	500MG	A076269	001	Jun 18, 2004	Jun	CTEC
AB1	TORRENT PHARM	500MG	A090014	001	Dec 30, 2009	Jun	CTEC
AB1	WATSON LABS FLORIDA	500MG	A076172	001	Jun 16, 2004	Jun	CTEC
AB1	WATSON LABS INC	500MG	A076818	001	Dec 14, 2004	Jun	CTEC
AB1	ZYDUS PHARMS USA	500MG	A077060	001	Apr 20, 2005	Jun	CTEC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

AB	TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842	001	Aug 29, 2005	Feb	CFTG
AB	+	850MG;EQ 15MG BASE	N021842	002	Aug 29, 2005	Feb	CFTG

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	MYLAN	500MG;EQ 15MG BASE	A090406	001	Feb 25, 2011	Feb	NEWA
AB		850MG;EQ 15MG BASE	A090406	002	Feb 25, 2011	Feb	NEWA

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	LANNETT HOLDINGS INC	500MG	A084756	002	Mar 31, 2003	Jun	CAHN
AA		750MG	A084756	001		Jun	CAHN
	@ PURACAP PHARM	500MG	A084231	002		Jun	CAHN
	@	750MG	A084471	001		Jun	CAHN

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

AB	+	NOVARTIS	0.2MG	N006035 003		Apr	CTEC
		METHYLERGONOVINE MALEATE					
AB		NOVEL LABS INC	0.2MG	A091577 001	May 02, 2011	Apr	NEWA

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB		JUBILANT CADISTA	4MG	A040189 001	Oct 31, 1997	Jan	CAHN
AB			8MG	A040189 002	Oct 31, 1997	Jan	CAHN
AB			16MG	A040189 003	Jul 20, 2007	Jan	CAHN
AB			32MG	A040189 004	Jul 20, 2007	Jan	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP		HEMOPARM	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008	Apr	CAHN
AP			EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008	Apr	CAHN
		@ HOSPIRA	EQ 500MG BASE/VIAL	A089173 001	Aug 18, 1987	Feb	DISC
		@	EQ 1GM BASE/VIAL	A089174 001	Aug 18, 1987	Feb	DISC

METHYLPREDNISOLONE SODIUM SUCCINATE

>A>	AP	MUSTAFA NEVSAT	EQ 40MG BASE/VIAL	A040888 001	Jul 18, 2011	Jul	NEWA
>A>	AP		EQ 125MG BASE/VIAL	A040888 002	Jul 18, 2011	Jul	NEWA
>A>	AP		EQ 500MG BASE/VIAL	A040888 003	Jul 18, 2011	Jul	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A040888 004	Jul 18, 2011	Jul	NEWA
>A>	AP		EQ 2GM BASE/VIAL	A040888 005	Jul 18, 2011	Jul	NEWA

SOLU-MEDROL

>D>	+	PHARMACIA AND UPJOHN	EQ 2GM BASE/VIAL	N011856 007	Feb 27, 1985	Jul	CTEC
>A>	AP	+	EQ 2GM BASE/VIAL	N011856 007	Feb 27, 1985	Jul	CTEC

METRONIDAZOLE

GEL; TOPICAL

METROGEL

>D>	+	GALDERMA LABS LP	1%	N021789 001	Jun 30, 2005	Jul	CTEC
>A>	AB	+	1%	N021789 001	Jun 30, 2005	Jul	CTEC

METRONIDAZOLE

AB		G AND W LABS INC	0.75%	A078178 001	Jan 19, 2011	Jan	NEWA
>A>	AB	TOLMAR	1%	A090903 001	Jul 22, 2011	Jul	NEWA

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+	PFIZER	500MG/100ML	N018353 002		Jun	CAHN
----	---	--------	-------------	-------------	--	-----	------

TABLET; ORAL

METRONIDAZOLE

AB		ALEMBIC PHARMS LTD	250MG	A079067 001	Mar 13, 2009	May	CAHN
AB			500MG	A079067 002	Mar 13, 2009	May	CAHN

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

	@	PFIZER	EQ 500MG BASE/VIAL	N018353 001		Jun	DISC
--	---	--------	--------------------	-------------	--	-----	------

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

+	ASTELLAS	100MG/VIAL	N021506 003	Jun 27, 2006	Jan	CRLD
---	----------	------------	-------------	--------------	-----	------

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

>A>	@	ORTHO JANSSEN	2%	N017494 001		Jul	CAHN
>D>	@	ORTHONEUTROGENA	2%	N017494 001		Jul	CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDOZALAM HYDROCHLORIDE

AP	SAGENT STRIDES	EQ 1MG BASE/ML	A090316 001	May 04, 2011	Apr	NEWA
AP		EQ 5MG BASE/ML	A090316 002	May 04, 2011	Apr	NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

@	HOSPIRA	EQ 1MG BASE/ML	A075884 001	May 28, 2002	Feb	DISC
---	---------	----------------	-------------	--------------	-----	------

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

>D>	AB	ACTAVIS TOTOWA	15MG	A076241 001	Jun 25, 2003	Jul	DISC
>A>		@	15MG	A076241 001	Jun 25, 2003	Jul	DISC
>D>	AB		30MG	A076241 002	Jun 25, 2003	Jul	DISC
>A>		@	30MG	A076241 002	Jun 25, 2003	Jul	DISC
>D>	AB		45MG	A076241 003	Jun 25, 2003	Jul	DISC
>A>		@	45MG	A076241 003	Jun 25, 2003	Jul	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

	AB	ACTAVIS ELIZABETH	15MG	A077959 001	Feb 14, 2011	Jan	NEWA
	AB		30MG	A077959 002	Feb 14, 2011	Jan	NEWA
	AB		45MG	A077959 003	Feb 14, 2011	Jan	NEWA
>D>	AB	ACTAVIS TOTOWA	15MG	A076689 001	Aug 31, 2005	Jul	DISC
>A>		@	15MG	A076689 001	Aug 31, 2005	Jul	DISC
>D>	AB		30MG	A076689 002	Aug 31, 2005	Jul	DISC
>A>		@	30MG	A076689 002	Aug 31, 2005	Jul	DISC
>D>	AB		45MG	A076689 003	Aug 31, 2005	Jul	DISC
>A>		@	45MG	A076689 003	Aug 31, 2005	Jul	DISC

MORPHINE SULFATE

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

+	EKR THERAP	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	May	CRLD
	@	15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	May	DISC

SOLUTION; ORAL

MORPHINE SULFATE

		LANNETT HOLDINGS INC	20MG/ML	N201517 001	Jun 23, 2011	Jun	NEWA
>A>	AA	MALLINCKRODT INC	100MG/5ML	A202348 001	Jul 15, 2011	Jul	NEWA

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

AB	GLENMARK PHARMS	2%	A090480 001	Jun 08, 2011	May	NEWA
----	-----------------	----	-------------	--------------	-----	------

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

+	GLAXOSMITHKLINE	EQ 2% BASE	N050746 001	Dec 11, 1997	Jan	CDFR
---	-----------------	------------	-------------	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	LUPIN LTD	500MG	A090445 001	Jan 12, 2011	Jan	NEWA
AB		750MG	A090445 002	Jan 12, 2011	Jan	NEWA
AB	WATSON LABS	500MG	A091083 001	Jun 13, 2011	May	NEWA
AB		750MG	A091083 002	Jun 13, 2011	May	NEWA

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP	IBI	EQ 1GM BASE/VIAL	A090002 001	Jun 30, 2011	Jun	NEWA
AP		EQ 2GM BASE/VIAL	A090002 002	Jun 30, 2011	Jun	NEWA
AP	INSTITUTO BIOCHEMICO	EQ 10GM BASE/VIAL	A090005 001	Apr 20, 2011	Apr	NEWA
AP	+ SANDOZ	EQ 10GM BASE/VIAL	A062527 004	Aug 02, 1984	Apr	CTEC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	ELITE LABS	50MG	A075274 001	May 26, 1999	Feb	CAHN
----	------------	------	-------------	--------------	-----	------

NAPROXEN

TABLET; ORAL

NAPROXEN

AB	MARKSANS PHARMA	250MG	A091416 001	Feb 14, 2011	Jan	NEWA
AB		375MG	A091416 002	Feb 14, 2011	Jan	NEWA
AB		500MG	A091416 003	Feb 14, 2011	Jan	NEWA

NARATRIPTAN

TABLET; ORAL

NARATRIPTAN

AB	APOTEX CORP	EQ 1MG BASE	A091373 001	Apr 22, 2011	Apr	NEWA
AB		EQ 2.5MG BASE	A091373 002	Apr 22, 2011	Apr	NEWA
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552 001	Feb 14, 2011	Jan	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	INDICUS PHARMA	EQ 1MG BASE	A200502 001	Feb 28, 2011	Feb	NEWA
AB		EQ 2.5MG BASE	A200502 002	Feb 28, 2011	Feb	NEWA

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

AB	WATSON LABS	60MG	A077462 001	Mar 30, 2011	Mar	NEWA
AB		120MG	A077462 002	Mar 30, 2011	Mar	NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL

VIRAMUNE XR

+	BOEHRINGER INGELHEIM	400MG	N201152 001	Mar 25, 2011	Mar	NEWA
---	----------------------	-------	-------------	--------------	-----	------

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

@	EKR THERAP	45MG	N020005 002	Feb 21, 1992	May	DISC
---	------------	------	-------------	--------------	-----	------

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB1	VALEANT INTL	30MG	A075269 001	Dec 04, 2000	Apr	CAHN
AB2		30MG	A075289 002	Feb 06, 2001	Apr	CAHN
AB1		60MG	A075269 002	Dec 04, 2000	Apr	CAHN
AB2		60MG	A075289 001	Sep 27, 2000	Apr	CAHN
AB1		90MG	A076070 001	Aug 16, 2002	Apr	CAHN

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

AB	MYLAN	8.5MG	A091001 001	Jan 26, 2011	Jan	NEWA
AB		17MG	A091001 002	Jan 26, 2011	Jan	NEWA
AB		25.5MG	A091001 003	Jan 26, 2011	Jan	NEWA
AB		34MG	A091001 004	Jan 26, 2011	Jan	NEWA
	SULAR					
AB	+ SHIONOGI PHARMA	8.5MG	N020356 008	Jan 02, 2008	Jan	CFTG
AB	+	17MG	N020356 007	Jan 02, 2008	Jan	CFTG
AB		25.5MG	N020356 006	Jan 02, 2008	Jan	CFTG
AB	+	34MG	N020356 005	Jan 02, 2008	Jan	CFTG

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

AB	+ SHIONOGI INC	25MG/5ML	N009175 001		Apr	CFTG
AB	AMNEAL PHARMS	25MG/5ML	A201679 001	May 11, 2011	Apr	NEWA

NITROGLYCERIN

OINTMENT; INTRA-ANAL

RECTIV

+	PROSTRAKAN INC	0.4%	N021359 001	Jun 21, 2011	Jun	NEWA
---	----------------	------	-------------	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

>A>	AB	GLENMARK GENERICS	150MG	A090618 001	Jul 15, 2011	Jul	NEWA
>A>	AB		300MG	A090618 002	Jul 15, 2011	Jul	NEWA

CAPSULE; ORALNIZATIDINE

AB	MYLAN	150MG	A075934 001	Jul 09, 2002	Feb	CAHN
AB		300MG	A075934 002	Jul 09, 2002	Feb	CAHN

NORTRIPTYLINE HYDROCHLORIDESOLUTION; ORALPAMELOR

>A>	AA	MALLINCKRODT INC	EQ 10MG BASE/5ML	N018012 001		Jul	CAHN
>D>	AA	TYCO HLTHCARE	EQ 10MG BASE/5ML	N018012 001		Jul	CAHN

NYSTATINSUSPENSION; ORALNYSTATIN

AA	VISTAPHARM	100,000 UNITS/ML	A065422 001	Mar 07, 2011	Feb	NEWA
----	------------	------------------	-------------	--------------	-----	------

OCTREOTIDE ACETATEINJECTABLE; INJECTIONOCTREOTIDE ACETATE

AP	WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986 001	May 11, 2011	Apr	NEWA
AP		EQ 1MG BASE/ML	A090986 002	May 11, 2011	Apr	NEWA

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP	BIONICHE PHARMA USA	EQ 0.05MG BASE/ML	A079198 001	Feb 10, 2011	Jan	NEWA
AP		EQ 0.1MG BASE/ML	A079198 002	Feb 10, 2011	Jan	NEWA
AP		EQ 0.5MG BASE/ML	A079198 003	Feb 10, 2011	Jan	NEWA
AP	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985 001	May 11, 2011	Apr	NEWA
AP		EQ 0.1MG BASE/ML	A090985 002	May 11, 2011	Apr	NEWA
AP		EQ 0.5MG BASE/ML	A090985 003	May 11, 2011	Apr	NEWA

ONDANSETRONTABLET, ORALLY DISINTEGRATING; ORALONDANSETRON

AB	RANBAXY	4MG	A078602 001	Feb 24, 2011	Feb	NEWA
AB		8MG	A078602 002	Feb 24, 2011	Feb	NEWA

ONDANSETRON HYDROCHLORIDEINJECTABLE; INJECTIONONDANSETRON HYDROCHLORIDE

AP	PFIZER	EQ 2MG BASE/ML	A078257 001	Apr 23, 2008	May	CAHN
AP	TEVA	EQ 2MG BASE/ML	A076876 001	Nov 22, 2006	Jan	CMFD

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

AP	+	HOSPIRA	EQ 0.64MG BASE/ML	A077348 001	Feb 01, 2007	Apr	CRLD
----	---	---------	-------------------	-------------	--------------	-----	------

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	PFIZER	EQ 2MG BASE/ML	A078244 001	Apr 23, 2008	May	CAHN
----	--------	----------------	-------------	--------------	-----	------

SOLUTION; ORALONDANSETRON HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 4MG BASE/5ML	A091483 001	Jan 31, 2011	Jan	NEWA
AA	SILARX	EQ 4MG BASE/5ML	A091342 001	Jan 27, 2011	Jan	NEWA

TABLET; ORALONDANSETRON HYDROCHLORIDE

AB	TARO	EQ 4MG BASE	A077729 001	Mar 28, 2011	Mar	NEWA
AB		EQ 8MG BASE	A077729 002	Mar 28, 2011	Mar	NEWA
AB		EQ 24MG BASE	A077729 003	Mar 28, 2011	Mar	NEWA

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

		ROCHE	EQ 6MG BASE/ML	N021246 002	Mar 21, 2011	Jun	NEWA
>D>	+		EQ 12MG BASE/ML	N021246 001	Dec 14, 2000	Jul	DISC
>A>	+ @		EQ 12MG BASE/ML	N021246 001	Dec 14, 2000	Jul	DISC

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP		SANDOZ	50MG/10ML (5MG/ML)	A078817 001	Jan 24, 2011	Jan	NEWA
AP			50MG/VIAL	A090849 001	Apr 28, 2011	Apr	NEWA
AP			100MG/VIAL	A090849 002	Apr 28, 2011	Apr	NEWA
AP			100MG/20ML (5MG/ML)	A078817 002	Jan 24, 2011	Jan	NEWA

OXAPROZIN

TABLET; ORAL

OXAPROZIN

AB		MYLAN	600MG	A075847 001	Feb 28, 2001	Feb	CAHN
----	--	-------	-------	-------------	--------------	-----	------

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXECTA

		KING PHARMS R AND D	5MG	N202080 001	Jun 17, 2011	Jun	NEWA
			7.5MG	N202080 002	Jun 17, 2011	Jun	NEWA
			OXYCODONE HYDROCHLORIDE				
AB		COASTAL PHARMS	5MG	A091313 001	Feb 18, 2011	Feb	NEWA
AB			15MG	A091313 002	Feb 18, 2011	Feb	NEWA
AB			30MG	A091313 003	Feb 18, 2011	Feb	NEWA
AB		RHODES PHARMS	5MG	A091490 001	Mar 09, 2011	Feb	NEWA
AB			10MG	A091490 002	Mar 09, 2011	Feb	NEWA
AB			15MG	A091490 003	Mar 09, 2011	Feb	NEWA
AB			20MG	A091490 004	Mar 09, 2011	Feb	NEWA
AB			30MG	A091490 005	Mar 09, 2011	Feb	NEWA

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

	+	MEDA PHARMS	50MG	N016848 001		May	CAHN
--	---	-------------	------	-------------	--	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB		TEVA	5MG	A091443 002	Feb 15, 2011	Jan	NEWA
AB			10MG	A091443 001	Feb 15, 2011	Jan	NEWA
			TABLET, EXTENDED RELEASE; ORAL				
			OPANA ER				
		@ ENDO PHARMS	7.5MG	N021610 005	Feb 29, 2008	Feb	DISC
		@	15MG	N021610 006	Feb 29, 2008	Feb	DISC

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

>A>		JANSSEN PHARMS	1.5MG	N021999 006	Aug 26, 2008	Jul	CAHN
>A>			3MG	N021999 001	Dec 19, 2006	Jul	CAHN

TABLET, EXTENDED RELEASE; ORAL

INVEGA

>A>	+	JANSSEN PHARMS	6MG	N021999 002	Dec 19, 2006	Jul	CAHN
>A>			9MG	N021999 003	Dec 19, 2006	Jul	CAHN
>A>	@		12MG	N021999 004	Dec 19, 2006	Jul	CAHN
>D>		ORTHO MCNEIL JANSSEN	1.5MG	N021999 006	Aug 26, 2008	Jul	CAHN
>D>			3MG	N021999 001	Dec 19, 2006	Jul	CAHN
>D>	+		6MG	N021999 002	Dec 19, 2006	Jul	CAHN
>D>			9MG	N021999 003	Dec 19, 2006	Jul	CAHN
>D>	@		12MG	N021999 004	Dec 19, 2006	Jul	CAHN

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

		JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264 001	Jul 31, 2009	Jun	CAHN
			78MG/0.5ML (78MG/0.5ML)	N022264 002	Jul 31, 2009	Jun	CAHN
			117MG/0.75ML (117MG/0.75ML)	N022264 003	Jul 31, 2009	Jun	CAHN
			156MG/ML (156MG/ML)	N022264 004	Jul 31, 2009	Jun	CAHN
	+		234MG/1.5ML (156MG/ML)	N022264 005	Jul 31, 2009	Jun	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP		MUSTAFA NEVZAT	30MG/10ML (3MG/ML)	A078373 001	Dec 23, 2008	May	CAHN
AP			90MG/10ML (9MG/ML)	A078373 002	Dec 23, 2008	May	CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

PANCREAZE

		JANSSEN PHARMS	17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS	N022523 001	Apr 12, 2010	Jun	CAHN
			43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS	N022523 002	Apr 12, 2010	Jun	CAHN
			70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS	N022523 004	Apr 12, 2010	Jun	CAHN
	+		61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS	N022523 003	Apr 12, 2010	Jun	CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB		ACTAVIS TOTOWA	EQ 20MG BASE	A090797 001	Feb 07, 2011	Jan	NEWA
AB			EQ 40MG BASE	A090797 002	Feb 07, 2011	Jan	NEWA
AB		DR REDDYS LABS LTD	EQ 20MG BASE	A077619 001	Jan 19, 2011	Jan	NEWA
AB			EQ 40MG BASE	A077619 002	Jan 19, 2011	Jan	NEWA
AB		KUDCO IRELAND	EQ 20MG BASE	A078281 001	Jan 20, 2011	Jan	NEWA
AB			EQ 40MG BASE	A078281 002	Jan 20, 2011	Jan	NEWA
AB		MATRIX LABS LTD	EQ 20MG BASE	A090970 001	Jan 19, 2011	Jan	NEWA
AB			EQ 40MG BASE	A090970 002	Jan 19, 2011	Jan	NEWA
AB		TORRENT PHARMS	EQ 20MG BASE	A090074 001	Jan 19, 2011	Jan	NEWA
AB			EQ 40MG BASE	A090074 002	Jan 19, 2011	Jan	NEWA
AB		WOCKHARDT	EQ 20MG BASE	A091231 001	Jan 19, 2011	Jan	NEWA
AB			EQ 40MG BASE	A091231 002	Jan 19, 2011	Jan	NEWA

PARICALCITOL

INJECTABLE; INJECTION

>A>		PARICALCITOL							
>A>	AP	SANDOZ CANADA INC	0.002MG/ML	A091108	001	Jul 27, 2011	Jul	NEWA	
>A>	AP		0.005MG/ML	A091108	002	Jul 27, 2011	Jul	NEWA	
		ZEMPLAR							
>D>	+	ABBOTT	0.002MG/ML	N020819	002	Feb 01, 2000	Jul	CFTG	
>A>	AP	+	0.002MG/ML	N020819	002	Feb 01, 2000	Jul	CFTG	
>D>	+		0.005MG/ML	N020819	001	Apr 17, 1998	Jul	CFTG	
>A>	AP	+	0.005MG/ML	N020819	001	Apr 17, 1998	Jul	CFTG	

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

	@	MONARCH PHARMS	EQ 250MG BASE	A062310	001		May	CAHN	
--	---	----------------	---------------	---------	-----	--	-----	------	--

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

AB		MYLAN	EQ 37.5MG BASE	A091427	001	Apr 14, 2011	Apr	NEWA	
AB	+	GLAXOSMITHKLINE	EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Apr	CTEC	

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB		VALEANT INTL	400MG	A075028	001	Jul 20, 1998	Apr	CAHN	
----	--	--------------	-------	---------	-----	--------------	-----	------	--

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

>D>	AA	ACTAVIS TOTOWA	15MG	A040460	001	Jan 14, 2003	Jul	DISC	
>A>		@	15MG	A040460	001	Jan 14, 2003	Jul	DISC	
>D>	AA		30MG	A040227	001	Jun 18, 1997	Jul	DISC	
>D>	AA		30MG	A040448	001	Jan 22, 2003	Jul	DISC	
>A>		@	30MG	A040448	001	Jan 22, 2003	Jul	DISC	
>A>		@	30MG	A040227	001	Jun 18, 1997	Jul	DISC	
>D>	AA		37.5MG	A040228	001	Jun 19, 1997	Jul	DISC	
>A>		@	37.5MG	A040228	001	Jun 19, 1997	Jul	DISC	
>A>	AA	LANNETT HOLDINGS INC	37.5MG	A201961	001	Jul 20, 2011	Jul	NEWA	

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

>D>	AA	ACTAVIS TOTOWA	37.5MG	A040190	001	May 30, 1997	Jul	DISC	
>A>		@	37.5MG	A040190	001	May 30, 1997	Jul	DISC	
	AA	ELITE LABS	37.5MG	A200272	001	Jan 31, 2011	May	CAHN	
	AA	EPIC PHARMA LLC	37.5MG	A200272	001	Jan 31, 2011	Jan	NEWA	

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

		CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011	Jun	NEWA	
	+		30MG	N202088	002	Jun 13, 2011	Jun	NEWA	

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

>A>		LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011	Jul	NEWA	
-----	--	----------------------	--------------	---------	-----	--------------	-----	------	--

CAPSULE, EXTENDED RELEASE; ORAL
PHENTERMINE RESIN COMPLEX

>A> LANNETT HOLDINGS INC EQ 30MG BASE A040872 002 Jul 28, 2011 Jul NEWA

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN SODIUM

AP X-GEN PHARMS 50MG/ML A040573 001 Sep 13, 2006 May CAHN

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC
ISOPTO CARPINE

ALCON RES 1% N200890 001 Jun 22, 2010 May CTNA
2% N200890 002 Jun 22, 2010 May CTNA
+ 4% N200890 003 Jun 22, 2010 May CTNA

PIMECROLIMUS

CREAM; TOPICAL
ELIDEL

>D> + NOVARTIS 1% N021302 001 Dec 13, 2001 Jul CAHN
>A> + VALEANT INTL 1% N021302 001 Dec 13, 2001 Jul CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

AP AUROBINDO PHARMA LTD EQ 2GM BASE/VIAL;EQ 250MG A065498 001 May 23, 2011 May NEWA
BASE/VIAL
AP EQ 3GM BASE/VIAL;EQ 375MG A065498 002 May 23, 2011 May NEWA
BASE/VIAL
AP EQ 4GM BASE/VIAL;EQ 500MG A065498 003 May 23, 2011 May NEWA
BASE/VIAL
AP HOSPIRA INC EQ 2GM BASE/VIAL;EQ 250MG A065386 001 Sep 15, 2009 Jan CAHN
BASE/VIAL
AP EQ 3GM BASE/VIAL;EQ 375MG A065386 002 Sep 15, 2009 Jan CAHN
BASE/VIAL
AP EQ 4GM BASE/VIAL;EQ 500MG A065386 003 Sep 15, 2009 Jan CAHN
BASE/VIAL
AP EQ 36GM BASE/VIAL;EQ 4.5GM A065446 001 Sep 15, 2009 Jan CAHN
BASE/VIAL
AP INSTITUTO BIOCHEMICO EQ 2GM BASE/VIAL;EQ 250MG A065523 001 May 31, 2011 May NEWA
BASE/VIAL
AP EQ 3GM BASE/VIAL;EQ 375MG A065523 002 May 31, 2011 May NEWA
BASE/VIAL
AP EQ 4GM BASE/VIAL;EQ 500MG A065523 003 May 31, 2011 May NEWA
BASE/VIAL
AP EQ 36GM BASE/VIAL;EQ 4.5GM A090498 001 May 31, 2011 May NEWA
BASE/VIAL

PIROXICAM

CAPSULE; ORAL
PIROXICAM

@ MYLAN 10MG A074043 001 Sep 22, 1992 Feb CAHN
@ 20MG A074043 002 Sep 22, 1992 Feb CAHN

PITAVASTATIN CALCIUM

TABLET; ORAL
LIVALO

>D> KOWA EQ 1MG BASE N022363 001 Aug 03, 2009 Jul CAHN
>D> EQ 2MG BASE N022363 002 Aug 03, 2009 Jul CAHN
>D> + EQ 4MG BASE N022363 003 Aug 03, 2009 Jul CAHN

TABLET; ORAL

LIVALO

>A>	KOWA CO	EQ 1MG BASE	N022363 001	Aug 03, 2009	Jul	CAHN
>A>		EQ 2MG BASE	N022363 002	Aug 03, 2009	Jul	CAHN
>A>	+	EQ 4MG BASE	N022363 003	Aug 03, 2009	Jul	CAHN

PODOFILOX

SOLUTION; TOPICAL

PODOFILOX

AT	PRECISION DERMAT	0.5%	A090184 001	Jul 21, 2010	Jun	CAHN
----	------------------	------	-------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

@ MEDA PHARMS

		120GM/PACKET;1.49GM/PACKET;3.36GM	N018983 005	Oct 26, 1984	Jun	CAHN
		/PACKET;2.92GM/PACKET;11.36GM/PAC				
		KET				
>D>		227.1GM/PACKET;2.82GM/PACKET;6.36	N018983 004	Oct 26, 1984	Jul	DISC
		GM/PACKET;5.53GM/PACKET;21.5GM/PA				
		CKET				
>A>	@	227.1GM/PACKET;2.82GM/PACKET;6.36	N018983 004	Oct 26, 1984	Jul	DISC
		GM/PACKET;5.53GM/PACKET;21.5GM/PA				
		CKET				
		227.1GM/PACKET;2.82GM/PACKET;6.36	N018983 004	Oct 26, 1984	Jun	CAHN
		GM/PACKET;5.53GM/PACKET;21.5GM/PA				
		CKET				
AA	+	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT	N018983 010	Jan 31, 1989	Jun	CAHN
		;5.53GM/BOT;21.5GM/BOT				
AA	+	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5	N018983 007	Jun 12, 1987	Jun	CAHN
		.84GM/BOT;22.72GM/BOT				
	@	360GM/PACKET;4.47GM/PACKET;10.08G	N018983 006	Oct 26, 1984	Jun	CAHN
		M/PACKET;8.76GM/PACKET;34.08GM/PA				
		CKET				
		COLYTE WITH FLAVOR PACKS				
AA	+	MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5	N018983 012	Oct 08, 1998	Jun
			.84GM/BOT;22.72GM/BOT			CAHN
		COLYTE-FLAVORED				
AA	+	MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT	N018983 008	Nov 14, 1991	Jun
			;5.53GM/BOT;21.5GM/BOT			CAHN
AA	+		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5	N018983 009	Nov 14, 1991	Jun
			.84GM/BOT;22.72GM/BOT			CAHN

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYCIN B SULFATE

AP	SAGENT STRIDES	EQ 500,000 UNITS BASE/VIAL	A090110 001	Jun 29, 2011	Jun	NEWA
----	----------------	----------------------------	-------------	--------------	-----	------

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

@ PINNACLE BIOLGS

75MG/VIAL

N020451 001 Dec 27, 1995 Jun DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB	PADDOCK LABS	8MEQ	A200185 001	May 18, 2011	May	NEWA
AB		10MEQ	A200185 002	May 18, 2011	May	NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

BOEHRINGER INGELHEIM 2.25MG

N022421 006 Jun 17, 2011 Jun NEWA

3.75MG

N022421 007 Jun 17, 2011 Jun NEWA

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

@ VINTAGE PHARMS EQ 5MG BASE/5ML

A078416 001 Oct 31, 2007 May DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

AB JUBILANT CADISTA 1MG

A040611 001 Jun 06, 2005 Jan CAHN

AB 5MG

A040362 002 Aug 29, 2001 Jan CAHN

AB 10MG

A040362 001 Aug 29, 2001 Jan CAHN

AB 20MG

A040362 003 Jun 29, 2005 Jan CAHN

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCOMP

AB JUBILANT CADISTA EQ 5MG BASE

A040268 001 Feb 27, 1998 Jan CAHN

AB EQ 10MG BASE

A040268 002 Feb 27, 1998 Jan CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

AP X-GEN PHARMS 25MG/ML

A040737 001 Apr 24, 2008 May CAHN

AP 50MG/ML

A040737 002 Apr 24, 2008 May CAHN

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

+ ROXANE 15MG

A080927 002 Jan CMFD

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

@ XANODYNE PHARM 65MG

N010997 003 Jan DISC

PROPOXYPHENE HYDROCHLORIDE

@ TEVA 65MG

A088615 001 Oct 22, 1984 Mar DISC

@ VINTAGE PHARMS 65MG

A040908 001 Jul 17, 2009 Mar DISC

@ WEST WARD 65MG

A083501 001 Jan DISC

PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVON-N

@ XANODYNE PHARM 100MG

N016862 002 Jan DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

>A> AB GLAXOSMITHKLINE 60MG

A078703 001 Jul 15, 2011 Jul NEWA

>A> AB 80MG

A078703 002 Jul 15, 2011 Jul NEWA

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

>A>	AB	GLAXOSMITHKLINE	120MG	A078703 003	Jul 15, 2011	Jul	NEWA
>A>	AB		160MG	A078703 004	Jul 15, 2011	Jul	NEWA
	AB	ZYDUS PHARMS USA INC	60MG	A090321 001	Mar 25, 2011	Mar	NEWA
	AB		80MG	A090321 002	Mar 25, 2011	Mar	NEWA
	AB		120MG	A090321 003	Mar 25, 2011	Mar	NEWA
	AB		160MG	A090321 004	Mar 25, 2011	Mar	NEWA

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

	AB	MYLAN	60MG	A070213 005	Apr 08, 2011	Mar	NEWA
--	----	-------	------	-------------	--------------	-----	------

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

	+	COREPHARMA	25MG	N008578 001		Jun	CAHN
--	---	------------	------	-------------	--	-----	------

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

>D>	AB	ACTAVIS TOTOWA	EQ 5MG BASE	A076459 001	Dec 22, 2004	Jul	DISC
>A>		@	EQ 5MG BASE	A076459 001	Dec 22, 2004	Jul	DISC
>D>	AB		EQ 10MG BASE	A076459 002	Dec 22, 2004	Jul	DISC
>A>		@	EQ 10MG BASE	A076459 002	Dec 22, 2004	Jul	DISC
>D>	AB		EQ 20MG BASE	A076459 003	Dec 22, 2004	Jul	DISC
>A>		@	EQ 20MG BASE	A076459 003	Dec 22, 2004	Jul	DISC
>D>	AB		EQ 40MG BASE	A076459 004	Dec 22, 2004	Jul	DISC
>A>		@	EQ 40MG BASE	A076459 004	Dec 22, 2004	Jul	DISC
	AB	MYLAN	EQ 5MG BASE	A076036 001	Jan 28, 2005	Feb	CAHN
	AB		EQ 10MG BASE	A076036 002	Jan 28, 2005	Feb	CAHN
	AB		EQ 20MG BASE	A076036 003	Jan 28, 2005	Feb	CAHN
	AB		EQ 40MG BASE	A076036 004	Jan 28, 2005	Feb	CAHN

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

	AB	AUROBINDO PHARMA LTD	1.25MG	A091604 001	Jun 08, 2011	May	NEWA
	AB		2.5MG	A091604 002	Jun 08, 2011	May	NEWA
	AB		5MG	A091604 003	Jun 08, 2011	May	NEWA
	AB		10MG	A091604 004	Jun 08, 2011	May	NEWA

TABLET; ORAL

RAMIPRIL

	AB	MATRIX LABS LTD	1.25MG	A090650 001	Jun 30, 2011	Jun	NEWA
	AB		2.5MG	A090650 002	Jun 30, 2011	Jun	NEWA
	AB		5MG	A090650 003	Jun 30, 2011	Jun	NEWA
	AB		10MG	A090650 004	Jun 30, 2011	Jun	NEWA

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

	@	MYLAN	EQ 150MG BASE	A075564 001	Oct 27, 2000	Feb	CAHN
	@		EQ 300MG BASE	A075564 002	Oct 27, 2000	Feb	CAHN

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA		HI TECH PHARMA	EQ 15MG BASE/ML	A091078 001	Mar 22, 2011	Mar	NEWA
AA		TARO	EQ 15MG BASE/ML	A077476 001	Jun 13, 2011	May	NEWA

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

AB	MYLAN	EQ 150MG BASE	A074023 001	Aug 22, 1997	Feb	CAHN
AB		EQ 300MG BASE	A074023 002	Aug 22, 1997	Feb	CAHN

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

>D>	AB	ACTAVIS TOTOWA	300MG	N050429 001		Jul	DISC
>A>		@	300MG	N050429 001		Jul	DISC

INJECTABLE; INJECTION

RIFAMPIN

AP	PFIZER	600MG/VIAL	A065421 001	May 22, 2008	May	CAHN
----	--------	------------	-------------	--------------	-----	------

RIFAXIMIN

TABLET; ORAL

XIFAXAN

+	SALIX PHARMS	550MG	N022554 001	Mar 24, 2010	Feb	CRLD
---	--------------	-------	-------------	--------------	-----	------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	TIBOTEC	EQ 25MG BASE	N202022 001	May 20, 2011	May	NEWA
---	---------	--------------	-------------	--------------	-----	------

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

>D>	AB	ACTAVIS TOTOWA	100MG	A076375 001	Jan 14, 2003	Jul	DISC
>A>		@	100MG	A076375 001	Jan 14, 2003	Jul	DISC

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

	JANSSEN PHARMS	12.5MG/VIAL	N021346 004	Apr 12, 2007	Jun	CAHN
+		25MG/VIAL	N021346 001	Oct 29, 2003	Jun	CAHN
		37.5MG/VIAL	N021346 002	Oct 29, 2003	Jun	CAHN
		50MG/VIAL	N021346 003	Oct 29, 2003	Jun	CAHN

SOLUTION; ORAL

RISPERDAL

AA	+	JANSSEN PHARMS	1MG/ML	N020588 001	Jun 10, 1996	Jun	CAHN
----	---	----------------	--------	-------------	--------------	-----	------

RISPERIDONE

AA		AMNEAL PHARMS	1MG/ML	A091384 001	May 25, 2011	May	NEWA
AA		TARO	1MG/ML	A090347 001	Feb 07, 2011	Jan	NEWA

TABLET; ORAL

RISPERDAL

AB		JANSSEN PHARMS	0.25MG	N020272 008	May 10, 1999	Jun	CAHN
AB			0.5MG	N020272 007	Jan 27, 1999	Jun	CAHN
AB	+		1MG	N020272 001	Dec 29, 1993	Jun	CAHN
AB			2MG	N020272 002	Dec 29, 1993	Jun	CAHN
AB			3MG	N020272 003	Dec 29, 1993	Jun	CAHN
AB			4MG	N020272 004	Dec 29, 1993	Jun	CAHN
		@	5MG	N020272 005	Dec 29, 1993	Jun	CAHN

RISPERIDONE

>D>	AB	ACTAVIS TOTOWA	0.25MG	A078071 001	Jun 17, 2009	Jul	DISC
>A>		@	0.25MG	A078071 001	Jun 17, 2009	Jul	DISC
>D>	AB		0.5MG	A078071 002	Jun 17, 2009	Jul	DISC

TABLET; ORAL

RISPERIDONE

>A>	@	ACTAVIS TOTOWA	0.5MG	A078071 002	Jun 17, 2009	Jul	DISC
>D>	AB		1MG	A078071 003	Jun 17, 2009	Jul	DISC
>A>	@		1MG	A078071 003	Jun 17, 2009	Jul	DISC
>D>	AB		2MG	A078071 004	Jun 17, 2009	Jul	DISC
>A>	@		2MG	A078071 004	Jun 17, 2009	Jul	DISC
>D>	AB		3MG	A078071 005	Jun 17, 2009	Jul	DISC
>A>	@		3MG	A078071 005	Jun 17, 2009	Jul	DISC
>D>	AB		4MG	A078071 006	Jun 17, 2009	Jul	DISC
>A>	@		4MG	A078071 006	Jun 17, 2009	Jul	DISC
	AB	CIPLA	0.25MG	A077543 001	May 18, 2011	May	NEWA
	AB		0.5MG	A077543 002	May 18, 2011	May	NEWA
	AB		1MG	A077543 003	May 18, 2011	May	NEWA
	AB		2MG	A077543 004	May 18, 2011	May	NEWA
	AB		3MG	A077543 005	May 18, 2011	May	NEWA
	AB		4MG	A077543 006	May 18, 2011	May	NEWA
	@	RATIOPHARM	0.25MG	A077784 001	Jun 08, 2010	Feb	DISC
	@		0.5MG	A077784 002	Jun 08, 2010	Feb	DISC
	@		1MG	A077784 003	Jun 08, 2010	Feb	DISC
	@		2MG	A077784 004	Jun 08, 2010	Feb	DISC
	@		3MG	A077784 005	Jun 08, 2010	Feb	DISC
	@		4MG	A077784 006	Jun 08, 2010	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

>A>	AB	JANSSEN PHARMS	0.5MG	N021444 001	Apr 02, 2003	Jul	CAHN
>A>	AB	+	1MG	N021444 002	Apr 02, 2003	Jul	CAHN
>A>	AB		2MG	N021444 003	Apr 02, 2003	Jul	CAHN
>A>	AB		3MG	N021444 004	Dec 23, 2004	Jul	CAHN
>A>	AB		4MG	N021444 005	Dec 23, 2004	Jul	CAHN
>D>	AB	ORTHO MCNEIL JANSSEN	0.5MG	N021444 001	Apr 02, 2003	Jul	CAHN
>D>	AB	+	1MG	N021444 002	Apr 02, 2003	Jul	CAHN
>D>	AB		2MG	N021444 003	Apr 02, 2003	Jul	CAHN
>D>	AB		3MG	N021444 004	Dec 23, 2004	Jul	CAHN
>D>	AB		4MG	N021444 005	Dec 23, 2004	Jul	CAHN

RISPERIDONE

	AB	MYLAN	0.5MG	A091537 001	Mar 30, 2011	Mar	NEWA
	AB		1MG	A091537 002	Mar 30, 2011	Mar	NEWA
	AB		2MG	A091537 003	Mar 30, 2011	Mar	NEWA
	AB		3MG	A091537 004	Mar 30, 2011	Mar	NEWA
	AB		4MG	A091537 005	Mar 30, 2011	Mar	NEWA
	AB	WATSON LABS FLORIDA	0.5MG	A076996 001	Apr 19, 2011	Apr	NEWA
	AB		1MG	A076996 002	Apr 19, 2011	Apr	NEWA
	AB		2MG	A076996 003	Apr 19, 2011	Apr	NEWA
	AB		3MG	A076996 004	Apr 19, 2011	Apr	NEWA
	AB		4MG	A076996 005	Apr 19, 2011	Apr	NEWA

>A> RIVAROXABAN

>A> TABLET; ORAL

>A> XARELTO

>A>	+	JOHNSON AND JOHNSON	10MG	N022406 001	Jul 01, 2011	Jul	NEWA
-----	---	---------------------	------	-------------	--------------	-----	------

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP		SAGENT STRIDES	50MG/5ML (10MG/ML)	A091458 001	Jul 28, 2010	Jan	CAHN
----	--	----------------	--------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

	ROCURONIUM BROMIDE								
AP	SAGENT STRIDES	100MG/10ML (10MG/ML)		A091458	002	Jul 28, 2010	Jan	CAHN	

ROFLUMILAST

TABLET; ORAL

DALIRESP

+	FOREST RES INST INC	500MCG		N022522	001	Feb 28, 2011	Feb	NEWA	
---	---------------------	--------	--	---------	-----	--------------	-----	------	--

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	PRINSTON PHARM LLC	EQ 0.25MG BASE		A078110	001	May 05, 2008	May	CAHN	
AB		EQ 0.5MG BASE		A078110	002	May 05, 2008	May	CAHN	
AB		EQ 1MG BASE		A078110	003	May 05, 2008	May	CAHN	
AB		EQ 2MG BASE		A078110	004	May 05, 2008	May	CAHN	
AB		EQ 3MG BASE		A078110	005	May 05, 2008	May	CAHN	
AB		EQ 4MG BASE		A078110	006	May 05, 2008	May	CAHN	

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

+	EISAI INC	40MG/ML		N201367	001	Mar 03, 2011	Mar	NEWA	
---	-----------	---------	--	---------	-----	--------------	-----	------	--

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+	MARATHON PHARMS	50MG		A086101	001	Oct 03, 1983	Jan	CAHN	
+		100MG		A086101	002	Oct 03, 1983	Jan	CAHN	

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

>D>	+	ORTHO DERMATOLOGICS	2%			N021385	001	Dec 10, 2003	Jul	CAHN
>A>	+	ORTHO JANSSEN	2%			N021385	001	Dec 10, 2003	Jul	CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@ ROXANE

EQ 20MG BASE/ML

				A076934	001	Jun 30, 2006	Mar	DISC	
--	--	--	--	---------	-----	--------------	-----	------	--

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>D>	AB	ACTAVIS TOTOWA	EQ 25MG BASE			A078175	001	Jul 21, 2010	Jul	DISC
>A>		@	EQ 25MG BASE			A078175	001	Jul 21, 2010	Jul	DISC
>D>	AB		EQ 50MG BASE			A078175	002	Jul 21, 2010	Jul	DISC
>A>		@	EQ 50MG BASE			A078175	002	Jul 21, 2010	Jul	DISC
>D>	AB		EQ 100MG BASE			A078175	003	Jul 21, 2010	Jul	DISC
>A>		@	EQ 100MG BASE			A078175	003	Jul 21, 2010	Jul	DISC
		@	IVAX SUB TEVA PHARMS	EQ 25MG BASE		A075719	003	Jun 30, 2006	Apr	DISC
		@		EQ 50MG BASE		A075719	001	Jun 30, 2006	Apr	DISC
		@		EQ 100MG BASE		A075719	002	Jun 30, 2006	Apr	DISC
	AB	MYLAN	EQ 25MG BASE			A076540	001	Mar 20, 2007	Feb	CAHN
	AB		EQ 50MG BASE			A076540	002	Mar 20, 2007	Feb	CAHN
	AB		EQ 100MG BASE			A076540	003	Mar 20, 2007	Feb	CAHN
>D>	AB	PLIVA HRVATSKA DOO	EQ 25MG BASE			A077299	001	Feb 06, 2007	Jul	DISC
>A>		@	EQ 25MG BASE			A077299	001	Feb 06, 2007	Jul	DISC

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>D>	AB	PLIVA HRVATSKA DOO	EQ 50MG BASE	A077299 002	Feb 06, 2007	Jul	DISC
>A>		@	EQ 50MG BASE	A077299 002	Feb 06, 2007	Jul	DISC
>D>	AB		EQ 100MG BASE	A077299 003	Feb 06, 2007	Jul	DISC
>A>		@	EQ 100MG BASE	A077299 003	Feb 06, 2007	Jul	DISC
		@ ROXANE	EQ 25MG BASE	A076881 001	Feb 06, 2007	Mar	DISC
		@	EQ 50MG BASE	A076881 002	Feb 06, 2007	Mar	DISC
		@	EQ 100MG BASE	A076881 003	Feb 06, 2007	Mar	DISC

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

>D>	AB	ACTAVIS TOTOWA	5MG	A078735 001	Aug 30, 2010	Jul	DISC
>A>		@	5MG	A078735 001	Aug 30, 2010	Jul	DISC
>D>	AB		10MG	A078735 002	Aug 30, 2010	Jul	DISC
>A>		@	10MG	A078735 002	Aug 30, 2010	Jul	DISC
>D>	AB		20MG	A078735 003	Aug 30, 2010	Jul	DISC
>A>		@	20MG	A078735 003	Aug 30, 2010	Jul	DISC
>D>	AB		40MG	A078735 004	Aug 30, 2010	Jul	DISC
>A>		@	40MG	A078735 004	Aug 30, 2010	Jul	DISC
>D>	AB		80MG	A078735 005	Aug 30, 2010	Jul	DISC
>A>		@	80MG	A078735 005	Aug 30, 2010	Jul	DISC

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+	MEDIGENE AG	15%	N021902 001	Oct 31, 2006	May	CAHN
---	-------------	-----	-------------	--------------	-----	------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

AB	+	SANOFI AVENTIS US	62.5MG/5ML	N020955 001	Feb 18, 1999	Mar	CFTG
		SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE					
AB		GENERAMEDIX	62.5MG/5ML	A078215 001	Mar 31, 2011	Mar	NEWA

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F 18

	@	NIH NCI DCTD	10-200mCi/ML	N022494 001	Jan 26, 2011	Apr	DISC
+			10-200mCi/ML	N022494 001	Jan 26, 2011	Jan	NEWA

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODOTE

+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5G M/50ML(250MG/ML)	N201444 001	Jan 14, 2011	Feb	CTNA
---	-------------	--	-------------	--------------	-----	------

SODIUM NITRITE

+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5G M/50ML(250MG/ML)	N201444 001	Jan 14, 2011	Jan	NEWA
---	-------------	--	-------------	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		PADDOCK LABS	15GM/60ML	A090590 001	May 13, 2011	May	NEWA
----	--	--------------	-----------	-------------	--------------	-----	------

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

@	PFIZER	EQ 2GM BASE/VIAL	N050347 001		Jun	DISC
@		EQ 4GM BASE/VIAL	N050347 002		Jun	CAHN

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	PARAPRO PHARMS	0.9%	N022408 001	Jan 18, 2011	Jan	NEWA
---	----------------	------	-------------	--------------	-----	------

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

>D>	+	PFIZER	EQ 1GM BASE/2.5ML	A060111 001		Jul	DISC
>A>	@		EQ 1GM BASE/2.5ML	A060111 001		Jul	DISC

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX STATDOSE

AB	+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080 003	Dec 23, 1996	Jun	CFTG
----	---	-----------------	-------------------------------------	-------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

AB		SUN PHARM INDS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358 001	Jun 21, 2011	Jun	NEWA
----	--	--------------------	-------------------------------------	-------------	--------------	-----	------

TABLET; ORAL

SUMATRIPTAN SUCCINATE

@	ROXANE	EQ 25MG BASE	A078241 001	Aug 10, 2009	Mar	DISC
@		EQ 50MG BASE	A078241 002	Aug 10, 2009	Mar	DISC
@		EQ 100MG BASE	A078241 003	Aug 10, 2009	Mar	DISC

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

COGNEX

@	SHIONOGI INC	EQ 10MG BASE	N020070 001	Sep 09, 1993	Jun	DISC
@		EQ 20MG BASE	N020070 002	Sep 09, 1993	Jun	DISC
@		EQ 30MG BASE	N020070 003	Sep 09, 1993	Jun	DISC
@		EQ 40MG BASE	N020070 004	Sep 09, 1993	Jun	DISC

TELAPREVIR

TABLET; ORAL

INCIVEK

+	VERTEX PHARMS	375MG	N201917 001	May 23, 2011	May	NEWA
---	---------------	-------	-------------	--------------	-----	------

TELBIVUDINE

SOLUTION; ORAL

TYZEKA

@	NOVARTIS	100MG/5ML	N022154 001	Apr 28, 2009	Jun	DISC
---	----------	-----------	-------------	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB		JUBILANT CADISTA	EQ 1MG BASE	A075317 001	Dec 20, 2004	Jan	CAHN
AB			EQ 2MG BASE	A075317 002	Dec 20, 2004	Jan	CAHN
AB			EQ 5MG BASE	A075317 003	Dec 20, 2004	Jan	CAHN

CAPSULE; ORAL

	TERAZOSIN HYDROCHLORIDE								
AB	JUBILANT CADISTA	EQ 10MG BASE	A075317	004	Dec 20, 2004	Jan	CAHN		

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

	TERBINAFINE HYDROCHLORIDE								
AB	MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007	Feb	CAHN		
	@ ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007	Feb	DISC		

TERBUTALINE SULFATE

TABLET; ORAL

	TERBUTALINE SULFATE								
AB	+ IMPAX LABS	5MG	A075877	002	Jun 26, 2001	Jan	CRLD		

TESTOSTERONE

GEL, METERED; TRANSDERMAL

ANDROGEL

	ABBOTT PRODS	1.62% (20.25MG/1.25GM ACTIVATION)	N022309	001	Apr 29, 2011	Apr	NEWA		
--	--------------	-----------------------------------	---------	-----	--------------	-----	------	--	--

FORTESTA

	ENDO PHARMS	10MG/0.5GM ACTIVATION	N021463	001	Dec 29, 2010	Mar	CPOT		
--	-------------	-----------------------	---------	-----	--------------	-----	------	--	--

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

	ACTIENT PHARMS	30MG	N021543	001	Jun 19, 2003	Jun	CAHN		
--	----------------	------	---------	-----	--------------	-----	------	--	--

TETRABENAZINE

TABLET; ORAL

XENAZINE

	VALEANT INTL	12.5MG	N021894	001	Aug 15, 2008	Jun	CAHN		
--	--------------	--------	---------	-----	--------------	-----	------	--	--

	+	25MG	N021894	002	Aug 15, 2008	Jun	CAHN		
--	---	------	---------	-----	--------------	-----	------	--	--

TETRACYCLINE HYDROCHLORIDE

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

	@ SCHIFF AND CO	12.7MG/FIBER	N050653	001	Mar 25, 1994	Jun	CAHN		
--	-----------------	--------------	---------	-----	--------------	-----	------	--	--

>D> SUSPENSION; ORAL

>D> SUMYCIN

>D>	+	PAR PHARM	125MG/5ML	A060400	001		Jul	DISC	
-----	---	-----------	-----------	---------	-----	--	-----	------	--

>A>		@	125MG/5ML	A060400	001		Jul	DISC	
-----	--	---	-----------	---------	-----	--	-----	------	--

>D> TABLET; ORAL

>D> SUMYCIN

>D>		PAR PHARM	250MG	A061147	001		Jul	DISC	
-----	--	-----------	-------	---------	-----	--	-----	------	--

>A>		@	250MG	A061147	001		Jul	DISC	
-----	--	---	-------	---------	-----	--	-----	------	--

>D>	+		500MG	A061147	004		Jul	DISC	
-----	---	--	-------	---------	-----	--	-----	------	--

>A>		@	500MG	A061147	004		Jul	DISC	
-----	--	---	-------	---------	-----	--	-----	------	--

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

BC	ACTIENT PHARMS	100MG	A087942	001	Aug 22, 1983	Jun	CAHN		
----	----------------	-------	---------	-----	--------------	-----	------	--	--

BC		200MG	A087943	001	Aug 22, 1983	Jun	CAHN		
----	--	-------	---------	-----	--------------	-----	------	--	--

BC		300MG	A087944	001	Aug 22, 1983	Jun	CAHN		
----	--	-------	---------	-----	--------------	-----	------	--	--

		400MG	A081034	001	Feb 28, 1992	Jun	CAHN		
--	--	-------	---------	-----	--------------	-----	------	--	--

SOLUTION; ORAL

THEOPHYLLINE

	+	SILARX	80MG/15ML	A091156	001	Apr 13, 2011	Mar	NEWA	
--	---	--------	-----------	---------	-----	--------------	-----	------	--

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HYDROCHLORIDE
@ HOSPIRA

100MG/ML

A040079 001 May 03, 1996 May DISC

>A> TICAGRELOR

>A> TABLET; ORAL

>A> BRILINTA

>A> + ASTRAZENECA LP 90MG

N022433 001 Jul 20, 2011 Jul NEWA

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLOPIDINE HYDROCHLORIDE

AB MYLAN 250MG

A075161 001 Sep 13, 1999 Feb CAHN

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AT APOTEX INC EQ 0.25% BASE

A075411 001 Sep 08, 2000 Jun CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL
TIZANIDINE HYDROCHLORIDE

>D> AB ACTAVIS TOTOWA EQ 2MG BASE

A076281 001 Oct 20, 2003 Jul DISC

>A> @ EQ 2MG BASE

A076281 001 Oct 20, 2003 Jul DISC

>D> AB EQ 4MG BASE

A076281 002 Oct 20, 2003 Jul DISC

>A> @ EQ 4MG BASE

A076281 002 Oct 20, 2003 Jul DISC

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBRAMYCIN

AT FERA PHARMS 0.3%

A065026 001 Sep 11, 2001 Mar CAHN

TOLCAPONE

TABLET; ORAL
TASMAR

+ VALEANT PHARM INTL 100MG

N020697 001 Jan 29, 1998 Jun CRLD

@ 200MG

N020697 002 Jan 29, 1998 Jun DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
TOPOTECAN HYDROCHLORIDE

AP DR REDDYS LABS LTD EQ 4MG BASE/VIAL

A201191 001 Mar 09, 2011 Feb NEWA

AP SAGENT PHARMS EQ 4MG BASE/VIAL

A091284 001 Jan 26, 2011 Jan NEWA

SOLUTION; INTRAVENOUS
TOPOTECAN

AP HOSPIRA INC EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

N200582 001 Feb 02, 2011 Feb NEWA

SANDOZ EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N200199 001 Feb 25, 2011 Feb NEWA

EQ 3MG BASE/3ML (EQ 1MG BASE/ML)

N200199 002 Feb 25, 2011 Feb NEWA

AP + EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

N200199 003 Feb 25, 2011 Feb NEWA

TORSEMIDE

TABLET; ORAL
TORSEMIDE

AB VINTAGE PHARMS 5MG

A090613 001 Mar 22, 2011 Mar NEWA

TABLET; ORAL

TORSEMIDE

AB	VINTAGE PHARMS	10MG	A090613 002	Mar 22, 2011	Mar	NEWA
AB		20MG	A090613 003	Mar 22, 2011	Mar	NEWA
AB		100MG	A090613 004	Mar 22, 2011	Mar	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	50MG	A090404 001	Jan 31, 2011	Jan	NEWA
----	----------------------	------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

ULTRAM ER

AB	+ VALEANT INTL	100MG	N021692 001	Sep 08, 2005	Jun	CAHN
AB		200MG	N021692 002	Sep 08, 2005	Jun	CAHN
BC		300MG	N021692 003	Sep 08, 2005	Jun	CAHN

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

@	ALCON	0.004%	N021257 001	Mar 16, 2001	May	DISC
---	-------	--------	-------------	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

+	ANGELINI LABOPHARM	150MG	N022411 001	Feb 02, 2010	Jun	CAHN
		300MG	N022411 002	Feb 02, 2010	May	CAHN

TRETINOIN

CREAM; TOPICAL

RENOVA

>D>	+	ORTHO DERMATOLOGICS	0.02%	N021108 001	Aug 31, 2000	Jul	CAHN
>D>	AB2	+	0.05%	N019963 001	Dec 29, 1995	Jul	CAHN
>A>	+	ORTHO JANSSEN	0.02%	N021108 001	Aug 31, 2000	Jul	CAHN
>A>	AB2	+	0.05%	N019963 001	Dec 29, 1995	Jul	CAHN

RETIN-A

>D>	AB	+	JOHNSON AND JOHNSON	0.025%	N019049 001	Sep 16, 1988	Jul	CAHN
>D>	AB1	+		0.05%	N017522 001		Jul	CAHN
>D>	AB	+		0.1%	N017340 001		Jul	CAHN
>A>	AB	+	ORTHO JANSSEN	0.025%	N019049 001	Sep 16, 1988	Jul	CAHN
>A>	AB1	+		0.05%	N017522 001		Jul	CAHN
>A>	AB	+		0.1%	N017340 001		Jul	CAHN

GEL; TOPICAL

RETIN-A

>D>	AB	+	JOHNSON AND JOHNSON	0.01%	N017955 001		Jul	CAHN
>D>	AB	+		0.025%	N017579 002		Jul	CAHN
>A>	AB	+	ORTHO JANSSEN	0.01%	N017955 001		Jul	CAHN
>A>	AB	+		0.025%	N017579 002		Jul	CAHN

SOLUTION; TOPICAL

RETIN-A

>D>	AT	+	JOHNSON AND JOHNSON	0.05%	N016921 001		Jul	CAHN
>A>	AT	+	ORTHO JANSSEN	0.05%	N016921 001		Jul	CAHN

SWAB; TOPICAL

RETIN-A

>D>	@	JOHNSON AND JOHNSON	0.05%	N016921 002		Jul	CAHN
>A>	@	ORTHO JANSSEN	0.05%	N016921 002		Jul	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP	LUITPOLD	100MG/ML	A091330 001	Mar 08, 2011	May	CAHN
AP	PHARMAFORCE	100MG/ML	A091330 001	Mar 08, 2011	Feb	NEWA
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE						
AP	LUITPOLD	100MG/ML	A091329 001	Mar 08, 2011	May	CAHN
AP	PHARMAFORCE	100MG/ML	A091329 001	Mar 08, 2011	Feb	NEWA

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

AB	NOVEL LABS INC	100MG	A091437 001	Jun 15, 2011	May	NEWA
----	----------------	-------	-------------	--------------	-----	------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

AB	MIKAH PHARMA	EQ 25MG BASE	A077361 001	Aug 02, 2006	Feb	CAHN
AB		EQ 50MG BASE	A077361 002	Aug 02, 2006	Feb	CAHN
AB		EQ 100MG BASE	A077361 003	Aug 02, 2006	Feb	CAHN

URSODIOL

TABLET; ORAL

URSODIOL

>A>	AB	GLENMARK GENERICS	250MG	A090801 001	Jul 12, 2011	Jul	NEWA
>A>	AB		500MG	A090801 002	Jul 12, 2011	Jul	NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	ACTAVIS PHARMA	EQ 500MG BASE	A090370 001	Mar 16, 2011	Feb	NEWA
AB		EQ 1GM BASE	A090370 002	Mar 16, 2011	Feb	NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	PFIZER	EQ 500MG BASE/VIAL	A065397 001	Dec 30, 2008	May	CAHN
AP		EQ 1GM BASE/VIAL	A065397 002	Dec 30, 2008	May	CAHN
AP		EQ 5GM BASE/VIAL	A065432 001	Dec 30, 2008	May	CAHN
AP		EQ 10GM BASE/VIAL	A091469 001	Jul 01, 2011	Jun	NEWA

VANDETANIB

TABLET; ORAL

VANDETANIB

	IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Apr	NEWA
+		300MG	N022405 002	Apr 06, 2011	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	PFIZER	10MG/VIAL	A090243 001	May 11, 2010	May	CAHN
AP		20MG/VIAL	A090243 002	May 11, 2010	May	CAHN

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834 001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A200834 002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A200834 003	Apr 14, 2011	Apr	NEWA
AB	DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421 001	May 06, 2011	Apr	NEWA
AB		EQ 75MG BASE	A078421 002	May 06, 2011	Apr	NEWA
AB		EQ 150MG BASE	A078421 003	May 06, 2011	Apr	NEWA
AB	MYLAN	EQ 37.5MG BASE	A078789 001	Jun 01, 2011	May	NEWA
AB		EQ 75MG BASE	A078789 002	Jun 01, 2011	May	NEWA
AB		EQ 150MG BASE	A078789 003	Jun 01, 2011	May	NEWA
AB	ORCHID HLTHCARE	EQ 37.5MG BASE	A091123 001	Jul 11, 2011	Jun	NEWA
AB		EQ 75MG BASE	A091123 002	Jul 11, 2011	Jun	NEWA
AB		EQ 150MG BASE	A091123 003	Jul 11, 2011	Jun	NEWA
AB	TORRENT PHARMS LLC	EQ 37.5MG BASE	A090899 001	Jun 01, 2011	May	NEWA
AB		EQ 75MG BASE	A090899 002	Jun 01, 2011	May	NEWA
AB		EQ 150MG BASE	A090899 003	Jun 01, 2011	May	NEWA
AB	VALEANT INTL	EQ 37.5MG BASE	A090071 001	Apr 15, 2011	Apr	NEWA
AB		EQ 75MG BASE	A090071 002	Apr 15, 2011	Apr	NEWA
AB		EQ 150MG BASE	A090071 003	Apr 15, 2011	Apr	NEWA
AB	WOCKHARDT	EQ 37.5MG BASE	A078865 001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A078865 002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A078865 003	Apr 14, 2011	Apr	NEWA
AB	ZYDUS PHARMS USA INC	EQ 37.5MG BASE	A090174 001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A090174 002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A090174 003	Apr 14, 2011	Apr	NEWA

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

>D>	AB	ALEMBIC LTD	EQ 25MG BASE	A078932 001	Dec 14, 2010	Jul	CAHN
>D>	AB		EQ 37.5MG BASE	A078932 002	Dec 14, 2010	Jul	CAHN
>D>	AB		EQ 50MG BASE	A078932 003	Dec 14, 2010	Jul	CAHN
>D>	AB		EQ 75MG BASE	A078932 004	Dec 14, 2010	Jul	CAHN
>D>	AB		EQ 100MG BASE	A078932 005	Dec 14, 2010	Jul	CAHN
>A>	AB	ALEMBIC PHARMS LTD	EQ 25MG BASE	A078932 001	Dec 14, 2010	Jul	CAHN
>A>	AB		EQ 37.5MG BASE	A078932 002	Dec 14, 2010	Jul	CAHN
>A>	AB		EQ 50MG BASE	A078932 003	Dec 14, 2010	Jul	CAHN
>A>	AB		EQ 75MG BASE	A078932 004	Dec 14, 2010	Jul	CAHN
>A>	AB		EQ 100MG BASE	A078932 005	Dec 14, 2010	Jul	CAHN

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

>A>	AB	GLENMARK GENERICS	120MG	A090700 001	Aug 03, 2011	Jul	NEWA
>A>	AB		180MG	A090700 002	Aug 03, 2011	Jul	NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

		FOREST LABS INC	10MG	N022567 001	Jan 21, 2011	May	CAHN
			20MG	N022567 002	Jan 21, 2011	May	CAHN
	+		40MG	N022567 003	Jan 21, 2011	May	CAHN
		TROVIS PHARMS	10MG	N022567 001	Jan 21, 2011	Jan	NEWA
			20MG	N022567 002	Jan 21, 2011	Jan	NEWA
	+		40MG	N022567 003	Jan 21, 2011	Jan	NEWA

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCRIStINE SULFATE

@ APP PHARMS	1MG/ML	A076401 001	Oct 28, 2003	Jan	DISC
--------------	--------	-------------	--------------	-----	------

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

AB	INVAGEN PHARMS	1MG	A090935 001	May 25, 2011	May	NEWA
AB		2MG	A090935 002	May 25, 2011	May	NEWA
AB		2.5MG	A090935 003	May 25, 2011	May	NEWA
AB		3MG	A090935 004	May 25, 2011	May	NEWA
AB		4MG	A090935 005	May 25, 2011	May	NEWA
AB		5MG	A090935 006	May 25, 2011	May	NEWA
AB		6MG	A090935 007	May 25, 2011	May	NEWA
AB		7.5MG	A090935 008	May 25, 2011	May	NEWA
AB		10MG	A090935 009	May 25, 2011	May	NEWA

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

AP	LUITPOLD	10MG/ML	A091457 001	May 06, 2010	Feb	CAHN
----	----------	---------	-------------	--------------	-----	------

TABLET; ORAL

ZIDOVUDINE

@ MATRIX LABS LTD	100MG	N200732 001	Feb 23, 2011	Feb	NEWA
-------------------	-------	-------------	--------------	-----	------

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

+ NOVARTIS	EQ 4MG BASE/100ML	N021223 003	Jun 17, 2011	Jun	NEWA
------------	-------------------	-------------	--------------	-----	------

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB	MYLAN	5MG	A078016 001	Apr 23, 2007	Feb	CAHN
AB		10MG	A078016 002	Apr 23, 2007	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

AB	ANCHEN PHARMS	6.25MG	A078148 002	Apr 14, 2011	Apr	NEWA
AB	SANDOZ	6.25MG	A090107 001	Jul 01, 2011	Jun	NEWA
AB		12.5MG	A090107 002	Jul 01, 2011	Jun	NEWA
AB	SYNTHON PHARMS	6.25MG	A078483 001	Apr 12, 2011	Apr	NEWA
>A>	AB	12.5MG	A078483 002	Jun 06, 2011	Jul	NEWA

OTC DRUG PRODUCT LIST - 31ST EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

2-1

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

SILARX	5MG/5ML	A091130	001	Apr 22, 2011	Apr	NEWA
TARO	5MG/5ML	A201546	001	May 20, 2011	May	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SILARX	5MG/5ML	A091130	002	Apr 22, 2011	Apr	NEWA
TARO	5MG/5ML	A201546	002	May 20, 2011	May	NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ CARDINAL HLTH	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Apr	CAHN
-----------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP SINGLE SWABSTICK

+ CARDINAL HLTH	2%;70% (1.75ML)	N021555	002	May 10, 2005	Apr	CAHN
-----------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP TRIPLE SWABSTICK

+ CARDINAL HLTH	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Apr	NEWA
-----------------	-----------------	---------	-----	--------------	-----	------

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

MYLAN	10MG	A075674	001	Dec 21, 2001	Feb	CAHN
-------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011	Jan	NEWA
---------------------	----------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011	Jan	NEWA
---------------------	----------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011	Jan	NEWA
---------------------	------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011	Jan	NEWA
---------------------	------	---------	-----	--------------	-----	------

TABLET; ORAL

ALLEGRA ALLERGY

SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011	Jan	NEWA
+	180MG	N020872	010	Jan 24, 2011	Jan	NEWA

ALLEGRA HIVES

SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011	Jan	NEWA
+	180MG	N020872	009	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA ALLERGY

SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011	Jan	NEWA
-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011	Jan	NEWA
-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011	Mar	NEWA
--------------------	------	---------	-----	--------------	-----	------

>A>

MYLAN	30MG	A077081	004	Jul 21, 2011	Jul	NEWA
-------	------	---------	-----	--------------	-----	------

TEVA	30MG	A076447	004	Apr 13, 2011	Mar	NEWA
------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011	Mar	NEWA
--------------------	------	---------	-----	--------------	-----	------

>A>

MYLAN	30MG	A077081	005	Jul 21, 2011	Jul	NEWA
-------	------	---------	-----	--------------	-----	------

TEVA	30MG	A076447	005	Apr 13, 2011	Mar	NEWA
------	------	---------	-----	--------------	-----	------

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

	DR REDDYS LABS LTD	60MG	A076502 006	Apr 12, 2011	Mar	NEWA
		180MG	A076502 008	Apr 12, 2011	Mar	NEWA
>A>	MYLAN	60MG	A077081 006	Jul 21, 2011	Jul	NEWA
>A>		180MG	A077081 008	Jul 21, 2011	Jul	NEWA
	TEVA	60MG	A076447 006	Apr 13, 2011	Mar	NEWA
		180MG	A076447 008	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	60MG	A076502 007	Apr 12, 2011	Mar	NEWA
		180MG	A076502 009	Apr 12, 2011	Mar	NEWA
>A>	MYLAN	60MG	A077081 007	Jul 21, 2011	Jul	NEWA
>A>		180MG	A077081 009	Jul 21, 2011	Jul	NEWA
	TEVA	60MG	A076447 007	Apr 13, 2011	Mar	NEWA
		180MG	A076447 009	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+	SANOFI AVENTIS US	60MG;120MG	N020786 002	Jan 24, 2011	Jan	NEWA
---	-------------------	------------	-------------	--------------	-----	------

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+	SANOFI AVENTIS US	180MG;240MG	N021704 002	Jan 24, 2011	Jan	NEWA
---	-------------------	-------------	-------------	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	DR REDDYS LABS LTD	180MG;240MG	A079043 002	Jun 22, 2011	Jun	NEWA
--	--------------------	-------------	-------------	--------------	-----	------

IBUPROFEN

TABLET; ORAL

IBUPROFEN

>A>	ADVENT PHARMS	200MG	A076460 001	Nov 26, 2003	Jul	CAHN
>D>	AVEMA PHARMA	200MG	A076460 001	Nov 26, 2003	Jul	CAHN
		200MG	A076460 001	Nov 26, 2003	May	CAHN
	MARKSANS PHARMA	200MG	A091237 001	Feb 08, 2011	Jan	NEWA
		200MG	A091239 001	Feb 01, 2011	Jan	NEWA
	MERRO PHARM	200MG	A070985 001	Oct 02, 1987	Jan	CAHN
	SVADS HOLDINGS SA	200MG	A079129 001	Mar 28, 2011	Mar	NEWA
		200MG	A091355 001	Apr 04, 2011	Mar	NEWA

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

NOVOLIN N

+	NOVO NORDISK INC	100 UNITS/ML	N019959 001	Jul 01, 1991	Jan	CRLD
---	------------------	--------------	-------------	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

PLAN B

+	TEVA WOMENS	0.75MG	N021045 002	Aug 24, 2006	Feb	CAHN
---	-------------	--------	-------------	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE

SUSPENSION; ORAL

LOPERAMIDE HYDROCHLORIDE

	PERRIGO R AND D	1MG/7.5ML	A091292 001	May 20, 2011	May	NEWA
--	-----------------	-----------	-------------	--------------	-----	------

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MINOXIDIL

PERRIGO ISRAEL

5%

A091344 001 Apr 28, 2011 Apr NEWA

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

MARKSANS PHARMA

EQ 200MG BASE

A090545 001 Mar 16, 2011 Feb NEWA

RANBAXY LABS LTD

EQ 200MG BASE

A091183 001 May 20, 2011 May NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

>A>

PERRIGO R AND D

EQ 2MG BASE

A091349 001 Jul 20, 2011 Jul NEWA

>A>

PERRIGO R AND D

EQ 4MG BASE

A091354 001 Jul 20, 2011 Jul NEWA

POTASSIUM IODIDE

TABLET; ORAL

IOSAT

ANBEX

65MG

N018664 002 May 12, 2011 Apr NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

MYLAN

EQ 75MG BASE

A075497 001 Jan 14, 2000 Feb CAHN

PERRIGO R AND D

EQ 150MG BASE

A091429 002 May 11, 2011 Apr NEWA

EQ 150MG BASE

A091429 001 May 11, 2011 Apr NEWA

SVADS HOLDINGS SA

EQ 150MG BASE

A200536 001 Jun 28, 2011 Jun NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 7 JULY 2011

NO JULY 2011 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2011 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N202379 001	5604213	Feb 18, 2014	DS DP U-1126		NCE	Apr 28, 2016
<u>ADAPALENE - DIFFERIN</u>						
N021753 001	7868044	Mar 12, 2023	U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	7964202	Sep 01, 2024	DP U-1078			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 001					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 002					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 003					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 004					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 001	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 002	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 003	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 004	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 005	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	5250542	Mar 29, 2016	DS DP U-878			
<u>AMBRISENTAN - LETAIRIS</u>						
N022081 001	>A> RE42462	Oct 07, 2015	DS			
<u>AMBRISENTAN - LETAIRIS</u>						
N022081 002	>A> RE42462	Oct 07, 2015	DS			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381 005					PC	Jul 02, 2011
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381 006					PC	Jul 02, 2011
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N021303 001	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N021303 006	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N021303 002	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N021303 004	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N021303 003	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N021303 005	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE</u>						
N022434 001	>A> 7589106	Sep 27, 2026	DP U-1163			
	>A> 7687516	Sep 26, 2027	DP U-1164			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 001					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 002					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 003					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 004					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 005					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 006					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021713 001					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021729 002					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021729 003					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021866 001					I-633	Feb 16, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 001					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 002					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 003					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 004					D-130	Feb 04, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZILSARTAN MEDOXOMIL - EDARBI</u>						
N200796 001	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN MEDOXOMIL - EDARBI</u>						
N200796 002	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZITHROMYCIN - ZMAX</u>						
N050797 001	7887844	Feb 14, 2024	DP			
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	7012066	Feb 22, 2022	DS DP U-1128		NCE	May 13, 2016
	7772178	Nov 11, 2027	DP U-1128			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	>A> 7967011	Aug 11, 2021	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	7897646	Sep 09, 2018	U-1118			
	>A> 7967011	Aug 11, 2021	DP			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 001	5326570	Jul 23, 2011	U-215			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 002	5326570	Jul 23, 2011	U-215			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 003	5326570	Jul 23, 2011	U-215			
<u>CELECOXIB - CELEBREX</u>						
N020998 001	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 002	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 003	5760068	Jun 02, 2015	U-672			
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7935093	Oct 02, 2027	DP U-1022			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N021441 001	7863287	Feb 28, 2027	DP			
<u>CICLOPIROX - LOPROX</u>						
N021159 001	>A> 7981909	Sep 16, 2017	U-1162			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 001	6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 002	6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 003	6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 001	4847265	Nov 17, 2011	DS DP		M-61 PED	May 06, 2014 Nov 06, 2014
	4847265*PED	May 17, 2012				
	5576328	Jan 31, 2014		U-432	Y	
	5576328*PED	Jul 31, 2014				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 002	4847265	Nov 17, 2011	DS DP		M-61 PED	May 06, 2014 Nov 06, 2014
	4847265*PED	May 17, 2012				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7906519	Feb 17, 2029		U-1116		
	7915269	Feb 17, 2029		U-1007		
	>A> 7935731	Dec 03, 2028		U-1116		
	>A> 7964647	Oct 06, 2028		U-1007		
	>A> 7964648	Feb 17, 2029		U-1161		
	>A> 7981938	Oct 06, 2028		U-1166		
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N021642 001	7879349	Jun 01, 2024	DP	U-1152		
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N022512 001	>A> 7866474	Aug 31, 2027	DP			
	>A> 7932273	Sep 07, 2025	DS DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N022512 002	>A> 7866474	Aug 31, 2027	DP			
	>A> 7932273	Sep 07, 2025	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			NCE	Jun 23, 2011
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157*PED	Dec 26, 2016			PED	Jun 18, 2012
	6248775	Aug 13, 2014	DS		PED	Apr 21, 2012
	6248775*PED	Feb 13, 2015			PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			NCE	Jun 23, 2011
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157*PED	Dec 26, 2016			PED	Jun 18, 2012
	6248775	Aug 13, 2014	DS		PED	Apr 21, 2012
	6248775*PED	Feb 13, 2015			PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		D-118	Oct 21, 2011
	5843946*PED	Jun 01, 2016			I-578	Oct 21, 2011
	6037157	Jun 26, 2016	U-935		NCE	Jun 23, 2011
	6037157*PED	Dec 26, 2016			PED	Jun 13, 2014
	6248775	Aug 13, 2014	DS		PED	Jun 18, 2012
	6248775*PED	Feb 13, 2015			PED	Apr 21, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N021986 005	6596746	Jun 28, 2020	DS DP U-780			
	6596746	Jun 28, 2020	DS DP U-748			
	7125875	Apr 13, 2020	U-780			
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			
<u>DASATINIB - SPRYCEL</u>						
N021986 006	6596746	Jun 28, 2020	DS DP U-780			
	6596746	Jun 28, 2020	DS DP U-748			
	7125875	Apr 13, 2020	U-780			
	7125875	Apr 13, 2020	U-779			
	7153856	Apr 28, 2020	U-780			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 007	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 008	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
<u>DICLOFENAC SODIUM - SOLARAZE</u>						
N021005 001	5929048	Jun 17, 2014	U-402			
	5985850	Aug 11, 2015	DP			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	6133251	Oct 25, 2016	DP U-828	Y		
	6133251	Oct 25, 2016	DP U-112	Y		
	6133251	Oct 25, 2016	DP U-1	Y		
	6884793	Oct 25, 2016	DP	Y		
<u>DORIPENEM - DORIBAX</u>						
N022106 001	5317016	Jun 05, 2015	DS DP U-282			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	5317016	Jun 05, 2015	DS DP U-282			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 001	7915307	Aug 24, 2027	U-620			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 002	7915307	Aug 24, 2027	U-620			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	>A> 5223510	Jul 26, 2012	DS DP U-992			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N022574 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	7547719	Jul 13, 2025	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	7547719	Jul 13, 2025	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	7547719	Jul 13, 2025	DS DP U-930			
<u>EPINASTINE HYDROCHLORIDE - EPINASTINE HYDROCHLORIDE</u>						
A090870 001					PC	Oct 29, 2011
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001					NPP PED	Feb 27, 2011 Aug 27, 2011
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002					NPP PED	Feb 27, 2011 Aug 27, 2011
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N022101 001					M-86 PED	Jun 18, 2012 Dec 18, 2012
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 001	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 002	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N022262 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N021840 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N022573 001	5552394	Jul 22, 2014	U-828			
	6667050	Apr 06, 2019	DP U-828			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	7887845	Mar 25, 2019	DP			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-1016		NCE	Jan 18, 2013
	7037917	Nov 05, 2019	DS DP U-1016			
	7887845	Mar 25, 2019	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	5665772	Sep 09, 2019	DS DP		I-638 ODE	May 05, 2014 Oct 29, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	5665772	Sep 09, 2019	DS DP		I-638 ODE	May 05, 2014 Oct 29, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003	5665772	Sep 09, 2019			I-638 NCE ODE	May 05, 2014 Mar 30, 2014 Oct 29, 2017
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2019	DS DP U-1049			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1049			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
<u>EZETIMIBE - ZETIA</u>						
N021445 001	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 004	RE37721	Oct 25, 2016	DS DP U-473	Y		
	RE37721*PED	Apr 25, 2017		Y		
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461*PED	Apr 25, 2017				
<u>EZOGABINE - POTIGA</u>						
N022345 001					NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N022345 002					NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N022345 003					NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N022345 004					NCE	Jun 10, 2016
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 001					M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002					M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003					M-98	Jan 31, 2014
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N022519 001					NC	Apr 23, 2014
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695 001	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695 003	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 001	7915247	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1000			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 002	7915247	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1000			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 001	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 002	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	>A> 7862832	Jun 15, 2028	DP			
	>A> 7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 001	>A> 6432440	Apr 20, 2018	DP U-1169		NDF	Jun 30, 2014
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 002					NDF	Jun 30, 2014
<u>FERUMOXYTOL - FERAHEME</u>						
N022180 001	7871597	Mar 08, 2020	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	7384980	May 11, 2019	DS DP U-913			
	7855230	May 11, 2019	U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	7384980	May 11, 2019	DS DP U-913			
	7855230	May 11, 2019	U-913			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N020872 007	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017			U-1160	
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012			U-1160	
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012			U-1160	
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N020872 010	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N020872 008	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N020872 009	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N020872 005	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N021909 002	5578610	Nov 26, 2013	DS DP U-1158			
	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1158			
	6187791	May 11, 2012	U-1158			
	6399632	May 11, 2012	U-1158			
	7138524	May 18, 2014	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N201373 001	5578610	Nov 26, 2013	DS DP U-1157			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017	U-1157			
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012	U-1157			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1157			
	6399632*PED	Nov 11, 2012				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N020872 006	5578610	Nov 26, 2013	DS DP U-1160			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	5932247	Feb 28, 2015	DP			
	5932247*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1160			
	6037353*PED	Sep 14, 2017				
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1160			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1160			
	6399632*PED	Nov 11, 2012				
	7135571	May 18, 2014	DS U-1160			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N021909 003	5578610	Nov 26, 2013	DS DP U-1158			
	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017	U-1158			
	6187791	May 11, 2012	U-1158			
	6399632	May 11, 2012	U-1158			
	7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N201373 002	5578610	Nov 26, 2013	DS DP U-1157			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017	U-1157			
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012	U-1157			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1157			
	6399632*PED	Nov 11, 2012				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION</u>						
N020786 002	5578610	Nov 26, 2013	DS DP U-1159			
	5578610*PED	May 26, 2014				
	5855912	Feb 28, 2015	DP			
	5855912*PED	Aug 28, 2015				
	6037353	Mar 14, 2017	U-1159			
	6037353*PED	Sep 14, 2017	U-138			
	6039974	Jul 31, 2018	DP			
	6113942	Feb 28, 2015	DP			
	6113942*PED	Aug 28, 2015				
	6187791	May 11, 2012	U-1159			
	6187791*PED	Nov 11, 2012	U-138			
	6399632	May 11, 2012	U-1159			
	6399632*PED	Nov 11, 2012	U-468			
	7135571	May 18, 2014	DS U-1159			
	7135571*PED	Nov 18, 2014				
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION</u>						
N021704 002	5578610	Nov 26, 2013	DS DP U-1159			
	5578610*PED	May 26, 2014				
	6037353	Mar 14, 2017	U-1159			
	6037353*PED	Sep 14, 2017				
	6187791	May 11, 2012	U-1159			
	6187791*PED	Nov 11, 2012				
	6399632	May 11, 2012	U-1159			
	6399632*PED	Nov 11, 2012				
	6613357	Dec 25, 2020	DP U-1159			
	7138524	May 18, 2014	DS			
	7138524*PED	Nov 18, 2014				
	RE39069	May 29, 2018	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N201699 001					NCE	May 27, 2016
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N021112 001	7915243	Mar 22, 2026	DP			
	7939516	May 04, 2025	DP			
<u>FULVESTRANT - FASLODEX</u>						
N021344 001	6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
	6774122*PED	Jul 09, 2021			M-103	May 17, 2014
	7456160	Jan 09, 2021	U-596		PED	Nov 17, 2014
	7456160*PED	Jul 09, 2021			PED	Mar 09, 2014
<u>GABAPENTIN - GABAPENTIN</u>						
A078974 001					PC	Aug 22, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN - GRALISE</u>						
N022544 001	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	6818787	Nov 06, 2022	DS DP		NCE	Apr 06, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 001	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 002	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 003	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 004	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 005	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983 001					PC	Jul 24, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983 002					PC	Jul 24, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A079183 001					PC	May 14, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 001					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 002					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 003					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 004					M-102	Apr 29, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 001					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 002					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 003					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 004					I-635	Feb 25, 2014
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N022041 001	5834448	Nov 14, 2016	DP		ODE	Dec 15, 2013
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N021945 001					ODE	Feb 03, 2018
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N021903 001	6342530	Nov 14, 2020	DP U-794			
	6342530	Nov 14, 2020	DP U-1127			
	6344479	Mar 20, 2021	DS DP U-794	Y		
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001					I-636	Mar 24, 2014
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 002					>A> NS	Jul 15, 2014
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N022383 001	>A> 6878721	Oct 10, 2020	DS DP U-1168		>A> NCE	Jul 01, 2016
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N020314 001	5384113	Jan 24, 2012	DP			
	5753627	May 19, 2015		U-1125		
	5776894	Jul 07, 2015	DS DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N021081 001	7918833	Sep 23, 2027	DP			
	7918833*PED	Mar 23, 2028				
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N021629 003	7918833	Sep 23, 2027	DP			
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R</u>						
N018780 001					NR	Mar 25, 2014
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R PEN</u>						
N018780 005					NR	Mar 25, 2014
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001					NCE	Jan 14, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 001	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 002	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 003	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 004	7919115	Jan 04, 2029	DS DP			
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 001	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 002	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 003	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 002	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	7855217	Nov 24, 2024	DS DP			
	>A> 7968569	Oct 07, 2023	U-1165			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	7855217	Nov 24, 2024	DS DP			
	>A> 7968569	Oct 07, 2023	U-1165			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	>A> 7968569	Oct 07, 2023	U-1165			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	7855217	Nov 24, 2024	DS DP			
	>A> 7968569	Oct 07, 2023	U-1165			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020517 003	>A> 6036976	Dec 13, 2016	DP		D-132	Jun 17, 2014
	>A> 7429559	Dec 13, 2016	DP		NS	Jun 17, 2014
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 001					I-637	Apr 29, 2014
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 002	6500829	Dec 31, 2019	DS DP		I-637 ODE	Apr 29, 2014 Mar 07, 2015
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 003	6500829	Dec 31, 2019	DS DP		I-637 ODE	Apr 29, 2014 Mar 07, 2015
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	6303661	Apr 24, 2017	U-774		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-493			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-493			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N200738 001					NDF PED	Apr 15, 2014 Oct 15, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 001	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1131			
	6469035	Mar 15, 2018	U-1130			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 002	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1131			
	6469035	Mar 15, 2018	U-1130			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 003	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1131			
	6469035	Mar 15, 2018	U-1130			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 004	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1131			
	6469035	Mar 15, 2018	U-1130			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
<u>MALATHION - OVIDE</u>						
N018613 001	>A> 7977324	Aug 14, 2026	DP			
<u>MESALAMINE - LIALDA</u>						
N022000 001				>A> I-640		Jul 14, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 001	7919116	Mar 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 002	7919116	Mar 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 001	7919116	Mar 20, 2018		U-973		
	7919116	Mar 20, 2018		U-1120		
	7959946	Jul 31, 2026	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 002	7919116	Mar 20, 2018		U-973		
	7919116	Mar 20, 2018		U-1120		
	7959946	Jul 31, 2026	DP			
<u>METRONIDAZOLE - VANDAZOLE</u>						
N021806 001	7456207	Sep 22, 2024	DP			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	7888342	Nov 05, 2021		U-882		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	7888342	Nov 05, 2021		U-882		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	7888342	Nov 05, 2021		U-882		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	7888342	Nov 05, 2021		U-882		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	7919483	Feb 28, 2027		U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	7919483	Feb 28, 2027		U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	7919483	Feb 28, 2027		U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	7919483	Feb 28, 2027		U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	7919483	Feb 28, 2027		U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	7919483	Feb 28, 2027		U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	7919483	Feb 28, 2027		U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	7919483	Feb 28, 2027		U-1078		
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N020762 001					M-99	Jan 19, 2014
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N022428 001	7671070*PED	Mar 29, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N050746 001	6025389	Oct 20, 2014	DP U-1122			
<u>NALTREXONE - VIVITROL</u>						
N021897 001	7919499	Oct 15, 2029	U-1124			
	7919499	Oct 15, 2029	U-1123			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 001	5366972	Nov 22, 2011	DS DP U-167		NDF	Mar 25, 2014
	5366972*PED	May 22, 2012				
<u>NIACIN - NIASPAN</u>						
N020381 002	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1143			
	6676967	Sep 20, 2013	U-1138			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7011848	Sep 20, 2013	U-1148			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 003	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1143			
	6676967	Sep 20, 2013	U-1138			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7011848	Sep 20, 2013	U-1148			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 004	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1143			
	6676967	Sep 20, 2013	U-1138			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7011848	Sep 20, 2013	U-1148			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 001	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-862			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 002	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-862			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 003	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-862			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 004	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 005	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
<u>NITROGLYCERIN - RECTIV</u>						
N021359 001					NP	Jun 21, 2014
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 001					NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 002					NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 003					NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 004					NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N021861 001	>A> 7977376	Feb 02, 2023	DP			
	>A> 7977376*PED	Aug 02, 2023	DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 001	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 002	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 003	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 001	5763483	Dec 27, 2016	DS	U-376		
	5763483	Dec 27, 2016	DS	U-1113		
	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080 001	>A> 7201920	Mar 16, 2025	DP			
	>A> 7510726	Nov 26, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N202080 002	>A> 7201920	Mar 16, 2025	DP			
	>A> 7510726	Nov 26, 2023	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	7923536	Dec 09, 2023	U-1117			
	RE41884	Aug 14, 2016	U-1117			
<u>PALIPERIDONE - INVEGA</u>						
N021999 001					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 002					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 003					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 004					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 006					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 001	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
	>A> 7960424	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 002	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
	>A> 7960424	Jan 30, 2024	DP			
<u>PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE</u>						
A091427 001					PC	Nov 01, 2011
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 001					M-61 PED	Mar 17, 2014 Sep 17, 2014
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 002					M-61 PED	Mar 17, 2014 Sep 17, 2014
<u>PERFLUTREN - DEFINITY</u>						
N021064 001	5527521	Feb 22, 2015	DP U-665			
	5585112	Dec 17, 2013	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 001	>A> 6149938	Jul 23, 2018	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 002	>A> 6149938	Jul 23, 2018	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	>A> 6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	>A> 6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	>A> 6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	>A> 6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	>A> 6207661	Feb 22, 2019	DP			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	>A> 6207661	Feb 22, 2019	DP			
	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	>A> 6207661	Feb 22, 2019	DP			
	7915229	Apr 14, 2023	DP			
<u>PLERIXAFOR - MOZOBIL</u>						
N022311 001	7897590	Jul 22, 2023		U-936		
	RE42152	Dec 10, 2013	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 001					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 002					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 003					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 005					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 006					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 007					M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 006	7695734	Apr 26, 2028	DP		I-623 NDF	Mar 19, 2013 Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 007	7695734	Apr 26, 2028	DP		>A> I-623 NDF	Mar 19, 2013 Feb 19, 2013
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001	7169780	Oct 03, 2023	DS DP			
<u>RANOLAZINE - RANEXA</u>						
N021526 001	6369062	May 27, 2019	DP	Y		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP U-805			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029	U-1121			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	6838464	Feb 26, 2021	DS DP		NCE	May 20, 2016
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP U-1153			
	7638522	Apr 14, 2023	DP			
<u>RIVAROXABAN - XARELTO</u>						
N022406 001	>A> 7157456	Feb 08, 2021	DS DP		>A> NCE	Jul 03, 2016
	>A> 7585860	Dec 11, 2020	DS			
	>A> 7592339	Dec 11, 2020	U-1167			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5602162	Feb 11, 2014		Y		
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5602162	Feb 11, 2014		Y		
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5602162	Feb 11, 2014	U-240	Y		
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5602162	Feb 11, 2014	U-240	Y		
<u>ROFLUMILAST - DALIRESP</u>						
N022522 001	5712298	Jan 27, 2015	DS DP U-1115		NCE	Feb 28, 2016
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001	>A> 4977138	Jul 06, 2012	DS DP			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 001	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 002	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 003	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 004	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 005	7927624	Dec 02, 2021	DP U-20			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 006	7927624	Dec 02, 2021	DP U-20			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 002	>A> 7030152	Apr 02, 2018	U-1032			
	>A> 7030152*PED	Oct 02, 2018				
	>A> 7964614	Apr 02, 2018	U-1032			
	>A> 7964614*PED	Oct 02, 2018				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 003	>A> 7030152*PED	Oct 02, 2018				
	>A> 7964614	Apr 02, 2018	U-1032			
	>A> 7964614*PED	Oct 02, 2018				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 004	>A> 7030152*PED	Oct 02, 2018				
	>A> 7964614	Apr 02, 2018	U-1032			
	>A> 7964614*PED	Oct 02, 2018				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N021366 005	>A> 7030152*PED	Oct 02, 2018				
	>A> 7964614	Apr 02, 2018	U-1032			
	>A> 7964614*PED	Oct 02, 2018				
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001	6699498	Nov 27, 2020	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002	6699498	Nov 27, 2020	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003	6699498	Nov 27, 2020	DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 001	>A> 6740669	Nov 14, 2022	DS DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 002	>A> 6740669	Nov 14, 2022	DS DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 003	>A> 6740669	Nov 14, 2022	DS DP			
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	6740669	Aug 17, 2020	DS DP		NCE ODE	Nov 14, 2013 Nov 14, 2015
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N022181 001	7947681	Nov 17, 2024	U-1156			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 001	7951400	Nov 30, 2028	DP			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 002	7951400	Nov 30, 2028	DP			
<u>SINECATECHINS - VEREGEN</u>						
N021902 001	>A> 7858662	Oct 02, 2026	DP U-172			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N201444 001					ODE	Jan 14, 2018

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	7668730	Jun 16, 2024	U-1110			
	7895059	Dec 17, 2022	U-1110			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N021923 001	7897623	Jan 12, 2020	DP			
<u>SPINOSAD - NATROBA</u>						
N022408 001	5496931	Mar 05, 2013	DS U-1105		NCE	Jan 18, 2016
	6063771	Jun 22, 2019	DP U-1105			
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	7776007	Nov 28, 2026	DP			
	7901385	Jul 31, 2026	DP			
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 003	7125905	Feb 15, 2021	DS DP		I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 001	>A> RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 002	>A> RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N022304 003	>A> RE39593	Aug 05, 2022	DS DP U-931			
<u>TECHNETIUM TC-99M MERTIATIDE KIT - TECHNESCAN MAG3</u>						
N019882 001	5573748	Nov 12, 2013	DP			
<u>TELAPREVIR - INCIVEK</u>						
N201917 001					NCE	May 23, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N022011 001	7858594	Sep 11, 2023	DS DP U-999			
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 001	6503894	Aug 30, 2020	U-1103		NP	Apr 29, 2014
<u>TESTOSTERONE - FORTESTA</u>						
N021463 001	6319913	Nov 09, 2018	U-490			
	6579865	Nov 09, 2018	DP			
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	7935690	Apr 21, 2023	U-1009			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
<u>TICAGRELOR - BRILINTA</u>						
N022433 001					>A> NCE	Jul 20, 2016
<u>TIGECYCLINE - TYGACIL</u>						
N021821 001	7879828	Feb 05, 2029	DP			
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>						
N021395 001	6908928	Sep 24, 2021	DS DP U-762			
	6908928	Sep 24, 2021	DS DP U-566			
	7309707	Sep 24, 2021	DS DP			
	7694676	Mar 12, 2027	DP			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N022430 001	7947739	Mar 04, 2025	DP			
<u>VANDETANIB - VANDETANIB</u>						
N022405 001	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
<u>VANDETANIB - VANDETANIB</u>						
N022405 002	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 001					>A> M-105	Jul 22, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - July 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N021928 002					>A> M-105	Jul 22, 2014
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N021817 001	7932241	Feb 05, 2028	DP			
	7932241*PED	Aug 05, 2028				
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N021223 003	7932241	Feb 05, 2028	DP			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A078148 001					PC	Jun 04, 2011

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>